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MSRE Methylation-Sensitive Restriction Endonuclease 
MuTE Mutation of TAL1 Enhancer 
MYB MYB Proto-Oncogene, Transcription Factor 
RUNX1 Runt-related Transcription Factor 1 
SNP Single-nucleotide polymorphism 
SNV Single-nucleotide variant 
TAL1 T-cell Acute Lymphocytic Leukaemia 
T-ALL T-cell acute lymphoblastic leukaemia 
TF Transcription Factor 
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Abstract	
 
T-cell acute lymphoblastic leukaemia (T-ALL) is the hyperproliferative 
transformation of T-cell lymphoid progenitor cells within the blood and bone marrow 
and is extremely heterogeneous. T-ALL has been linked to the overexpression of 
transcription factors, such as TAL1, that is specific within the late-cortical subtype of 
T-ALL. This project has utilised clonal cell line populations for testing phenotypic 
intra-tumoural heterogeneity seen within cancer cell lines, such as the Jurkat cell line, 
to generate clonal populations relative to the parental cell line they are derived from 
at passages 1, 5 and 9 as a cost-effective model. We tested the phenotype of 
proliferation using a carboxyfluorescein succinimidyl ester (CFSE) assay which 
identified Jurkat clonal populations as highly proliferative and displayed lower 
expression of the TAL1 gene, relative to the parental cell line using real-time PCR 
analysis. We also identified four differentially bound putative regulatory element sites 
using bioinformatics analysis of publicly available data. This analysis displayed a 
Jurkat-specific predicted intragenic regulatory element and intergenic enhancer 
regions that map to the known upstream TAL1 Jurkat super-enhancer as stated by 
Mansour et al. (2014). DNA methylation is known to fine-tune intragenic and 
intergenic enhancer-mediated transcription. Thus, we used a methylation-sensitive 
restriction endonuclease (MSRE) assay that provided insight of dynamic and stable 
DNA methylation patterns at the intragenic and intergenic sites across the TAL1 locus 
between Jurkat clonal populations, respectively, at passages 1 and 9. Finally, using 
MinION nanopore sequencing, we identified single-nucleotide variants common 
between Jurkat clonal populations tested at passages 1 and 9, which map to regulatory 
elements, SNPs in linkage disequilibrium across the TAL1 locus and sites of predicted 
transcription factor binding, therefore suggesting regulatory functionality of these 
SNVs in the context of the TAL1-mediated T-ALL.  
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Chapter	1 -	Background	
1.1. Cell Differentiation Programs can be Hijacked by Cancer  
 
Inter- and intra-cell signalling determines cell-lineage identity and is required for the 
coordinated function of cells and tissues within the body (Porcher et al., 2017). These 
coordinated events are regulated through cell- and tissue-specific programming of 
genes as well as the timing, magnitude and duration of gene expression. The 
production of hematopoietic stem cells (HSCs), which are precursors of myeloid and 
lymphoid lineages, and the processes of differentiation of HSCs, allow for the 
functioning of the innate and adaptive immune system in a coordinated fashion. 
Dysregulation of the differentiation of HSCs and/or the lymphoid and myeloid 
precursors can result in atypical cell proliferation and differentiation, ultimately 
leading to malignancy (Porcher et al., 2017).  
 
1.2. Acute Lymphoblastic Leukaemia (ALL) 
 
Acute lymphoblastic leukaemia (ALL) is the transformation and hyperproliferation of 
clonal lymphoid-progenitor cells in the blood and bone marrow of patients. This 
malignancy of B- or T- lymphocytes is the second most prevalent leukaemia in adults, 
with 300 cases diagnosed each year amongst children and adults in Australia 
(Chiaretti et al., 2016; Leukaemia Foundation, 2019). However, the incidence of ALL 
is bimodally distributed between children and adults, with the occurrence of the 
disease appearing between ages 2-4 and on average 50 and older (respectively) 
(Chiaretti et al., 2016). ALL develops in response to endogenous factors, such as 
genetic susceptibility, although the significant phenotypic and genetic differences 
between ALL subtypes poses challenges when identifying causative events and 
genetic changes that are the foundation of ALL development (Chiaretti et al., 2016). 
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The most common form of ALL is B-cell acute lymphoblastic leukaemia (B-ALL), and 
therapies for this subtype have greatly improved the survival rate to where 90% of 
children and 40% of adult patients with the disease remain in remission over the span 
of 5 years (Malouf and Ottersbach, 2018). The T-lymphoid progenitor equivalent (T-
ALL), has a similar long-term survival rate within children, where over 85% of 
childhood cases undergoing therapy will be in remission for five years, however has 
a significantly higher rate of relapse with a median point of 1.2 years in contrast to 2.5 
years in B-ALL seen amongst 125 T-ALL patients after cessation of treatment 
(Goldberg et al., 2003; Terwilliger and Abdul-Hay, 2017). Therefore, understanding of 
the genetic basis of T-ALL may provide insight into the higher rate of relapse seen for 
this subtype of ALL.  
 
The development of T-ALL can be due to inherited genetic mutation(s) or sporadic 
somatic mutations (Girardi et al., 2017; Inaba et al., 2013). In the last decade, 
advancements in understanding the genetic basis of ALL has distinguished multiple 
subtypes within B-cell and T-cell ALL (Iacobucci and Mullighan, 2017). Both these 
subtypes of ALL are distinguished individually by unique structural DNA 
rearrangements and sequence mutations that affect critical steps in lymphoid 
development, cytokine receptor signalling, Ras-kinase signalling and tumour 
suppressive chromatin remodelling processes (Iacobucci and Mullighan, 2017). 
Analysis of the T-cell subtype of ALL shows that 50% of patients harbour 
chromosomal translocations involving T-cell receptor genes (TCRA-TCRD and TCRB) 
and genetic alterations to pivotal transcription factor (TF) genes (Table 1.1) (Iacobucci 
and Mullighan, 2017).   
1.3. A Subtype of ALL: T-Cell Acute Lymphoblastic Leukaemia (T-ALL) 
 
T-ALL is a highly malignant subtype of ALL that accounts for approximately 20% of 
ALL cases amongst children and adults (Litzow and Ferrando, 2015). T-ALL is highly  
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| Table 1.1. Summary of gene categories and targets that have genetic rearrangements or 
mutations that are commonly found within T-cell acute lymphoblastic leukaemia (T-ALL) 1. 
1Genetic alterations seen within the genes listed are seen within >2% of T-ALL cases. This table displays a compilation of 
   Frequency (%) 
Gene Category Gene Target 
Genetic 
Rearrangement 
Paediatric Adult 
Basic Helix-Loop-Helix 
(bHLH) 
TAL1 
t(1;14)(p32;q11) 
t(1;7)(p32;q34) 
1p32 deletion 
30 34 
TAL2 t(1;7)(q34;q32) 1* 
LYL1 t(7;19)(q34;q13) 1* 
BHLHB1 t(14;21)(q11.2;q22) 1* 
LIM-only domain (LMO) 
LMO1 t(11;14)(p15;q11) 6* 
LMO2 t(11;14)(p13;q11) 10 2 
HOXA Homeobox (HOX) 
TLX1/HOX11 t(11;14)(p15;q11) 8 20 
TLX3/HOX11L2 t(11;14)(p15;q11) 19 9 
NKX2.1 inv(14)(q11.2q13) 8* 
NKX2.2 t(14;20)(q11;p11) 
NOTCH1-related NOTCH1 t(7;9)(q34;q34.3) 50 57 
Cell Cycle Alterations 
CDKN2A/2B 9p21 deletion methylation 61/58 55/46 
CCND2 T(7;12)(q34;p13) 1* 
Cell Growth Tumour 
Suppressors 
RB1 13q14 deletion 12* 
CDKN1B 12p13 deletion 2* 
MYC t(8;14)(q24;q11) 1* 
WT1 Inactivating mutation/deletion 19 11 
LEF1 Inactivating mutation/deletion 10 2 
ETV6 Inactivating mutation/deletion 8 14 
BCL11B Inactivating mutation/deletion 10* 
RUNX1 Inactivating mutation/deletion 8 10 
Signal Transduction 
GATA3 Inactivating mutation/deletion 5 3 
PTEN Inactivating mutation 19 11 
NRAS Activating mutation 14 9 
NF1 Inactivating mutation/deletion 4 4 
JAK1 Activating mutation 5 7 
Chromatin Remodelling 
IL7R Activating mutation 10 12 
EZH2 Inactivating mutation/deletion 12 12 
SUZ12 Inactivating mutation/deletion 11 5 
EED Inactivating mutation/deletion 5 5 
Proto-oncogene MYB t(6;7)(q23;q32) 7 17 
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genetic alterations and their frequencies based on the studies by Girardi et al. (2017) and Van Vlierberghe and Ferrando 
(2012). * Frequencies for pediatric and adult cases could not be separated. 
2Yellow, green and orange boxes indicate characteristic gene mutations found within the subtypes of late cortical T-ALL, pro 
T-ALL and early cortical T-ALL, respectively. LMO1 and LMO2 are seen in some cases of late cortical T-ALL (Girardi et al. 2017). 
 
 
heterogeneous with several subtypes that are distinguished by differences in the rate 
of survival and clinical prognosis, such as pro-T-ALL and cortical T-ALL (early and 
late) (Fig 1.1).  
 
 
 
 
 
 
 
 
 
 
 
| Figure 1.1. T-Cell Acute lymphoblastic leukaemia (T-ALL) development occurs within the lymphoid 
differentiation process for T-cells.  
 
T-ALL develops within the bone marrow at the early pro- and pre-T stages of T-cell development. However, T-ALL can 
progress to stages of maturation in the cortex and medulla within the thymus where T-cell differentiation is blocked 
(Khera et al., 2014). The subtypes of T-ALL are defined based on the maturation of the T-ALL cell through stages of pro-, 
pre-, early cortical, late cortical and medullary T-ALL. Key genes are dysregulated within T-ALL subtypes and this is linked 
to clinical prognosis. The subtype pro-T-ALL is characterised by the LYL1 gene in which LYL1-specific T-ALL is known to 
have a poor prognosis. The subtypes of early cortical and late cortical T-ALL are characterised by TLX3/HOX11 and 
TAL1/LMO1 respectively. Clinical prognosis is better within the early cortical stages of T-ALL, relative to the late cortical 
stage of T-ALL (McCormack et al., 2013; You et al., 2015). Created with BioRender. 
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Due to subtypes of T-ALL harbouring different genetic rearrangements and  smaller 
substitutions/insertions and deletions (indels), these subtypes can be distinguished 
and linked to different clinical outcomes (Yadav et al., 2016).   
 
T-ALL is subdivided into further subtypes dependent on intra-thymic differentiation 
such as pro-T-ALL, pre-T-ALL, cortical T-ALL and medullary T-ALL (Litzow and 
Ferrando, 2015). Early and late stages of the cortical subtype of T-ALL display 
dysregulated expression of genes TLX1 and TAL1, respectively, however prognosis is 
favourable within TLX1-specific T-ALL in comparison to TAL1-specific T-ALL. Pro-T-
ALL is distinguished by the overexpression of the LYL1 gene within early T-cell 
precursor cells and is linked to a poor prognosis similar to TAL1-T-ALL (McCormack 
et al., 2013; You et al., 2015) (Fig 1.1). These gene expression profiles have shown that 
T-ALL cases can be subtyped into mutually exclusive groups, based on the expression 
of these key oncogenes (Tan et al., 2019) (Table 1.1).  Therefore, linking genes to 
specific subtypes in T-ALL can be used to understand the impact the genetic 
mutations within these genes have on molecular pathways that induce differential 
clinical outcomes.  
 
An example of  a chromosomal translocation that induces oncogenic activity within 
T-ALL is the, t(7;9)(q34;q34) translocation between the T-cell receptor B (TCRB) gene 
and NOTCH1, which is a common mutation seen within 60% of T-ALL pathogenesis 
(Litzow and Ferrando, 2015) (Table 1.1). This translocation fuses the NOTCH1 gene to 
regulatory elements, such as promoters and enhancers, of the TCRB gene and 
dysregulates the expression of NOTCH1 (Yamamoto et al., 2013). Other T-ALL 
subtypes commonly show T-cell receptor gene chromosomal translocations (such as 
the TCRB/NOTCH1 translocation) that result in the atypical expression of TF 
oncogenes: LMO1, LMO2/LYL1, TLX1 and TLX3 for late cortical, early pro- and early 
cortical T-ALL subtypes, respectively  (Table 1.1 – green and orange boxes). In 
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addition to T-cell receptor gene translocations, genetic translocations and mutations 
can also confer loss of TF activity such as differentiation, tumour suppressor and cell-
cycle inhibitor TFs (e.g. TAL1, RUNX1, ETV6,  EZH2, CDKN2A and CDKN1B) that 
become dysregulated within T-ALL and confer malignancy, specifically seen in TAL1 
overexpression within the late cortical subtype of T-ALL (Table 1.1 – Yellow box) 
(Litzow and Ferrando, 2015; Van Vlierberghe and Ferrando, 2012).  
 
Chromosomal aberrations in T-ALL are a common occurrence, specifically involving 
translocations of the basic helix-loop-helix (bHLH), cysteine-rich (LIM-domain) 
and/or homeodomain genes (Sanda and Leong, 2017). Currently, T-ALL patients with 
activating oncogenic mutations for bHLH proteins, like TAL1, have a poor response 
to current therapeutics and are associated with high-risk failure (50% patient 
remission within five years) (Sanda and Leong, 2017). These include genes such as 
MYC, TAL1, TAL2, LYL1 and bHLHB1 in the bHLH category, LMO1 and LMO2 (LIM-
domain genes) and HOX11/TLX1 and HOX11L2/TLX3 (Litt et al., 2013). These TFs 
regulate distinct differentiation pathways in T-cells, however are seen to be aberrantly 
co-expressed within their respective T-ALL subtypes (Sanda and Leong, 2017).  
1.3.1 The TAL1 gene in T-ALL 
 
The T-cell acute lymphocytic leukaemia (TAL1) gene is located on chromosome 1p32 
and encodes for a class I bHLH transcription factor TAL1 (Litt et al., 2013). The ectopic 
expression of TAL1 is specifically associated with the most common T-ALL subtype, 
late cortical T-ALL, accounting for 40-60% of all cases (Tan et al., 2019). The expression 
of TAL1 is essential for the genesis of HSCs in embryogenesis and in turn, erythroid 
and lymphoid maturation (Litt et al., 2013). Within murine lymphoid progenitor cells, 
the expression of TAL1 is silenced at the double negative (CD4-/CD8-) phase for thymic 
T-lymphocytes (Tan et al., 2019). However, the mutations already described within 
TAL1 (Table 1.1) drive its continued expression,  resulting in a differentiation block 
for developing T-cells (Sanda and Leong, 2017; Tan et al., 2019).  
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The translocation t(1;14)(p32;q11) is found in 3% of all T-ALL childhood cases and 
results in the over-expression of TAL1 through a fusion with regulatory elements 
within the TCRA/D oncogene (Van Vlierberghe and Ferrando, 2012). A more frequent 
TAL1 translocation in 12-25% of late cortical T-ALL cases is a 90-kb deletion that fuses 
the first exon of the SCL interrupting locus (SIL) gene to the TAL1 gene, increasing 
expression of TAL1 through the SIL regulatory elements  (Carlotti et al., 2002; Janssen 
et al., 1993; Litt et al., 2013; Tan et al., 2019).  Although these examples have identified 
translocations that increase TAL1 expression, 60% of late cortical T-ALL cases show 
overexpression of TAL1 in the absence of any detectable gene rearrangements within 
the TAL1 gene (Litt et al., 2013). In the absence of large chromosomal rearrangements, 
smaller mutations may drive changes in TAL1 expression. An example of this is the 
heterozygote 12-bp insertion described by Mansour et al. (2014), that creates a 
powerful enhancer that turns on TAL1 gene expression. This suggests there may be 
other genetic changes associated with the TAL1 locus that target regulatory elements 
and increase TAL1 expression.   
 
The over-expression of TAL1 promotes T-ALL by two mechanisms. In the first 
mechanism, TAL1 forms a heterodimer with class A bHLH proteins such as HEB, E2A 
and E47, and also forms large complexes with TFs such as GATA1 and other LIM-only 
proteins (O’Neil et al., 2004). The TAL1 heterodimer recognises an E-box sequence, 
CANNTG, at promoter sites of targeted genes (Palomero et al., 2006). The 
overexpression of TAL1 inhibits the formation of E2A/HEB heterodimers and instead 
favours the formation of TAL1/E2A heterodimers. The E2A/HEB heterodimer aids in 
tumour suppressive functions through its involvement in the chromatin-remodelling 
complex, specifically inducing histone-deacetylase 1 and 2 activity (HDAC1 and 
HDAC2) (Litt et al., 2013). However, the formation of TAL1/E2A heterodimers 
promotes oncogenic transformation by interfering with E2A/HEB heterodimerisation  
(Sanda and Leong, 2017). It is this shift in heterodimer composition through TAL1  
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overexpression that disrupts E2A/HEB-dependent gene expression and switches to a 
T-ALL gene expression program (Sanda and Leong, 2017; Sanda et al., 2012). 
 
In the second mechanism, the dysregulated expression of TAL1 allows continued 
TAL1-dependent gene expression in late cortical T-ALL cells through combining with 
TFs, GATA3 and RUNX1, that are also expressed in T-ALL (Table 1.1). TAL1 binds to 
similar regulatory sites within genes with GATA3, and RUNX1 (Sanda et al., 2012).  
Although TAL1, GATA3, and RUNX1 do not directly interact, they cooperate to form 
| Figure 1.2. TAL1 core regulatory circuit (CRC) positive auto-regulatory loop.  
 
The TAL1 protein forms a complex with transcription factors which coordinate the regulation of 
downstream target genes for T-ALL malignancy, such as MYB. This autoregulatory loop of T-ALL core 
regulatory circuit (CRC) TFs (boxes), TAL1, GATA3 and RUNX1 bind to and initiate transcription of each 
other’s and their own regulatory elements (circles), as well as the oncogene, MYB to maintain the T-
ALL pathogenesis through mechanisms of cell survival, proliferation and blocking differentiation of the 
T-Cell through TRIB2, GIMAP protein, CDK6 and MYCN and blocking of E-protein heterodimerisation 
pathways (Sanda and Leong, 2017; Tan et al., 2019). Created with BioRender. 
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a core TF regulatory circuit (CRC) that binds to regulatory elements within genes that 
sustain the T-ALL pattern of gene expression as well as co-occupying their own and 
each other’s regulatory elements (Sanda et al., 2012). This creates an autoregulatory 
loop unique to T-ALL pathogenesis in late cortical stages (Sanda and Leong, 2017) (Fig 
1.2). Hence, the TAL1 CRC reinforces and promotes the stability of the T-ALL 
leukemogenicity program (Litt et al., 2013).  
 
The feed-forward loops established by TAL1 creates a process of ‘forced’ expression 
of TFs which are part of a set of ‘master TFs’. These master TFs then dysregulate gene 
expression programs that lead to a change in cell identity associated with T-ALL 
(Sanda and Leong, 2017). Chromatin-immunoprecipitation sequencing (ChIP-seq) 
experiments and gene expression assays confirm genome-wide occupancy of TAL1 
and its CRC partners GATA3 and RUNX1 in T-ALL cells. ChIP-seq also shows co-
occupancy of TAL1, GATA3 and RUNX1 at regulatory elements in key T-ALL-specific 
genes, including the oncogene MYB (Palomero et al., 2006). Independent studies show 
co-occupancy of regulatory DNA sequences by these TFs as seen at the eR1 (RUNX1 
enhancer) and the MuTE region (Mutation of TAL1 enhancer) that introduce MYB-
binding motifs within late cortical T-ALL (Mansour et al., 2014; Tan et al., 2019; 
Yamamura et al., 2017). The eR1 enhancer element resides between the promoters of 
the RUNX1 gene and drives the expression of RUNX1 within HSCs, but is also seen 
within other tissue types (Yamamura et al., 2017). The MuTE region mutation is an 
insertion of 12-bp that introduces binding motifs for the oncogenic TF, MYB, and is 
linked to the overexpression of the TAL1 gene downstream (Mansour et al., 2014). 
These examples support the idea that the TAL1 CRC maintains a program of gene 
expression required for T-ALL leukemogenesis. In summary, TAL1-dependent 
dysregulation increases the CRC activity, increasing the expression of genes, 
including TAL1 itself, in the context of late cortical T-ALL (Fig 1.3). 
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1.4. Epigenetic Landscapes: DNA Methylation 
 
As already discussed, a number of large chromosomal rearrangements leading to 
over-expression of TAL1 have been found in T-ALL (Table 1.1). However, in 60% of 
late cortical T-ALL cases showing an over-expression of TAL1, there is no evidence of 
such chromosomal rearrangements. The identification of a small insertion mutation 
upstream of the TAL1 gene and the resulting increase in TAL1 expression suggests 
| Figure 1.3. Model of TAL1-induced transformation in late cortical T-ALL.  
 
TAL1 is normally not expressed during maturation stages of T-cell development, however due to 
chromosomal and intrachromosomal rearrangements or mutations, changes in regulatory elements such 
as enhancer elements may occur that induce TAL1 overexpression. The two TAL1-dependent mechanisms 
of leukemogenesis are shown: assembly of the T-ALL CRC initiation with GATA3 and RUNX1 and TAL1 
heterodimerisation of either E2A or HEB, leading to the inhibition of E2A/HEB heterodimerisation for 
tumour suppressive functions. This leads to aberrant cell proliferation, cell survival and a differentiation 
block by affecting downstream targets, such as CDK6 and MYCN, TRIB2 and GIMAP protein genes and 
additional generic alterations in key T-ALL genes such as NOTCH1 (Sanda and Leong, 2017; Tan et al., 2019). 
Created with BioRender. 
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there may be other as-of-yet uncharacterised small mutations and/or epigenetic 
modifications within regulatory DNA sequences at the TAL1 locus that result in 
increased expression of TAL1 in T-ALL.  
 
An epigenetic modification is defined as a reversible and stable change in gene 
expression without the alteration of a DNA sequence  (Luczak and Jagodziński, 2006). 
These modifications include DNA methylation and histone subunit post-translational 
modifications such as methylation and acetylation. Alteration in DNA methylation is 
associated with a variety of haematological disorders, and DNA methylation can be 
used as a prognostic marker due to the significant impact it has on gene expression 
(Luczak and Jagodziński, 2006). Epigenetic alterations, such as DNA methylation,  
show specific signatures in cancers which can be used to further classify malignancies, 
such as T-ALL, and establish a connection between epigenetic profiles and 
pathogenesis (Haider et al., 2019).   
 
DNA methylation consists of the addition of a methyl group to a cytosine base within 
CpG dinucleotides by DNA methyltransferases (Kulis and Esteller, 2010). The 
presence of a methyl group bound to a CpG dinucleotide promotes condensation of 
chromatin and transcriptional silencing that can be tissue-specific and is also vital for 
stabilisation of chromosomes (Luczak and Jagodziński, 2006) (Fig 1.4, Differentiation-
Specific DNA Methylation). In non-cancer cells, it allows for the regulation of gene 
expression by initiating and maintaining stable gene silencing (Kulis and Esteller, 
2010). With its association with post-translational histone modifications, it is crucial 
for the architecture of chromatin and its effect on transcriptional activity (Kulis and 
Esteller, 2010). For example, proteins such as m5CpG-binding domain (MBD) and 
m5CpG-binding-proteins (MeCP) induce DNA methylation-dependent repression  by 
interacting with HDAC1 and HDAC2 to alter patterns of chromatin remodelling 
(Luczak and Jagodziński, 2006).  
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CpG islands are defined as stretches of DNA 500-1500bp long with a CG:GC ratio of 
more than 0.6 (Bird et al., 1995). These CpG islands are typically found at promoters 
and contain the 5' end of the transcript (Bird et al., 1995). These islands are frequently 
found at transcription start sites (TSSs) which are unmethylated within healthy cells 
(Qu et al., 2012). 
 
 
This contrasts with the remaining regions of the genome, which are predominantly 
methylated (King et al., 2016). Hypomethylated regions are not limited to TSSs but 
include intragenic and intergenic regions that are associated with non-coding 
| Figure 1.4. DNA methylation patterns amongst haematopoietic stem cells (HSCs) and the changes of 
DNA methylation during differentiation within somatic cells.  
 
Promoter methylation is indicated by filled in markers and unmethylated promoters are indicated by the 
open markers. HSCs typically have patterns of DNA methylation that allow for the transcription of 
pluripotency and developmental genes during development, whereas specific somatic differentiation 
genes are inhibited by DNA methylation of associated promoters. However, within somatic cells that are 
differentiated, genes involved in pluripotency and developmental pathways are inhibited through DNA 
methylation in conjunction with somatic differentiation gene expression, allow for the differentiation of 
somatic cells. This ensures that the development of differentiating cells is mutually exclusive when 
controlling gene expression from pluripotency/development genes and somatic gene expression. Created 
with BioRender. 
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regulatory DNA elements such as enhancers (Qu et al., 2012). Intragenic regions are 
defined as sequences within a gene body (i.e. defined by exons and intervening 
introns), whereas intergenic regions are the regions of the genome outside of a gene 
body. Therefore, DNA methylation is found throughout the genome, with dynamic 
changes in DNA methylation at TSSs, intergenic and intragenic regions and is 
associated with changes in cell identity and state (Varley et al., 2013). In the context of 
cancer, CpG islands can become atypically hypermethylated, leading to the 
suppression of tumour suppressor genes and their associated pathways (Kraszewska 
et al., 2012).  
 
Within T-ALL, DNA methylation has prognostic relevance that is based on the CpG 
island methylation phenotype (Haider et al., 2019). Within the TAL1 gene, promoter 
hypomethylation is associated with dysregulated transcriptional control of the gene, 
leading to TAL1-overexpression and a worsened prognosis (Haider et al., 2018). 
However, changes in DNA methylation patterns are not limited to TSSs and promoter 
regions, therefore, a deeper understanding of the patterns of DNA methylation across 
intragenic and intergenic regulatory non-coding sequences within the TAL1 locus can 
further identify how DNA methylation can influence gene expression in late cortical 
T-ALL.  
 
1.5. Epigenetic Landscapes: Regulatory Elements - Enhancers  
 
Our understanding of the relationship between DNA methylation and post-
translational histone subunit  modifications, such as acetylation and methylation, and 
their importance in maintaining inducible and cell-specific patterns of gene expression 
is in large part due to the Encyclopedia of DNA elements (ENCODE) project 
(Consortium, 2004; Davis et al., 2018; Qu and Fang, 2013; Sloan et al., 2016; The 
ENCODE Project Consortium, 2011). The ENCODE project has provided a map of the 
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epigenetic landscape of the human genome, which identifies putative transcription 
regulatory DNA elements through the co-localisation of specific patterns of DNA 
methylation and histone subunit methylation and acetylation (Davis et al., 2018). The 
ENCODE project is fundamental to understanding the 98% of the human genome that 
does not encode proteins, with early publications from the ENCODE project claiming 
80% of the human genome can be assigned a “biochemical function” (The ENCODE 
Project Consortium, 2011). This knowledge is in stark contrast to the historical view of 
non-coding DNA as ‘junk DNA’ (Palazzo and Gregory, 2014). It is with this 
understanding that key regulatory elements such as enhancers and promoters are 
mapped across the genome.  
 
Promoters are proximal regulatory regions near TSSs of genes and mediate the 
binding of RNA polymerase II through promoter recognition of TFs (Carelli et al., 
2018). Most promoters are CpG-rich, whilst other regulatory regions, such as 
enhancers are CpG poor (Carelli et al., 2018). However, it is the accessibility of 
chromatin at these regions that determines their functionality in the context of the 
spatial and temporal regulation of gene transcription (The ENCODE Project 
Consortium, 2011).  Through ENCODE and other studies on putative enhancers, as 
many as 400,000 distinct enhancer elements are mapped in specific human cell lines 
(Calo and Wysocka, 2013). Enhancers can interact with TSSs and promoters 
independently of location (up to 1 million base pairs away) (Tippens et al., 2018). 
Currently, the mechanism of promoter-enhancer interactions is proposed to involve 
“looping”. Looping interactions involve enhancer-associated factors and co-factors 
that directly interact with the promoter through the looping of the intervening DNA 
sequence (Calo and Wysocka, 2013). This mechanism has been validated through the 
results obtained using chromosome conformation capture technologies such as 3C 
and derivatives 4C, 5C and Hi-C (Calo and Wysocka, 2013).  
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The core of an enhancer (200-500bp) is recognised by the presence of clustered 
recognition sites for multiple TFs. This forms a platform for non-DNA binding 
transcription coactivators such as mediator complexes, CREB-binding proteins and 
p300 (Jia et al., 2019). The combinatorial mechanisms of these activating factors 
ensures the integration of intrinsic and extrinsic cues within the cellular environment 
(Witte et al., 2015). Flanking sites of these TF binding regions are flagged with specific 
histone subunit modifications that are used to identify enhancer activity at specific 
loci (Benveniste et al., 2014). Active enhancers are associated with high levels of 
histone subunit 3 lysine 27 acetylation (H3K27ac) and low levels of histone subunit 3 
lysine 4 trimethylation (H3K4me3) (Jia et al., 2019) (Fig 1.5). Another signal associated 
with active enhancers is the occupancy of TFs at nucleosomal depleted sites (Teif et 
al., 2017). These sites display high sensitivity to cleavage by the enzyme 
deoxyribonuclease I (DNaseI), that cleaves DNA. With the combination of DHS and 
chromatin modification data provided by ENCODE and other studies, a robust 
identification method for active enhancer sites in the genome can be utilised to 
understand gene regulatory landscapes (Teif et al., 2017) (Fig 1.5). 
 
Enhancers can be located away from a target gene locus (intergenic) or embedded 
within the gene body in an intron (intragenic). Intergenic enhancers can be seen as the 
“classical” type of enhancer that influences transcriptional activity of genes in nearby 
loci by looping and contacting a promoter. In the case of intragenic enhancers, gene 
regulation may involve the “classical” function of looping and contact with adjacent 
genes, or it may involve a different mechanism of transcriptional regulation of the 
gene in which it is embedded. This alternate mechanism involves the RNA 
polymerase II-mediated transcription of short lived enhancer RNAs (eRNAs) (Cinghu 
et al., 2017) (Fig 1.6A).   
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| Figure 1.5.  Open chromatin is identified by H3K27ac and H3K4me3 and DNAse1 hypersensitivity (DHS). 
  
Left: Digital genomic footprinting creates a map of DNaseI cleavage at single base-pair resolution across the 
genome. TF binding at these sites is marked by decreased cleavage (tag counts), leaving a “footprint” flanked 
by increased cleavage by DNAseI. Middle: Open chromatin can also be marked and initiated by histone 
modifications such as H3K27ac and H3K4me3. Right: Enhancers are marked by high levels of H3K27ac and 
DHS, while promoters are differentiated from enhancers through the presence of H3K4me3 (Sullivan et al., 
2015; Vierstra and Stamatoyannopoulos, 2016). Created with BioRender. 
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It is well known that transcriptionally active genes show hypomethylation at 
promoter sites and increased methylation throughout the body of a gene (intragenic 
regions) (King et al., 2016; Neri et al., 2017; Rauscher et al., 2015; Varley et al., 2013). It 
is now shown that gene body methylation regulates intragenic enhancers, whereby 
methylation within the gene body prevents cryptic transcription from intragenic 
enhancer sites. These sites would otherwise promote RNA polymerase II-dependent 
bi-directional transcription of short eRNAs, which are believed to inhibit RNA 
polymerase II transcription from the promoter (Fig 1.6B – right side) (Cinghu et al., 
2017; King et al., 2016; Sharifi-Zarchi et al., 2017; Weigel et al., 2019). This shows the 
importance of intragenic enhancers in the attenuation or fine tuning of the 
transcription of the gene in which they are embedded (King et al., 2016). This model 
would also suggest that intragenic DNA methylation is dynamic and is regulated 
according to gene activating or repressing signals (Varley et al., 2013). In contrast, 
intergenic DNA hypermethylation is associated with downregulation of functionally-
associated genes as seen in pre B-ALL (Almamun et al., 2017). This demonstrates that 
the correlation between DNA methylation and gene expression is related to the 
methylation status of intragenic and/or intergenic enhancers (Almamun et al., 2017) 
(Fig 1.6B). Consequently, when considering the possibility of genetic variants within 
the TAL1 locus, it is also important to consider intragenic as well as intergenic 
enhancers. 
 
Other enhancer types that are also seen within intragenic and intergenic regions of the 
genome are known as super-enhancers (Khan et al., 2018a). The super-enhancers 
regulate the expression of cell identity genes and a number of disease-associated 
genetic variants map to these super-enhancers (Khan et al., 2018a) (Fig 1.7).  Super-
enhancers are regions of clustered enhancers that are occupied by master TFs, 
chromatin modifiers and/or histone markers of active activity (Jia et al., 2019). Super-
enhancers are more enriched for active chromatin markers and more transcriptionally  
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active than typical enhancers specific for cell-lineage biological functions (Khan et al., 
2018a) (Fig 1.7). It is currently unknown whether super-enhancers represent a small 
clustering of typical enhancers or act as an independent element with multiple facets 
of enhancer activity (Jia et al., 2019).   
 
1.5.1. Enhancers within T-ALL – Jurkat Super Enhancer 
 
The translocation t(1;14)(p34;q11) between the TCRB and TAL1 gene and SIL-TAL 
deletions are found in 2% and 20% of T-ALL cases respectively, yet more than half of 
the TAL1-specific cases lack TAL1 lesions, therefore suggesting unidentified 
Figure 1.6 (A-B). Model for transcription at intergenic and intragenic enhancers and the 
influence of DNA methylation at intragenic and intergenic enhancer sites for transcription.  
 
(Previous Page). A. Left: Intergenic enhancers loop and bind to promoter regions of genes to 
initiate transcription. Right: Intragenic enhancers inhibit the expression of the gene in which 
they are located. Bi-directional transcription from an intragenic enhancer (red and yellow 
circles) attenuates promoter-dependent transcription (green circle) during productive 
elongation through transcription interference with RNA Pol II. B. A model for DNA methylation 
regulation of enhancer activity. Left: DNA methylation at intergenic enhancers is associated with 
reduced levels of transcription of the target gene. When intergenic enhancers are 
unmethylated, functional enhancer-promoter contacts are formed, and transcription occurs at 
gene targets. Right: Consistent with the known inverse pattern of DNA methylation between 
the promoter and the gene body, it is proposed that methylated intragenic enhancers are 
transcriptionally inactive and do not inhibit RNA Pol II-dependent transcription from the 
promoter.  A loss of methylation at the intragenic enhancer is thought to allow for attenuation 
or fine-tuning of promoter-dependent transcription from the gene in which it is embedded, 
and/or contact and transcription from promoter(s) of other gene(s). (Figure adapted from 
Cinghu et al. (2017) and Kowalczyk et al. (2012)). Created with BioRender. 
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epigenetic dysregulation patterns within TAL1-specific T-ALL (Navarro et al., 2015).  
Through ChIP-seq analysis, Jurkat cells are shown to have a strong H3K27ac signal 
upstream of the TAL1 TSS that spreads towards the first exons of the gene (Mansour 
et al., 2014). A further study shows a high density of enrichment and breadth for 
H3K27ac spanning over -20kb to +10kb from the TAL1 TSS (Rivera-Reyes et al., 2016). 
The TAL1-specific super-enhancer is enriched in the late cortical T-ALL Jurkat cell line 
relative to foetal thymocytes, hematopoietic (CD34+) stem and progenitor cells, and to 
other T-ALL cell lines such as DND41 and RPMI-8402 (Rivera-Reyes et al., 2016). The 
TAL1 super-enhancer loops to make contact with the TAL1 TSS, therefore playing a 
role in the overexpression of TAL1 (Mansour et al., 2014). 
 
 
 
 
| Figure 1.7. Differences between typical enhancers and super enhancers.  
Typical enhancers range in a size of 200-500bp, and are bound by TFs, mediator proteins and the p300 
complex when looping with a promoter to initiate transcription. Super-enhancers are clusters of enhancer 
modules that regulate the transcription of genes and are exponentially more potent in regulating gene 
expression relative to typical enhancers. Super-enhancers can bind multiple sets of TFs as well as mediator 
proteins to establish an increased function in regulating gene expression (Khan et al., 2018a). Made with 
BioRender. 
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| Figure 1.8. The organisation of TAL1 loci within the Jurkat T-ALL cell line displaying an acquired 
super-enhancer upstream of the TAL1 gene (chr1:47,705,000). 
 
The acquired super-enhancer maps to a 12-bp heterozygote insertion mutation (mutation of TAL1 
enhancer – MuTE). This insertion provides a binding site for the oncogenic MYB transcription factor, 
as well as other members of the TAL1 CRC. The Jurkat enhancer directly loops with the TAL1 
promoters (1b and 1a - green) to induce the overexpression of TAL1 (Mansour et al., 2014). Created 
with BioRender. 
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The TAL1-specific super-enhancer in the Jurkat T-ALL cell line is formed as a result of 
a heterozygous 12-bp insertion (GTTACCAAACGG) at the core of the super-enhancer 
site (Fig 1.8). The binding of TAL1 CRC TFs is seen in the TAL1-T-ALL Jurkat cell line 
at the MuTE insertion site (Mansour et al., 2014). Along this MuTE region, oncogenic 
master TF MYB binding motifs were identified de novo, completing the auto-
regulatory loop of the TAL1 CRC  (Sanda et al., 2012). CRISPR/Cas9 genomic editing 
to delete the MuTE insertion in Jurkat cells was unsuccessful, possibly reflecting the 
dependency of the Jurkat cell line on this region and TAL1 expression for cellular 
proliferation (Rivera-Reyes et al., 2016).  
 
1.7. Heterogeneity within Cancer Cell lines 
 
The identification of a heterozygous somatic mutation upstream of TAL1 is associated 
with monoallelic expression of TAL1 in Jurkat T-cells (Mansour et al., 2014). However, 
the investigation of other key epigenetic modifications, such as DNA methylation, that 
could contribute to TAL1 gene expression has not been thoroughly investigated in 
combination with mapped intragenic and intergenic enhancer regions within the 
TAL1 locus.  
 
It is evident that clonal heterogeneity within T-ALL patients could be a possible 
contributor to malignancy, as cells within a single tumour may be composed of 
multiple cell populations that may harbour different phenotypes and underlying 
genetics (Stockholm et al., 2007).  Phenotypic heterogeneity is also seen within in vitro 
cell lines grown in controlled environments (Stockholm et al., 2007). These phenotypes 
between clonal cells can be diverse, as seen through examples of malignant cell lines 
in culture reverting to a stable non-malignant phenotype (Lavrovsky et al., 1992). 
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The frequent use of cell lines to investigate biological processes makes the 
understanding the heterogeneity of cell line phenotypes essential (Stockholm et al., 
2007). Stockholm et al. (2007) propose a model that simulates the growth of clonal cell 
populations within cell lines and is a simple way to test phenotypic heterogeneity. It 
is found that ‘intrinsic’ spontaneous phenotypic switches occurred in the cell 
autonomously. This refers to the probability of phenotypic dynamics being based on 
underlying epigenetic and transcriptional regulatory mechanisms within each clonal 
population. This in vitro analysis can also contribute to a better understanding of in 
vivo processes as well as mimicking the heterogeneity established within a variety of 
cancer subtypes (Yadav et al., 2016).  
 
Expanding from phenotypic heterogeneity, Martin-Pardillos et al. (2019) established 
a similar model of testing clonal cell lines at the phenotypic and molecular level using 
the breast cancer cell line, MDA-MB-231 (Martín-Pardillos et al., 2019). This was done 
to understand the accumulation of genetic alterations from an initial clonal population 
undergoing Darwinian selection, and complemented phenotype functional testing 
assays. Despite tumours being comprised of distinct clones that are phenotypically or 
genetically different, these clones interact to benefit one or more of the clones within 
the tumour, known as clonal cooperation (Neelakantan et al., 2015). Whilst 
competition amongst clones may result in dominant clones based on their survival 
fitness, the theory of clonal cooperation within populations demonstrates that 
complementary genetic alterations synergistically contribute to tumorigenesis and 
metastasis (Martín-Pardillos et al., 2019). This has been supported by single-cell 
sequencing studies, whereby clones cooperate to develop advantageous 
characteristics selective for  atypical survival and angiogenesis (Martín-Pardillos et al., 
2019).  A conclusion of their study is that they have established a model in which the 
physical and chemical messenger interplay between cells in each population favours 
tumorigenic capacities of the breast cancer cell line. 
  
24 
 
The extent to which transcriptional heterogeneity contributes to phenotypic 
heterogeneity is still currently unknown (Ben-David et al., 2018). The study by Ben-
David et al. (2018) expanded on ideas from the study by Martin-Pardillos et al. (2019) 
by using 106 human cell lines to analyse clonal diversity and the response of these 
clonal populations to various anti-cancer compounds. They demonstrated that 
ongoing instability within these cancerous cell lines can translate to heterogeneity, 
with each clone expressing differing responses to various drugs (Ben-David et al., 
2018). Ben-David et al. (2018) further suggest that due to the instability of cancer cell 
lines, minimising variability within culture conditions between cell lines is 
recommended. This includes the generation of clonal populations derived from single 
cells, tracking passages and avoiding prolonged culturing of cell lines. Therefore, 
cancer cell lines must be thought of as highly heterogeneous due to pre-existing 
subclones within the population and from continuous instability while in culture 
(Ben-David et al., 2018) (Fig 1.9). 
 
The Jurkat cell line has been used as an extensive model for T-cell activation and 
signalling, as well as a model for TAL1-specific T-ALL (Abraham and Weiss, 2004; 
Fernández-Ramos et al., 2017; Gioia et al., 2018; Mansour et al., 2014; Moharram et al., 
2017). However, as research using the Jurkat cell line continues, irregularities 
concerning the Jurkat genetic and epigenetic profile have become apparent (Gioia et 
al., 2018). Using short-read sequencing, abnormalities of the Jurkat genome were 
identified in relation to damaging variants associated with cancer such as the 
apoptosis-related BAX gene (Gioia et al., 2018). Despite the documented instability of 
the Jurkat cell line, experimental designs used to minimise cell line variability within 
testing populations has not been commonly communicated, but can be tested to mimic 
intra-tumoural heterogeneity (ITH) and exploit cell line diversity as a cost-effective 
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method of profiling heterogeneity within cell line types (Fig 1.9) (Ben-David et al., 
2018).  
 
 
 
 
 
| Figure 1.9. Model of testing cancer cell line heterogeneity through the generation of clonal populations 
from single cells.  
 
Cancer cell line populations are composed of subclones that may have genetic, transcriptional and 
phenotypic differences which may be due to epigenetic or genetic mutations or alterations that are selected 
for during tumorigenesis. A cell model to test this phenomenon of intra-tumoural heterogeneity (ITH) can 
be conducted through the isolation of single cells from the malignant parental (original) cell line population 
and grown to develop sub-clonal population cell lines to analyse for genetic, epigenetic and phenotypic 
differences to mimic processes seen within malignancy in vivo. Created with BioRender. 
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1.8 Hypothesis 
 
This project will test the  hypothesis that TAL1 is associated with the proliferation of 
late cortical T-ALL cells, and the isolation of clonal populations from the Jurkat cell 
line will show that differences in proliferation may be due to genetic or epigenetic 
differences at the TAL1 locus between clones at varying passages of culture.  
 
1.9. Objectives and Aims 
 
Therefore, this project will be conducted with the following aims: 
 
1. To generate clonal cell lines from a parental Jurkat cell line and to test these cell 
lines for differences in proliferation by using a cell-based carboxyfluorescein 
succinimidyl ester (CFSE) proliferation assay.  
2. To test clonal cell lines for differences in the expression of T-ALL CRC genes, 
TAL1, RUNX1, GATA3 and MYB using real-time PCR (qPCR) analysis.  
3. Complete a bioinformatic analysis of the TAL1 locus by using publicly available 
datasets from ENCODE and other genomic studies to map histone 
modifications, DNA methylation and DNaseI hypersensitivity sites in multiple 
different cell lines. 
4. Use the bioinformatic analysis of the TAL1 locus to target sites for DNA 
methylation analysis in the parental and clonal cell lines using a methylation-
sensitive restriction endonuclease (MSRE) assay.  
5. Clonal populations will be tested for genetic sequence differences through 
MinION nanopore sequencing of key regions across TAL1.  
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Chapter	2 -	Characterisation	of	
Jurkat	Clonal	Cell	Lines	
2.1. Introduction 
 
The generation of clonal populations of cells is essential for minimising phenotypic, 
genetic and epigenetic variation in cancer cell lines in vitro (Ben-David et al., 2018; 
Martín-Pardillos et al., 2019; Stockholm et al., 2007). No single clone will exhibit all 
characteristics of a cancer, and it is the cooperation between genetically and 
phenotypically diverse clonal cell lines that drive cancer progression (Martín-
Pardillos et al., 2019). Therefore, the study of clonal cell lines within the Jurkat cell line 
can reveal the heterogeneity of tumour cells within the context of T-ALL.  
 
Within the ten hallmarks of cancer, high proliferation is associated with 
aggressiveness and poor clinical outcomes. (Fouad and Aanei, 2017; Hanahan and 
Weinberg, 2011). Within cancer cells, driver mutations can allow for growth-factor 
dependent activation through dysregulated cell cycle processes. When this ability of 
cell cycle control is lost, tumours harbour the ability to bypass the tightly-regulated 
processes of the cell cycle and hyper-proliferate (Gutschner and Diederichs, 2012).  
 
The uncontrolled proliferation of cancer cells reflects changes in the genetic and 
epigenetic landscape in the cancer cell (Gutschner and Diederichs, 2012). Different 
genetic and epigenetic alterations have been shown to give rise to different 
proliferative phenotypes for subtypes of T-ALL (Navarrete-Meneses and Pérez-Vera, 
2017). Therefore, proliferation is a suitable phenotype to test for ideas of ITH within 
Jurkat clonal populations. 
 
Cell proliferation assays are a simple technique to assess this phenotype amongst the 
derived Jurkat clones (Koyanagi et al., 2016). Flow cytometry-based analysis of 
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lymphocyte cell division uses the dye carboxyfluorescein succinimidyl ester (CFSE) 
(Azarsiz et al., 2018; Bocharov et al., 2013). This compound passively diffuses into cells 
and is not fluorescent until acetate groups are cleaved by esterases within the 
intracellular environment, resulting in fluorescent carboxyfluorescein succinimidyl 
ester (Azarsiz et al., 2018). CFSE stably labels intracellular proteins and the dye is 
equally partitioned between daughter cells during cell division. Therefore, each cell 
division results in each daughter cell having half the fluorescence intensity of the 
parental cell population (Azarsiz et al., 2018). This can be used in conjunction with 
real-time PCR (qPCR) expression analysis to test for phenotypic differences and 
transcriptional activity of T-ALL related genes. 
 
The use of qPCR is predominantly done for the purpose of quantifying specific gene 
expression by amplification of cDNA (Kralik and Ricchi, 2017). Genes that are 
characteristic of the TAL1 CRC (TAL1, GATA3, MYB and RUNX1) can be quantified 
for expression within Jurkat clonal cell lines to further characterise the gene expression 
profiles of these cell lines.  
 
The rationale of the study described here is that the generation of clonal populations 
of T-ALL Jurkat cells could be a way to understand ITH by identifying different clonal 
cell lines with different phenotypes that can be linked to genetic and/or epigenetic 
changes in each cell line. This chapter will describe the use of the CFSE assay to 
characterise the proliferation of the parental Jurkat T-ALL cell line as well as clonal 
cell lines derived from this cell line. This is linked to the analysis of gene expression 
to correlate proliferation with the expression of genes found within the TAL1 CRC.  
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2.2. Methods and Materials 
 
2.2.1. Jurkat Cell Thawing and Culturing 
 
Jurkat Clone E6-1 (ATCC TIB-152) was used to generate clonal populations. Jurkat 
cells were retrieved from cryogenic storage and immediately placed in a bead bath at 
37oC to thaw. Complete media (Gibco RPMI 1640 GlutaMAX + 25mM HEPES media 
supplemented with 10% Foetal Bovine Serum (FBS) and 1% Penicillin-Streptomycin-
Fungizone (PSF) (Gibco)) was pre-warmed to 37°C. Once cells were thawed, cells were 
aliquoted into 15mL Falcon tubes and 6mL of pre-warmed complete media was added 
to the tube within a sterile Biological Safety Class II cabinet. Cells were centrifuged at 
300 x g for 5 minutes, supernatant was discarded, and cells were resuspended in 7mL 
of complete media and aliquoted into a T25 Cellbind Surface flask (Corning). Cells 
were then cultured in a humidified incubator at 37°C and 5% CO2.  
 
2.2.2. Jurkat Cell Clonal Population Generation  
 
Thawed cells were passaged 2-3 times and clonal populations were isolated from the 
parental cell line (P0). Another parental population (P00) was also established as one 
passage different from P0. To do this, cells from the parental Jurkat cell line were 
resuspended at a concentration of 1x106/mL in RPMI 1640 complete media and 10µL 
was removed and diluted into 990µL of complete media. This was used to prepare 
two serial dilutions of 10 and 1 cell/200µL in a volume sufficient for plating 200µL into 
each well of a 96-well round-bottom plate (typically one plate was divided equally 
between the two serial dilutions). Each 96-well plate was left to grow for up to 2 weeks 
to allow for growth of clonal populations. Although the 10 cells/200µL dilution 
increased the likelihood of generating a clonal cell line, analysis of cell lines generated 
from the 1 cell/200µL concentration were prioritised.  
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Cell populations were grown to confluency based on appearance within the field of 
view (80% of FOV) within the 96 round-bottom plate and then passaged into a larger 
volume 12-well plate (Corning). Once cells reached a cell concentration of at least 
1x105/mL (Total of 1x106), cells were re-passaged into T25 flasks. Jurkat populations 
were then frozen down at a concentration of 1x106/mL with 10% DMSO at -80°C for at 
least 24 hours, then placed within cryogenic storage.  
 
2.2.3. Jurkat Clonal Populations 
 
A single stock of vials for each parental cell line and each clonal cell line was created 
and stored within the cryogenic storage and all experiments were conducted by taking 
one vial from this stock. Jurkat cell lines brought up from the storage were considered 
passage 1 after thawing. This was done as Ben-David et al. (2018) found that freeze-
thawing did not induce significant genetic variation. In this way, we generated 13 
Jurkat cell lines. This included the two parental cell lines (P0 and P00) and clonal cell 
lines 1-11 (C1-C11). However, due to the lack of growth of C7, it was excluded from 
any further analysis in all experiments done within this project. Therefore, the 
functional cell lines used were P0, P00, C1, C2, C3, C4, C5, C6, C8, C9, C10 and C11.  
 
2.2.4. Carboxyfluorescein Succinimidyl Ester (CFSE) assay 
 
CFSE (eBioscience ThermoScientific) was reconstituted with 90µL of anhydrous 
Dimenthyl Sulfoxide (DMSO) (Sigma Aldrich) for a stock concentration of 10mM. A 
CFSE stock dilution to 10µM was done by aliquoting 50µL of 10mM CFSE into 
49.05mL of Dulbecco’s phosphate-buffered saline (PBS) (Gibco). This was further 
diluted to 2µM and 1µM CFSE by aliquoting 10mL or 5mL into a final stock of 50mL 
with PBS, respectively. This was stored at -20°C covered in foil to avoid fluorescent 
bleaching.  
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Jurkat cell lines were grown in complete RPMI 1640 media (10% FBS, 1% PSF) until 
passages 1, 5 and 9. Cells were then harvested and resuspended in 0.1% FBS and 1% 
PSF RPMI 1640 media at a concentration of 1x105/mL for a 24 hours starvation. 
 
The CFSE experiments were done using 5x104 cells/well, with additional cells required 
from the parental P0 cell line for CFSE negative and 0-hour controls, and for cells to 
be stained with propidium iodide (PI) (Invitrogen). Cells were washed once in 1 x PBS 
by centrifugation at 300 x g for 5 minutes in a 15mL Falcon tube.  To label cells with a 
saturating concentration of CFSE, cells were then resuspended at a concentration of 
5x104 cells/200µl in 1 x PBS and mixed with an equal volume of 1µM CFSE (final 
concentration of 0.5µM CFSE) and incubated at room temperature covered in foil for 
10 minutes (as recommended by ThermoScientific). CFSE labelling was stopped by 
the addition of 4-5x volumes of 10% FBS, 1% PSF RPMI 1640 media (room 
temperature) and placed on ice for 5 minutes protected from the light. Cells were then 
centrifuged at 300 x g for 5 minutes, supernatant was removed, and cells were washed 
3 more times. Cells were then resuspended in pre-warmed (37°C) 5% FBS, 1% PSF 
RPMI 1640 media at a concentration of 5x104 cells/200µl and aliquoted at 200µL per 
well into the appropriate number of wells in a 96 well round-bottom plates. Positive 
(0-hour CFSE) controls were aliquoted at 200µL into 1.5mL centrifuge tubes. Cells 
were then incubated at 5% CO2 at 37°C for 48 and 72 hours until flow cytometry 
analysis.  
 
Negative (no CFSE) controls and 0-hour CFSE (positive) controls were run through 
the BD Biosciences Accuri C6 Plus flow cytometer to establish negative and positive 
gates to be used for CFSE analysis. The BD Accuri C6 Plus flow cytometer contains a 
488 nm (blue) and 640nm (red) laser with 4 detectors. Filters FL1-FL4 detect ranges of 
wavelengths of 533/30, 585/40, 670LP and 675/25, respectively as stated by BD 
Biosciences 
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(https://www.bdbiosciences.com/documents/BD_Accuri_C6Flow_Cyto_Instrument_
Manual.pdf). For CFSE detection, FL1 was used as CFSE has an emission spectrum of 
521nm (Thermo Fisher Scientific) and the PI stain (Invitrogen) was detected using the 
FL3 detector for an emission of 493/636nm. 
 
2.2.5. Propidium Iodide (PI) Staining  
Jurkat cells that were grown over 48 or 72 hours within 5% FBS and 1% PSF of 
complete RPMI 1640 media were harvested. Cells were then washed twice by adding 
2mL of PBS, centrifuging at 300 x g for 5 minutes and decanting the supernatant. Cells 
were then resuspended in 100µL of staining buffer (5% FBS in PBS) and mixed gently 
with 5µL of PI (250µg/mL) (Invitrogen) and incubated for one minute and avoiding 
light. Fluorescence of PI was then determined by flow cytometry as stated above.  
 
2.2.6. CFSE Analysis  
 
Jurkat cell lines were run through the BD Accuri C6 Plus Flow Cytometer and gated 
based on no CFSE, 0-hour CFSE controls and PI cell death stain controls. A limit of 
10,000 events was placed on the analysis per cell line (if possible) to avoid over 
saturation of fluorescence due to a large cell count. FCS files from the BD Accuri C6 
plus program were extracted and used to visualise results in the FlowJo Program 
(Version 10).  
 
FlowJo is a commonly used program for analysing and visualising Flow Cytometry 
data in an easy-to-use interface (Lugli et al., 2010; Quah et al., 2007). Raw overlay 
histograms were generated using FlowJo to display positive controls, negative 
controls and CFSE samples at 48 hours and 72 hours. The FlowJo proliferation module 
identifies patterns expressed by cells loaded with fluorescent dyes, such as CFSE. 
Using optimised algorithms, it models cell division based on gates created around the 
original 0-hour control population and conducts a peak analysis. 
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The FlowJo proliferation module outputs various values including: division index: 
average number of cell divisions that all cells have undergone, proliferation index: the 
average number of cell divisions that the ‘responding’ cells have undergone, 
expansion index: the fold-expansion of the overall population and replication index: 
fold-expansion of the ‘responding’ cells. The term ‘responding cells’ refers to the cells 
in the population that have undergone cell division at least once and is detected by 
FlowJo. FlowJo have recommended that the proliferation index (PI) is the most 
appropriate value to analyse as it is the closest to analysing proliferation processes 
biologically. Jurkat cell lines at specific passages were run through the proliferation 
module and gated based on the starting population and adjusted for optimal model 
fit of peaks through changing the option of the number of peaks within the module 
interface. Values were extracted and placed into .csv files and analysed per cell line 
and per passage.  
 
CFSE data was visualised using the R package and online platform, Plotly 
(https://plot.ly) to generate boxplots of PI values amongst clonal and parental cell 
lines. Data was further analysed using Socscistatistics Mann-Whitney U calculator 
(https://www.socscistatistics.com/tests/mannwhitney/). The Mann-Whitney U Test 
was used as a non-parametric test to see if sample values originate from the same 
distribution and compare between two independent samples (parental and clonal cell 
line populations) (Nahm, 2016).  
 
The data was also analysed by the Astatsa Kruskal-Wallis rank sum calculator 
(https://astatsa.com/KruskalWallisTest/) to identify statistical differences amongst 
multiple samples and further adjusted for multiple comparisons using a Dunn’s test 
(Nahm, 2016). The Dunn’s test was utilised as a Post-Hoc test after Kruskal-Wallis 
testing and recommended for its ability to identify precise statistical differences and 
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account for multiple sample comparisons (Lee and Lee, 2018). It is further 
recommended to use a Holm Family-Wise Error Rate (FWER) or Benjamini-Hochberg 
false discovery rate (FDR) p-value adjustments for rigorous testing (Lee and Lee, 2018) 
 
For box plot analysis of mild and extreme outliers, Plotly was used to retrieve values 
of the lower quartile (Q1) and the upper quartile (Q3). These values were used to 
calculate the inner and outer, upper and inner fences to establish thresholds to 
determine groups of proliferative ability of clonal cell lines at specific passages. The 
following calculations were used: 
 
Interquartile range (IQ): Q3 – Q1 
Lower inner fence: Q1 – 1.5 x IQ 
Upper inner fence: Q3 + 1.5 x IQ 
Lower outer fence: Q1 – 3 x IQ 
Upper outer fence: Q3 + 3 x IQ 
 
The Socscistatistics Friedman test calculator 
(https://www.socscistatistics.com/tests/friedman/default.aspx) was also used along 
with the Socscistatistics Wilcoxon-Signed Rank test calculator 
(https://www.socscistatistics.com/tests/signedranks/default.aspx). A Friedman Test 
was conducted due to its ability to assess non-parametric data and compare 
differences between multiple repeated measures (such as passages). This utilises a 
procedure called the ‘method of ranks’, similar to other non-parametric tests, and does 
not assume normality or homogeneity of variance amongst samples (Eisinga et al., 
2017). A pairwise comparison can then be conducted if differences are found within 
the Friedman test using the Wilcoxon-Signed Rank as a Post-Hoc test (Kim, 2014).  
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2.2.7. RNA isolation 
 
As described in sections 2.2.2 and 2.2.4, Jurkat cell lines (P0, P00, C1-C6 and C8-C11) 
were generated and tested for rate of proliferation at passages 1, 5 and 9. This was 
done after a 0.1% FBS and 1% PSF  starvation in RPMI 1640 media for 24 hours and 
cells were then grown in 5% FBS 1% PSF RPMI 1640 media for 48 and 72 hours 
(Methods: 2.2.1-2.2.4). In order to test the gene expression profiles of these Jurkat cell 
lines under the same treatment, Jurkat cell lines were grown under the same 
conditions for 72 hours and RNA was then harvested for gene expression analysis.  
 
RNA isolation was done using the Bioline RNA ISOLATE II Mini Kit 
(https://www.bioline.com/us/downloads/dl/file/id/885/isolate_ii_rna_mini_kit_prod
uct_manual.pdf). Purification was done according to the manufacturers’ instructions, 
with the exception that prior to the elution of RNA, an extra two-minute 
centrifugation at 11,000 x g was done with no added wash buffer. RNA was then 
eluted with 60µL of double-distilled H2O (ddH2O) and centrifuged at 11,000 x g for 
one minute. Eluted RNA was then measured for concentration using the Qubit 2.0 
Fluorometer using the Qubit 2.0 Fluorometer BR assay kit (ThermoFisher) as per the 
manufacturers’ instructions.  
 
2.2.8. cDNA Preparation  
 
For cDNA synthesis, 50ng of RNA was used in conjunction with a 5x TransAmp Buffer 
(Bioline) at a final concentration of 1x, and 1µL of reverse transcriptase (Bioline) in a 
total of 20µL. cDNA was synthesized using a thermocycler at: 25°C for 10 minutes, 
42°C for 15 minutes, 85°C for 5 minutes and hold at 4°C. The synthesised cDNA 
reactions were then diluted at a 1:1 ratio to have a final volume of 40µL to be used for 
qPCR gene expression analysis.  
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2.2.9. Primer Design  
 
Primers were designed based on the following method. Initially, the NCBI gene search 
engine (https://www.ncbi.nlm.nih.gov/gene/) was used to identify gene mRNA 
transcripts. Exon sequences that spanned at least one intron were copied into the 
Primer3 program (http://bioinfo.ut.ee/primer3-0.4.0/)  with the following parameters: 
Primer Length: 19-21, Tm: 59-61°C with a max Tm Difference of 1°C.  Primer sequences 
outputted from Primer3 were copied into the UCSC database through the ‘In-Silico 
PCR’ function (https://genome.ucsc.edu/cgi-bin/hgPcr). If targeted amplicons were 
identified in the UCSC database and showed mapping of primers to amplify exon 
sequences that span an intron, the primer was used. The following primer sets were 
made for the genes, TAL1, GATA3, RUNX1, MYB and NFYB (Reference Gene).  
 
| Table 2.1. Sequences for Forward and Reverse Primers of the genes, TAL1, GATA3, MYB, 
RUNX1 and NFYB. 
 
 
1Primer amplicon sequence information in Appendix – Supp. Table 7.7 and section 7.1.2.a. 
 
Primer efficiencies were tested with Jurkat cDNA at a starting concentration of 5ng 
with sequential 1:1 dilutions to 0.3125ng (5, 2.5, 1.25, 0.625 and 0.3125ng). Primer 
efficiencies were tested in triplicate at these concentrations and cycle threshold values 
(CT values) were extracted from qPCR analysis (Fig 2.9, y-axis). A standard curve of 
best fit was placed on all data points and the equation of the slope was derived and 
used to calculate for efficiency using the ‘qPCR Primer Efficiency Calculator’ by 
Gene1 Forward Primer 5’-3’ Reverse Primer 5’-3’ 
TAL1 CCCCCTATGAGATGGAGATT AAAGGCCCCGTTCACATT 
GATA3 CTCTCTGCTCTTCGCTACCC GCGACGACTCTGCAATTCT 
MYB TGGACCAAAGAAGAAGATCAGA TCTCCCCTTTAAGTGCTTGG 
RUNX1 ACTCGGCTGAGCTGAGAAATG GACTTGCGGTGGGTTTGTG 
NFYB AGATTGCAAAAGATGCCAAAG CGTTTCTCTTGATGGCACCT 
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ThermoFisher Scientific (https://www.thermofisher.com/au/en/home/brands/thermo-
scientific/molecular-biology/molecular-biology-learning-center/molecular-biology-
resource-library/thermo-scientific-web-tools/qpcr-efficiency-calculator.html). Primer 
efficiencies of 90-110% are ideal for conducting qPCR analysis (Rogers-Broadway and 
Karteris, 2015). 
 
2.2.10. Quantitative Analysis of Gene Expression (qPCR) 
 
The qPCR gene expression reactions were done using the SensiFAST SYBR No-ROX 
Kit (Bioline) that provides a 2x Master Mix containing SYBR Green I dye, dNTPs and 
qPCR stabilisers and enhancers (BioLine: 
https://www.bioline.com/downloads/dl/file/id/2754/sensifast_sybr_no_rox_kit_man
ual.pdf ). qPCR reactions were conducted in a final volume of 10µL that included 2x 
SYBR No-ROX (Bioline) at a final concentration of 1x, 2µL of diluted cDNA, and 
forward and reverse primers at a final concentration of 0.2µM each.  
 
qPCR reactions were carried out using an Applied Biosystems 7500 Fast Real-Time 
PCR System with the following cycling conditions: Initial denaturation at 95°C for 20 
seconds, cycling stage of 95°C for three seconds and 60°C for 30 seconds for 40 cycles. 
This was followed by a melt curve analysis with the following cycling conditions: 95°C 
for 15 seconds, 60°C for 60 seconds, 95°C for 15 seconds and 60°C for 15 seconds. After 
analysis was done, CT values were extracted and used for gene expression analysis.  
 
 
 
2.2.11. qPCR Gene Expression Analysis  
 
Gene expression was analysed using the 2- ddCT method (Rao et al., 2013) whereby CT 
values of target genes were normalised to a reference gene (dCT) and then relative to 
a control sample (ddCT). Fold difference was then calculated by using the 2-ddCT 
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formula. This formula assumes amplification of PCR products with 100% efficiency 
(Rao et al., 2013) which was confirmed prior to the analysis of gene expression.  
 
qPCR fold change data was visualised using the R package, ‘Pheatmap’ 
(https://www.rdocumentation.org/packages/pheatmap/versions/1.0.12) to generate 
the Euclidean Distance Hierarchical Clustering heatmap of all Jurkat cell lines at all 
passages (Command line in Appendix – section 7.1.2.b). Data was further analysed 
using Socscistatistics Friedman Test calculator 
(https://www.socscistatistics.com/tests/friedman/default.aspx) and the Wilcoxon-
Signed Rank Test (https://www.socscistatistics.com/tests/signedranks/default.aspx). 
The data was also analysed by the Astatsa Kruskal-Wallis rank sum calculator 
(https://astatsa.com/KruskalWallisTest/).  
 
A permutation test of gene sets is widely used in genomic research as it provides 
statistical inference with assumptions not being based on strict distributions of data 
(Bůžková et al., 2011). It conducts analysis through the comparison of observed values 
to the distribution of data from groups of permutations that would not affect the 
distribution if no difference between groups was observed (Bůžková et al., 2011). 
Despite permutation testing being widely used, it is computationally-demanding and 
the speed of the analysis can be compromised (Chang and Tian, 2016). Therefore, the 
package ‘GSALightning’ (https://github.com/billyhw/GSALightning) within the R 
programming language was used for this analysis. The GSA-Lightning package 
computes student-T statistics for each gene set and provides gene set statistics of 
significance (Chang and Tian, 2016). Command line in Appendix – section 7.1.2.c. 
2.3. Results 
 
2.3.1. Optimisation of CFSE assay using the Jurkat Clonal Populations 
 
Typically, CFSE staining of lymphocytes uses cell concentrations ranging from 0.5x106 
– 1x108/mL, with the concentration of CFSE ranging from a final of 0.5µM to 5µM, 
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dependent on the brand of CFSE used (Quah et al., 2007). It must be thoroughly 
resuspended in fresh media to buffer the toxic effects of the CFSE (Quah and Parish, 
2010).  Therefore, optimising the ratio of cell concentration to CFSE concentration is 
essential to maximise cell labelling while avoiding the toxic effects of  CFSE (Quah et 
al., 2007). Furthermore, the fluorescence intensity of CFSE is not stable within the first 
24-48 hours of an assay and labelled cells should be cultured for a minimum of 18 
hours before analysis, although changes in cell proliferation are not typically seen 
until after 48 hours of treatment (Quah et al., 2007). In the experiments described here, 
cells were left to grow for up to 72 hours to ensure valid detection of fluorescence.  
 
Initially, varying cell concentrations and CFSE concentrations were tested. The 
parental Jurkat cell line P0 was initially tested at a concentration of 2x104 cells/well. A 
lower concentration of cells was grown relative to that cited in the literature due to 
our use of 96-well round-bottom plates that have a cellular capacity of 2-10x104 
cells/well, and to ensure equal labelling of CFSE dye to cells as stated by ThermoFisher 
Scientific (https://www.thermofisher.com/au/en/home/references/gibco-cell-culture-
basics/cell-culture-protocols/cell-culture-useful-numbers.html).  
 
A separate control group of cells were permeabilised and stained with PI stain to 
detect a PI-positive population that represents dead cells (Fig 2.1A, i and ii). This 
allowed for the gating of the live cell population within the tested populations in 
conjunction with FSC and SSC parameters for size and granularity (Fig 2.1, i). Prior to 
labelling testing populations with CFSE, cells were starved in 0.1% FBS for 24 hours. 
This was required as Jurkat cells maintained in 10% FBS proliferated rapidly, diluting 
the CFSE out of the cell population within the first 48 hours (Appendix – Supp. Fig 
7.1). Therefore, cells were labelled at a final concentration of 0.5µM or 1µM of CFSE 
after starvation in 0.1% FBS and then cultured for up to 72 hrs in 0.5, 1, 2, 5 and 10% 
FBS (data not shown). It was found that at 5% and 10% FBS, a live cell population was 
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established relative to the 0.5-2% FBS which only displayed the dead cell population 
based on PI staining (data not shown).  
 
 
 
 
 
 
 
 
It was found that at 5% and 10% FBS, a live cell population was established relative to 
the 0.5-2% FBS which only displayed the dead cell population based on PI staining 
(data not shown and Fig 2.1). Therefore, further analysis of 5% and 10% FBS conditions 
were conducted for final 0.5µM and 1µM CFSE concentrations. Cell populations gated 
within 0.5µM and 1µM conditions varied in cell percentage at 5% FBS (19.6% vs 13.9% 
of the total population), similar to those seen using 10% FBS for duplicates tested (data 
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| Figure 2.1. Identification of Dead Cells using Propidium Iodide.  
 
(A) Propidium Iodide (PI) stained permeabilised Jurkat cells (P0, passage 1) gated within the dot plot (i) and 
displayed in the histogram plot (ii - red) as validation of the accurate gating of the dead cell population. Dot 
plot consists of the x and y axis displaying FSC and SSC, respectively and displaying dead cell population of 
34.9% and live stained cell population of 9.92% due to permeabilisation of Jurkat clonal cell lines. Histogram 
overlay plot displaying the dead cell gated population for fluorescence intensity of PI along the x-axis and 
cell count along the y-axis. Live stained and dead cells have a cell count of 2141 and 7522, respectively. 
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not shown). This suggests that CFSE a final concentration of 1µM becomes toxic to 
cells at concentrations of 2x104/well, despite FBS concentrations of 5% and 10% within 
each cell population.  
 
| Figure 2.2. Flow cytometry histogram plots of CFSE fluorescence at 0 and 72 hours post-labelling in the 
presence of 5% FBS.  
 
(A-B). Negative and positive controls are gated from the overall population of cells to show the non-stained 
cells in the population (negative control) and CFSE-stained cells (positive control) (respectively). A. Negative 
control showing fluorescence from cells not labelled with CFSE and cultured for 72 hours post-starvation and 
positioning of no CFSE gate (81.9% of cells exhibit no CFSE). B. Fluorescence of positive CFSE loaded cells and 
cultured for 0 hours after staining and positioning of CFSE stained gate (8.53%). Histogram plot of CFSE 
fluorescence immediately after labelling cells with a final concentration of 0.5μM CFSE and 0-hour CFSE-
positive gate.  
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| Figure 2.3. Flow-cytometry dot plots demonstrating the forward scatter (FSC) (x-axis) and side scatter 
(SSC) (y-axis) of Jurkat Cells to distinguish cell populations. 
 
Cells were grown over 72-hours with a final CFSE concentration of 0.5μM and tested with varying cell 
concentrations: A. 2x105/well (38.3% live cells); B. 1x105/well (30.2% live cells); C. 5x104/well (21.3% live 
cells) and D. 2x104/well (5.01% live cells). Gated cell populations (circle) display percentage of cells that are 
predicted to be live within the entire cell population based on size and granularity (FSC and SSC) and PI 
staining of dead cells (Fig 2.1).  
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| Figure 2.4. Flow cytometry histogram plots of CFSE stained Jurkat Clone 2 at cell concentrations of 
2x105, 1x105 and 5x104/well.  
 
(A-C, respectively) after 0.1% FBS starvation for 24 hours and grown in 5% FBS for 72 hours and stained 
with a final concentration of 0.5μM CFSE.  Gates were established based on the negative control (no CFSE 
stained sample) and display the percentage of cells within the total population that fall within the 
fluorescence of the negative control (8.81, 12.2 and 21.4% respectively). Cell count is demonstrated on the 
x-axis and CFSE fluorescence intensity is plotted logarithmically along the y-axis. 
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Flow cytometry histograms were graphed and gated based on CFSE unlabelled 
negative controls from the live cell gated populations and 0-hour CFSE-labelled 
positive controls (Fig 2.2,A and B, No CFSE and 0-hour, respectively). In a CFSE 
proliferation experiment, CFSE-positive cell populations should be visible as multiple 
peaks that represent differences in the proliferation of cells over the course of an 
experiment (Quah et al., 2007). At 5% FBS, a clearer resolution for multiple peaks were 
detected relative to the 10% FBS condition for 2x104/well (22% vs 9.58% - data not 
shown). However, despite higher cell numbers being available for analysis when 
using a final concentration of 0.5µM CFSE and 5% FBS, approximately 80% of cells 
were either not stained or fell within the dead cell population (data not shown). This 
led to further testing using different cell concentrations with 5% FBS and a final 
concentration of 0.5µM CFSE.  
 
Having observed that the outcome of a CFSE labelling experiment is dependent upon 
the concentration of FBS in the culture media, we next verified the optimal cell 
concentration to be used for this assay. Based on PI staining (Fig 2.1), live cell 
populations were gated with the percentage of live cells differing between cell 
concentrations:  38.3, 30.2, 21.3 and 5.01% of the total cell population at concentrations 
of 2x104, 1x105, 5x104 and 2x105 cells/well, respectively (Fig 2.3 – percentage in gated 
circle). At a cell concentration of 2x104/well, only 5% of cells were alive and therefore 
omitted from further analysis (Fig 2.3D – 5.01%), whereas all concentrations above this 
(2x105/well, 1x105/well and 5x104/well) displayed a range of 21-38% of cells being 
stained and alive (Fig 2.3A-C – 38.3%, 30.2% and 21.3%, respectively). Therefore, a 
histogram peak analysis of proliferation was done for cells grown at 5x104/well, 
1x105/well and 2x105/well (Fig 2.4). 
 
Using histogram peak analysis, cell concentrations of 2x105 and 1x105/well displayed 
a minimal number of CFSE peaks, and an absence of different proliferating cell 
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populations (Fig 2.4A,B). In contrast, a cell concentration of 5x104/well displayed 
multiple CFSE peaks that represented the differences in the proliferation of cell 
populations over 72 hours (Fig 2.4C). Therefore, it was concluded that prior to 
labelling with CFSE, cells would be starved in 0.1% FBS for 24 hours, labelled with a 
final concentration of 0.5µM CFSE, and plated at a concentration of 5x104 cells/well in 
5% FBS, and assayed at for 0, 48 or 72 hours. 
 
2.3.2. Analysis of proliferation index between Jurkat parental cell lines and the clonal cell lines 
 
The CFSE assay was used to test for differences in proliferation between clonal 
populations and in comparison, to the parental Jurkat populations (P0 and P00). As 
earlier work has shown cell passage number is an important determinant of genetic 
and phenotypic variability within cultured cell lines (Ben-David et al., 2018), and as 
the rationale for experiments described here is the correlation between phenotypic 
variability with genetic and/or epigenetic variability, all cell lines were grown 
continuously and analysed at passage numbers 1, 5 and 9.  
 
First, a comparison of proliferation between parental and clonal cell lines (C1-C6 and 
C8-C11) was conducted and plotted as a box plot using proliferation index (PI) values 
across all passages combined (Fig. 2.5A), as well at passages 1, 5 and 9 individually 
(Fig 2.5, B-D, respectively). No significant difference was found between parental and 
clonal cell lines for PI at passages 1 and 5 (Fig. 2.5, B and C, p > 0.05, Mann-Whitney 
2-tailed U-test, see also Table 2.2), although significant differences in PI between 
parental and clonal cell lines were found when all data for all passages was combined, 
and at passage 9 only (Fig. 2.5, A and D respectively, p < 0.05, Mann-Whitney 2-tailed 
U-test, see also Table 2.2). These results showed that parental and clonal cell lines are 
similar in terms of their proliferative ability within the first 5 passages but differ in 
their proliferative ability at passage 9, which also accounted for the significant 
difference in PI when all passage number data was analysed together.  
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| Figure 2.5. Proliferation indices for Jurkat parental and clonal cell lines.  
 
A. Proliferation indices for parental Vs clonal cell lines for all passages combined. B-D. Proliferation indices for 
parental Vs clonal cell lines at passage numbers 1, 5 and 9, respectively. Parental clone lines (P0 and P00) are 
represented in blue boxplots and the derived clones are displayed as red box plots. Passage 1 and 5 have a 
significance of p > 0.05 and passage 9 and all passages have a significance of p < 0.05 (*) as determined by a two-
tailed Mann-Whitney U test. (Parental cell line data, n=12;  clonal cell line data n=20). 
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2.3.3. Analysis of the proliferation index between different Jurkat clonal cell lines 
 
Next, differences in proliferation between individual clonal cell lines relative to the 
parental cell lines were investigated by plotting duplicate PI values from passages 1, 
5 and 9 (Fig 2.6). In comparison to the parental cell lines P0 and P00, and in particular 
when compared to P0, a large variation in PI between clones was seen across passages, 
such as C1, C5, C6, C9, C10 and C11 (Fig 2.6). This contrasts with clonal populations 
C3, C4 and C8 which showed a smaller variation of PI despite a higher median PI 
relative to the parental cell lines (P0 and P00) (Fig 2.6). Thus, the PI of each cell line 
per passage was tested using a Kruskal-Wallis rank test.  
 
Statistically significant differences were seen when analysing all cell lines at all 
passages using the Kruskal-Wallis test (p < 0.05). However when p-value 
readjustments were conducted using the Holm FWER and the Benjamini-Hochberg 
FDR method, no statistical differences were seen between cell lines at all passages 
(Appendix – Supp. Table 7.1-7.6). 
 
2.3.4. Subgrouping of Jurkat Clones based on a parental Jurkat cell line (P0) outlier analysis 
 
The analysis of parental and clonal cell lines showed statistically different 
distributions of PI, but Post-Hoc testing was unable to identify differences between 
individual cell lines. This led us to consider a different approach to understand 
differences in PI between individual cell lines. Using box plot outlier analysis (Kwak 
and Kim, 2017),  all cell lines at all passages were graphed and grouped based on 
outlier values within upper and lower inner and outer fences to determine 
subgroupings of proliferative ability. Upper and lower inner and outer fences were 
calculated based on the data distribution of the parental population (P0) (Methods: 
2.2.6) as all Jurkat clonal populations are derived from this original population. This 
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displayed how clonal populations isolated from this original population differ in PI. 
Values between inner fences and outer fences are considered as mild outliers and  
 
| Table 2.2. Mann-Whitney U test statistical test results of proliferation index (PI) of parental 
Jurkat cell lines (P0 and P00) and Jurkat clones (C1-C6, C8-C11). 
 
Sample p-value Significance (p < 0.05) 
All Passages 0.02 Yes 
Passage 1 0.27 No  
Passage 5 0.86 No 
Passage 9 0.03 Yes 
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| Figure 2.6. Boxplot display of proliferative index (PI) duplicate values per clone (n=6) at passages 1, 5 and 
9. 
 
Data points are displayed on the left of the respective boxplot. Dashed lines and solid lines indicate the mean 
and median of data distributed per boxplot, respectively. There is a significant difference in the PIs across all 
cell lines (Kruskal-Wallis test (p < 0.05), see also Appendix – Supp. Table 7.1-7.6). However, using the Dunn 
Post-Hoc test with p-value adjustments by Holm Family-Wise Error Rate (FWER) method, statistical 
differences were not seen between individual cell lines. 
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grouped as moderate high or low proliferation (Fig 2.7, values that fall between the 
upper or lower black dashed lines and the corresponding upper or lower boundary of 
the grey shaded region). Cell lines at all passages that fell outside of outer fences (Fig 
2.7, values that above or below upper or lower black dashed lines, respectively) were 
considered as extreme outliers and grouped as extreme high or low proliferation. The 
results of this outlier analysis showed that the majority of clones were placed within  
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| Figure 2.7. Outlier analysis of proliferative index for parental and clonal cell lines.  
 
Shown are coloured boxplots of individual cell lines, in each case representing duplicate PI values for each of 
passage 1, 5 and 9 (n=6). The horizonal black dashed lines represent the lower and upper outer fences 
calculated from P0 PI distribution for all cell lines at all passages. The upper and lower boundaries of the grey 
shaded area show the upper and lower inner fences. The grey shaded area is the region within which PI data 
values are not considered an outlier based on the distribution of data from the parental Jurkat cell line (P0) as 
the clonal cell lines are derived from this original population. Data points are displayed on the left of the 
respective boxplot, with a display of the median and mean of PI as indicated by the solid and dashed lines, 
respectively. Standard deviation of the data per passage is indicated by the peaks of the dashed lines (±).  
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| Table 2.3. List of Jurkat cell lines categorised by their proliferative ability from the boxplot 
outlier analysis (Fig 2.7) (see also Methods: 2.2.6 for calculation method).  
 
Category Cell Line Passage 
Extreme High 
C2 
1 
C3 
C8 
C10 
P00 
5 
C1 
C2 
C3 
C5 
C5 
C6 
C8 
C1 
9 
C2 
C3 
C5 
C6 
C8 
C9 
C10 
C11 
Moderate High 
C4 1 
C9 5 
Extreme Low 
C5 
1 
C6 
C11 5 
Moderate Low 
C1 1 
C10 5 
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the extreme high proliferation group (Table 2.3). This analysis also revealed a pattern 
of extreme high proliferation at passage 9 for a majority of the clonal cell lines but not 
the parental cell lines P0 or P00 (Fig. 2.7 and Table 2.3). Therefore, using the boxplot 
outlier analysis allowed the identification of subgroups within the Jurkat cell lines at 
different passages (Fig 2.7).  
 
The outlier analysis shows that a majority (n=9 out of 12) clonal cell lines exhibited 
extreme high proliferation at passage 9 (Table 2.3), therefore, the distribution of PI for 
cell lines was graphed per passage (Fig 2.8). This shows that the passage with the  
highest values are seen at passage 9, relative to passage 1 and 5. Differences in the PI 
between passages 1, 5 and 9 for all clonal cell lines were found to be of statistical 
significance using a Friedman Test (p < 0.1) (Fig 2.8). This was further analysed using 
a Wilcoxon Signed-Rank Two-Tailed test as a Post-Hoc test to do a pairwise 
comparison of two related samples/repeated measurements. Statistical differences 
between passage 1 and 9 as well as passage 5 and 9 (p < 0.03 and p < 0.003, respectively) 
were found (Table 2.4). Overall, this demonstrates that statistical significance between 
passages were identified. This follows the similar trend seen in earlier results of 
parental vs clone differences at passage 9 and through variability of PI values amongst 
specific cell lines to identify differential proliferative groups (Fig 2.7 and Table 2.3).  
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| Figure 2.8. Boxplot display of proliferative index (PI) data distribution of all clones at passage 1, 5 and 
9.  
 
Passages 1, 5 and 9 are shown as blue, red and yellow, respectively. Data points are displayed on the left 
of the respective boxplot, with a display of the median and mean of PI as indicated by the solid and 
dashed lines, respectively. Standard deviation of the data per passage is indicated by the peaks of the 
dashed lines (±). Statistical significance was tested using a Friedman Test, p < 0.1. Post-Hoc testing was 
done using a two-tailed Wilcoxon Signed-Rank test which conferred differences at passages 1 and 9, p < 
0.03 (*) and passages 5 and 9, p < 0.003 (**) (Table 2.4).   
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| Table 2.4. Post-Hoc test using Wilcoxon-Rank Sum Test results of pairwise-comparisons 
between passages 1, 5 and 9 (P1, P5, P9, respectively). Significance determined by p < 0.05 
(*). 
p-value P1 P5 
P5 0.91 - 
P9 0.03 * 0.003 ** 
 
Having characterised the proliferation profiles of parental and clonal cell lines, we 
next analysed the expression of genes found within the TAL1 CRC with a view to 
correlating phenotypic profiles with gene expression results.  
 
2.3.5. Optimisation of qPCR Gene Expression assay 
 
SYBR green is a commonly used fluorescent dye for quantifying dsDNA during 
amplification. However, limitations of non-specific binding must be considered when 
conducting analysis with this dye (Bustin et al., 2009). This includes primer efficiency 
analysis of primers used to amplify key cDNA transcripts (Wagner, 2013). This must 
be done to avoid differences in amplification and misrepresentation of fold change 
between genes using the 2-(ddCT) method (Sreedharan et al., 2018). Therefore, efficiency 
calculations of individual primer pairs are required prior to gene expression analysis. 
Primer pairs for TAL1, GATA3, RUNX1 and MYB were tested for amplification 
efficiency (Methods: 2.2.9) and all fell between the acceptable efficiency range of 90-
110% (Fig 2.9 A-D).  
 
It is also required to assess the ‘melting’ of template cDNA to assess for specific 
amplification of one product with the primers of interest (Wagner, 2013). This was 
done during the primer efficiency qPCR analysis for cycling conditions (Methods: 
2.2.10). All primers tested displayed similar melt curves between replicates for each 
gene tested (Fig 2.10), which displayed a single peak that represented the single 
melting temperature (Tm) that confirmed a single product being amplified (Bustin and 
Huggett, 2017).  
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2.3.6. Clustering of Jurkat clonal cell lines based on gene expression of the TAL1 CRC genes 
 
Data normalised using the 2- ΔΔCT were displayed as a Euclidean Distance Hierarchal 
Clustering Heatmap (Fig. 2.11). Euclidean Distance was used as a measure of 
correlation-based distances to distinguish patterns of expression amongst all parental 
and clonal cell lines at all passage points (Glazko and Mushegian, 2010). Glazko and 
Musehgian (2010) show that Euclidean Distance identifies similarity in gene 
expression profiles between samples, whereas other correlation-based distance 
measures over-estimate the divergence of gene expression patterns. This was paired 
with a hierarchical cluster analysis to further group the patterns of expression 
amongst all the parental and  clonal cell lines (Zhang et al., 2017c). Using this method, 
three groups can be seen amongst the highlighted black boxes from the clustering 
analysis (Fig 2.11).  
 
The hierarchical analysis displays three groups that have varying levels of expression 
of the four T-ALL complex genes, relative to the parental cell line at passage 1 (P0). 
These groups were classified as GATA3+, TAL1+ and RUNX1/MYB+ based on Euclidean 
distance that accounts for overall distance amongst cell lines at passage points and 
gene expression, expressing the relative relationship of these two parameters (Fig 
2.11). 
 
The range of standardised expression is between -2 and +2, representing that these 
differences that are highlighted are across a small range of fold expression (Fig 2.11 – 
scale bar). For the GATA3+ group fold change ranged between 0.52 to 2.02 for GATA3 
expression, the TAL1+ group displayed a range of fold change from 0.39 to 2.02 for 
TAL1 expression, and the RUNX1/MYB+ group displayed a range of fold change from 
0.25 and 0.2 to 2.17 and 1.58 for RUNX1 and MYB expression, respectively. Through 
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| Figure 2.9. (A-D) Primer Efficiencies for TAL1 CRC genes.  
 
Scatter plots of triplicate CT values (y-axis) against log sample quantity (Dilution factor 2) (x-axis) for gene 
primers, TAL1, GATA3, RUNX1 and MYB, respectively (10ng of cDNA with a final primer concentration of 0.2μM 
in reaction). The slope equation of the standard curve (light blue line) is displayed (red) which was used to test 
the primer efficiency (black) per gene set (Methods 2.2.9). 
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| Figure 2.10. (A-D) Melt Curve analysis of TAL1 CRC primers.  
 
Melt Curve plot of triplicate amplicons generated through primer efficiency optimisation for 
gene primers (Fig 2.9), TAL1, GATA3, RUNX1 and MYB, respectively (10ng of cDNA with a final 
primer concentration of 0.2μM in reaction). Derivative reporter (negative first derivative of 
normalised fluorescence (Rn) by the reporter) on the x-axis and temperature on the y-axis. A 
single peak indicates the ‘melting’ of a single amplicon product after qPCR gene expression 
analysis. 
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the use of Euclidean Distance, these fine-tuned patterns of differential expression of 
relative genes can be seen amongst all Jurkat cell lines and passages.  The heatmap 
further displays an inverse relationship of TAL1 expression and GATA3 (Fig 2.11 - 
indicated by the dark blue regions). However, RUNX1 and MYB expression was 
moderate (values of 0.5-1) amongst all cell lines that didn’t fall within the 
RUNX1/MYB+ group regardless of TAL1 and GATA3 expression (Fig 2.11).  
 
Based on the Euclidean Distance Hierarchical Clustering heatmap (Fig 2.11), patterns 
amongst Jurkat cell lines and their expression per passage point revealed sub-groups 
of Jurkat parental and clonal cell lines (Table 2.5). This displayed a pattern of each 
Jurkat population falling within the same gene grouping amongst all passages with 
specifically the parental cell lines grouping within the TAL1+ group (Table 2.5).  
However, clones 1 and 2 displayed differential gene expression patterns which fall 
between different groupings. Specifically, C1 was seen to fall within the GATA3+ 
group at passage 1 as opposed to its placement in the RUNX1/MYB+ group at passage 
5 and 9 (Table 2.5). For C2, at passage 1 and 9 it has expression patterns that fall into 
the TAL1+ group as opposed to its placement in the GATA3+ group at passage 5 (Table 
2.5). Individual cell lines at each passage were not tested for differential gene 
expression as each value represents duplicates and did not provide sufficient data for 
a robust analysis. Overall, three distinct gene expression groupings were identified 
and could be used for further analysis into the correlation of these groupings with 
proliferative ability.  
 
2.3.7. Permutation Analysis for TAL1 CRC genes 
 
In order to analyse functional properties of differentially expressed genes, a gene set 
analysis must be done. This is a self-contained method of testing a pre-defined gene 
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| Figure 2.11. Euclidean Distance Hierarchical clustering of TAL1 CRC gene expression amongst Jurkat cell 
lines at passages 1, 5 and 9. 
 
 Euclidean Distance heatmap of fold expression patterns for parental cell lines and Jurkat cell lines (y-axis) at 
passages 1, 5 and 9 (brackets) for genes TAL1, GATA3, RUNX1 and MYB (x-axis) displayed through hierarchical 
clustering. Fold expression was calculated with the 2-ddCT method relative to the NFYB reference gene and the 
Jurkat parental clonal cell line (P0 at passage 1). Scale of Euclidean Distance is shown from -2 to +2 and 
hierarchical clustering dendrograms display patterns of Jurkat cell line fold expression of each gene. Black 
boxes indicate gene groupings of cell lines based on hierarchical clustering.  
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set for differential expression across two different experimental conditions (such as 
parental cell line vs clonal cell line) (Chang and Tian, 2016).  
 
A q-value output is utilised as it measures level of significance in regards to a more 
stringent false discovery rate method rather than the p value false positive rate (Table 
2.6) (Storey and Tibshirani, 2003). The results of the permutation analysis display no 
statistical differences between gene sets when comparing Jurkat parental (P0) at each 
passage (Control) and the remaining cell lines at all passages and amongst each 
passage (Table 2.6). It is only at passage 5 (*) that a statistical difference between the 
TAL1 gene set can be seen to be significantly up-regulated in the control (P0 and 
passage 5) (q < 0.1 – threshold determined by GSALightning developers) (Table 2.6). 
This suggests that within passage 5, TAL1 gene expression is significantly higher 
within the parental cell line, P0, in comparison to the remaining clonal cell lines. 
 
2.3.8. Differences between Jurkat clonal cell line gene expression between passages 
 
Based on the permutation analysis, further investigation into the differences within 
gene sets between passages was instigated. This was done using a Friedman Test as 
an assessment of multiple sets non-parametric data representing different analysis at 
different passage points (Eisinga et al., 2017). This concluded that all genes tested 
amongst the cell lines (n=12) were differentially expressed between passages (p < 0.05 
for TAL1 and MYB, p < 0.01 for GATA3 and RUNX1) (Appendix – Supp. Table 7.8). As 
a result of this, a Wilcoxon Signed-Rank Test was done for all comparisons as a Post- 
Hoc test (P1 vs 5, P1 vs 9 and P5 vs 9) (Appendix – Supp. Table 7.9). The Wilcoxon test 
concluded that significant differences within TAL1 and GATA3 gene expression was 
seen for passages 1 and 5 and 9 and 5 (p < 0.05). However, for expression of RUNX1, 
passages 1 and 5 and 1 and 9 were statistically different (p < 0.05) (Appendix – Supp. 
Table 7.9). For the expression of MYB, passages 1 and 5 were the only comparisons 
that were of significance (p < 0.05) (Appendix – Supp. Table 7.9). Therefore, for genes 
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| Table 2.5. List of Jurkat cell lines and their passage number for the gene expression groups 
identified through Euclidean Distance and Hierarchical Clustering of fold expression patterns. 
Group Cell Line Passage 
GATA3+ 
C1 1 
C2 5 
C4 
1 
5 
9 
C11 
1 
5 
9 
TAL1+ 
P0 
1 
5 
9 
P00 
1 
5 
9 
C2 
1 
9 
C10 
1 
5 
9 
RUNX1/MYB+ 
C1 5 
9 
C3 
1 
5 
9 
C5 
1 
5 
9 
C6 
1 
5 
9 
C8 
1 
5 
9 
C9 
1 
5 
9 
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| Table 2.6. Permutation q-values amongst gene sets at passage 1, 5, 9 and all passages 
combined determined by GSALightning R package.  
q-value Passage 1 Passage 5 Passage 9 All Passages 
Gene Control Experiment Control Experiment Control Experiment Control Experiment 
GATA3 0.16 0.85 0.43 0.99 0.56 1 0.50 0.88 
MYB 0.16 0.92 0.28 0.99 0.35 1 0.50 0.88 
RUNX1 0.16 0.83 0.27 0.99 0.37 1 0.59 0.88 
TAL1 0.16 1 0.03* 0.99 0.42 1 0.17 0.96 
1 Analysis based on the upregulation of the control (P0) or experiment (all clones). Significance at p < 0.1 (*). 
 
TAL1 and GATA3, there is a progression of change between passages 1 and 5 and 5 
and 9, however the difference is not large enough between passage 1 and 9 to be 
detected. Whereas RUNX1 showed changes of expression from passage 5 and 
onwards. For the expression of MYB, changes are seen between passages 1 and 5, 
however are reverted back to similar distributions of expression after passage 5 
according to the Wilcoxon-Rank Sum test (Appendix – Supp. Table 7.9). This shows 
that differential expression of each of these genes is observed between passages. 
 
2.3.9. Statistical testing of Jurkat gene expression groups  
 
Gene expression groups identified through the Euclidean Distance Hierarchical 
Clustering were statistically tested for differences between expression of each gene. 
This was conducted using a Kruskal-Wallis test as a non-parametric assessment of 
multiple samples (Nahm, 2016) (Table 2.7). The initial Kruskal-Wallis test will identify 
differences between at least two samples and a further Post-Hoc test must be done for 
pairwise comparisons (Kim, 2014). This found statistical differences between groups 
with TAL1 and GATA3 expression (p < 0.03 and 0.02, respectively), however not found 
for RUNX1 and MYB (Table 2.7). A Post-Hoc test was conducted to further adjust p-
values for multiple comparisons. This was done with the Dunn test and further 
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adjusted using the Holm FWER and the Benjamini-Hochberg FDR test. Both 
adjustments concluded that no statistical differences between the expression of TAL1 
and GATA3 amongst the expression groups were found (Appendix – Supp. Table 7.10-
7.13).  
 
Due to no statistical differences being found for gene expression groups TAL1+, 
GATA3+ and RUNX1/MYB+, a correlation test was conducted. A Spearman’s Rho 
assessment was done for the genes expressed amongst each expression group. The 
Spearman’s Rho test accounts for non-parametric data and develops a correlation 
coefficient based on the calculated ranks from the data tested (Akoglu, 2018). It was 
determined that all groups and all samples tested had gene expression correlation 
amongst all genes (Appendix – Supp. Table 7.14 - 7.17).  
 
| Table 2.7. Kruskal-Wallis test statistics of differences between gene expression groups 
(TAL1+, GATA3+ and RUNX1/MYB+) for expression of the genes TAL1, GATA3, RUNX1 and MYB.  
 
Gene Expression p-value < 0.05 Significance 
TAL1 0.03 Yes 
GATA3 0.02 Yes 
RUNX1 0.94 No 
MYB 0.61 No 
 
2.3.10. Gene Expression and its relationship with the Jurkat cell line proliferation phenotypes 
 
An understanding of the phenotypic differences identified within Jurkat cell lines and 
the gene expression profiles of these cell lines is required to understand heterogeneity. 
Jurkat cell lines were characterised by their proliferative ability as a measure of a 
proliferation index (PI) – an average number of cell divisions of cells ‘responding’ to 
the re-introduction of serum after starvation. These cell lines were categorised into 
groups determined by their proliferative ability and a boxplot analysis of outliers. The 
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groups identified were the moderate and extreme high and low proliferative groups, 
where a majority of cell lines fell within the extreme high category (n = 20 out of 27).  
 
The cell lines within these groupings were then correlated to the expression profiles 
of the tested genes. This was conducted with the Spearman’s Rho Test for non-
parametric data. It was found that there was no correlation of the relative fold gene 
expression of the T-ALL genes to the proliferative abilities of the cells within the 
extreme high proliferation group (p > 0.05) (Appendix – Supp. Table 7.18). Analysis 
could not be done with the moderate high, moderate low and extreme low categories 
as their sample sizes ranged from n=4-6. Therefore, no relationship between 
proliferation and proliferative abilities of the moderate high, extreme high, moderate 
low and extreme low proliferative groups were found. A correlation test between the 
gene expression groups (TAL1+, GATA3+ and RUNX1/MYB+) and proliferation was 
also conducted, which yielded no correlations (Appendix – Supp. Table 7.19). Overall, 
demonstrating that TAL1 CRC genes tested had no correlation to the proliferation of 
Jurkat cell lines. 
 
2.4. Conclusion 
 
In conclusion, the aim of this analysis was set out to identify differences between 
Jurkat clonal populations and establish groupings of these cell lines by their 
proliferative ability using a cell proliferation CFSE assay and were correlated to gene 
expression profiles by qPCR with relative expression to the parental Jurkat population 
(P0) at passage 1. It was found that proliferation (as measured by PI) between parental 
populations (P0 and P00) and the derived clonal cell lines was statistically different at 
passage 9. The qPCR gene expression analysis identified key gene identity groups 
(TAL1+, GATA3+ and RUNX1/MYB+) that suggest differential gene expression patterns 
between cell lines. However, despite these patterns being revealed through Euclidean 
Distance Hierarchical Clustering, no statistical differences between these groups 
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could be distinguished. Finally, correlations between proliferation index values 
acquired from phenotype characterising of Jurkat cell lines and gene expression 
profiles for these cell lines was conducted. This concluded no correlations between 
gene expression groups and proliferation groups amongst Jurkat cell lines. Therefore, 
these patterns suggest a deeper-rooted mechanism, or a larger scope of genes that may 
be involved or reflect Jurkat proliferative abilities.  
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Chapter	3 -	Bioinformatic	
analysis	of	the	TAL1	locus	
 
3.1. Introduction 
 
Bioinformatics is an interdisciplinary field at the intersection of molecular biology, 
genetics, computer science and statistics (Can, 2014). It investigates complex biological 
problems using large data sets by using computational algorithms and models (Can, 
2014). The potential power of genomics in a clinical health setting is exemplified by 
the Broad Cancer Genome atlas, as well as the UK Biobank (Sudlow et al., 2015; 
Tomczak et al., 2015), with initiatives such as these providing a detailed molecular 
picture of our genomes with a view to translating genomics into better healthcare. 
Through advancements in next-generation sequencing technology and robust data 
sets created by the ENCODE project, bioinformatics pipelines are becoming 
increasingly easy to use and understand (Coccaro et al., 2019). Not only does 
bioinformatics analysis allow for robust high-throughput processing of such complex 
data but, there is a community of practice that requires authors to make their data 
public through submission to open and accessible databases, such as the NCBI GEO 
datasets (Clough and Barrett, 2016). This allows for analysis of the data by scientists 
who work within the field but may not have generated the data themselves. The 
involvement of a larger community in data analysis has benefits in terms of quality 
control of the data as well as novel analyses that arise from the combination of 
multiple data sets.   
 
Next-generation DNA sequencing of DNA recovered from chromatin 
immunoprecipitation experiments (ChIP-Seq) maps the genome-wide locations of 
transcription factor (TF) binding and the sites of histone modifications (Jiang and 
Mortazavi, 2018). The ENCODE project has provided a valuable archive of data that 
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maps epigenetic markers throughout the genome in multiple cell types (Consortium, 
2004; Davis et al., 2018; ENCODE Project Consortium, 2011; Zacher et al., 2017). These 
epigenetic markers identify regulatory DNA elements, such as enhancers, that 
modulate gene expression (Blinka et al., 2017). To map putative enhancers requires 
information on specific chromatin markers such as histone subunit 3 lysine 27 
acetylation (H3K27ac) and DNAseI Hypersensitivity (DHS) (Calo and Wysocka, 
2013). Promoters can be differentiated from enhancers through the additional 
enrichment of histone subunit 3 lysine 4 trimethylation (H3K4me3) in combination 
with H3K27ac and DHS (Calo and Wysocka, 2013). 
 
Within Jurkat T-ALL cells, Mansour et al. (2014) have discovered a key functional 
super-enhancer region that is enriched in read depth and breadth for the active 
enhancer marker, H3K27ac. It was revealed that this region contains a heterozygous 
12-bp insertion that aligns with TAL1, GATA3, RUNX1 and MYB ChIP-seq 
enrichment (Mansour et al., 2014). This mono-allelic overexpression of TAL1 in Jurkat 
T-ALL cells is also further correlated with DNA hypomethylation at the TAL1 TSS, 
allowing for expression of the gene, however DNA methylation across the locus at 
intergenic and intragenic regions that map to regulatory elements in the context of 
clonal heterogeneity is not known (Haider et al., 2018). Although the 12-bp insertion 
mutation has created a super-enhancer, we suggest that other intra- or intergenic 
enhancers may exist across the TAL1 locus.  
 
The aims of this chapter are to use bioinformatic analysis of large genomic datasets to 
identify intra- and intergenic enhancers across the TAL1 locus and to then determine 
the DNA methylation patterns in the parental and clonal Jurkat T-cell lines (Chapter 
2) at possible intra- and intra-genic enhancers in Chapter 4.  
  
67 
 
 
3.2. Methods  
 
3.2.1. Source and type of ChIP-seq Data 
 
ChIP-seq BAM files (aligned reads) and BroadPeak/NarrowPeak files (Peak Data) 
were downloaded for markers of DHS, H3K27ac and H3K4me3 (BroadPeak files were 
prioritised over NarrowPeak files because histone modifications are better analysed 
as broad domains of enrichment (Starmer and Magnuson, 2016)) from the ENCODE 
Project Consortium, which  provides high-quality data available in file formats that 
include processed and aligned raw sequencing data 
(https://www.encodeproject.org/). ChIP-seq data for Jurkat and T-cell primary cell 
lines for H3K27ac and H3K4me3 were downloaded from the European Nucleotide 
Archive from The European Bioinformatics Institute (https://www.ebi.ac.uk/ena) for 
FASTQ files. ChIP-Seq data included: Jurkat cell line, a B-cell line (CD20RO01794 and 
CD20RO01778), monocyte primary cells (MonoCD14+), normal CD4+ T-cells (primary 
T-Helper (Th) 1, 2 and 0) and other cell lines that aren’t categorised in these groups 
such as A549 (small lung carcinoma), HMEC (endothelial mammary) and NHEK 
(Keratinocytes). Origins and accession numbers for all files downloaded are in 
Appendix – Supp. Table 7.20 – 7.23.   
 
3.2.2. Quality Control Processing of ChIP-Seq Files 
 
All BAM and FASTQ files were run through the ‘FastQC’ program 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc). The FastQC program is 
one of the most commonly used quality control programs for FASTQ, SAM and BAM 
files that provides metrics on the quality of the sequencing run per sample (Park et al., 
2017; Trivedi et al., 2014). One of the metrics that can be derived from the FastQC 
program is a Phred Score. Phred scores determine the quality of base-calling during 
sequencing and thus has been used as a measure for the files processed for this project. 
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Phred scoring of data is essential for ensuring quality for bioinformatics analysis, as 
processing of low-quality files will result in inaccurate outputs for analysis  (Zhang et 
al., 2017b).  It is recommended that files with a median Phred score below 25 or 20 are 
flagged with a warning or a failure for quality, respectively 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc). This measure was used 
to assess files tested and generated metrics from FastQC of the overall quality and for 
specific categories that included: sequencing adaptor content and the need to trim 
sequencing files, GC content, and sequence length distribution (example of quality 
score across all bases in Appendix - Supp Fig 7.2).  
 
In cases where sequencing files displayed a Phred score below 25 (but not below 20), 
trimming was conducted to remove low quality reads and remaining adaptors. The 
package ‘FastP’ was utitlised for its ability to provide pre-processed clean data for 
ChIP-seq analysis (Chen et al., 2018) (command line in Appendix – 7.2.3.a). The FastP 
program also provides metrics on quality of the files before and after trimming (Supp. 
Table 7.24). After trimming, files were run through ‘FastQC’ again to reassess quality, 
if they still fell below the threshold of a Phred score of 25, they were eliminated from 
further analysis (Supp. Table 7.24).  
 
3.2.3. FASTQ sequencing file genome alignment, conversion and peak calling 
 
After testing the quality of FASTQ files downloaded from the ENA database, FASTQ 
files were aligned to a reference genome (GRCh37/hg19) using the Python package, 
‘Bowtie2’ (Bailey et al., 2013; Zhang et al., 2016b). The resulting SAM files were 
converted using the default parameters for single end read files and further converted 
to a BAM file using the ‘Samtools’ package (Li et al., 2009; Steinhauser et al., 2016). 
Examples of command lines for this processing pipeline can be found in Appendix 
(7.2.3.b and c).  
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Quality checks of SAM and BAM files can be done using the FastQC program to 
ensure that processing milestones within the pipeline are conducted properly. These 
were done for the remaining files left for the analysis. When these SAM/BAM files are 
generated through the processing pipeline, they are unsorted and require an 
additional step to have them sorted by coordinate (Li et al., 2009). The ‘Samtools’ 
package also conducts sorting of converted BAM files (command line in Appendix – 
7.2.3.c).  
 
Once all BAM files from ENA were processed, the remaining files needed for 
differential binding analysis required calling of ChIP-seq read peaks. Using the online 
database ‘Galaxy’ (https://usegalaxy.org/), all BAM files were uploaded, including 
control files from designated experiments, and were called for peaks using the 
‘MACS2 peakcall’ option. The following default parameters for MACS2 were used: 
Building of a shifting model, lower mdfold bound: 5, upper mfold bound: 50, band 
width: 300, peak detection based on: q-value, FDR threshold: 0.05. The output 
provided a quality assessment through a peak model plot of the aligned datasets and 
cross-correlation plot as well as provide BroadPeak files and a BED file of the peaks 
called.  
 
Peak model plots and the cross-correlation plots provided by MACS2, display a visual 
representation of the quality of the ChIP-Seq data. Within the cross-correlation plot, a 
single peak should appear displaying a larger fragment-length peak compared with a 
read-length peak (see: https://hbctraining.github.io/Intro-to-
ChIPseq/lessons/06_combine_chipQC_and_metrics.html) (Appendix - Supp. Fig 
7.3A). Through the output of a peak model plot by MACS2, further verification of the 
quality of the ChIP-seq files could be seen through the combination of positional 
information and reads from both strands to more accurately map the location of a 
  
70 
peak. (see: https://hbctraining.github.io/Intro-to-
ChIPseq/lessons/05_peak_calling_macs.html) (Appendix - Supp. Fig 7.3B).  
 
3.2.4. ChIP-Seq Differential Binding Analysis (DBA) 
 
A common issue found with the analysis of ChIP-seq data is the comparison and 
normalisation of the total sequencing library and peak analysis between different 
experiments (Wu et al., 2015). Typically, input controls are used to account for 
background noise, however, regions with extreme copy number variation could still 
impact the final result (Wu et al., 2015).  
 
The R programming package ‘DiffBind’ was utilised for its full library normalisation 
and its use of the known ChIP-seq differential binding programs ‘DESeq2’ and ‘edgeR’ 
(Brown, 2011; Steinhauser et al., 2016). As a first step in identifying differentially 
bound peaks between different samples, DiffBind was used to assess the quality of 
replicate samples by assessing the degree of consensus of identified peaks, as FastQC 
does not assess the quality of the experiment prior to sequencing (biological replicate 
consensus). We set a minimum threshold of 70% peak consensus between replicate 
samples. However, an exception was made for data from the Jurkat cell line (Table 
3.1).  
 
Next, the correlation between samples were analysed through counting the reads 
within the data which was normalised using the TMM method (Trimmed mean of M). 
This normalises two samples by detecting overall enrichment between loci without 
the assumption of differentially expressed reads (Robinson and Oshlack, 2010). 
Parameters were set to have a minimum overlap of 2 samples with consensus peaks 
(see: https://support.bioconductor.org/p/57809/). After normalisation, read count 
heatmaps that display relationships between samples were produced with the 
inclusion of a z-score plot to show the standard deviation distribution of data 
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according to the population mean (e.g. Fig 3.2) (Curtis et al., 2016). Then, a differential 
binding analysis (DBA) was conducted to identify contrasts between various groups 
established, such as Lymphocyte vs Other Non-Immune cell lines (H3K27ac and 
H3K4me3) OR Immune vs Non-Immune cell lines (DHS), T-cell vs Jurkat and Jurkat 
vs DND41 (command line in Appendix – 7.2.3.d). This outputs a DBA heatmap that 
displays the relationship between samples that were contrasted and a DBA report of 
the Genomic Ranges (GRanges Object). The GRanges report displays the regions of 
differential binding, the fold change between contrasts, raw p-values and corrected 
FDR values found between contrasted regions (example of Top 50 results for DHS 
DBA – Supp. Table 7.25).  
 
Using ‘DiffBind’ the following assessments of differential binding were conducted: 
immune cells and cell lines (Jurkat, primary cell lines, Th1, Th2, Th0 and MonoCD14) 
in comparison to other non-immune cell lines (SAEC, NHEK, A549, HMEC and 8988t) 
to establish a differential binding signature of immune cells overall for DHS DBA, or 
non-immune cell lines in comparison to lymphocyte cell lines (B-cells CD20RO01778 
and CD20RO01794 and Jurkat) and primary cells (primary Th1, Th2 and Th0) for 
H3K27ac and H3K4me3 DBA. Lastly, a comparison between other primary CD4+ T-
cell lymphocytes (primary Th1 and Th2) and the Jurkat T-ALL cell line was conducted 
to establish differential binding specific to TAL1+ T-ALL. To further this analysis, 
ENCODE H3K4me3 and DHS data from the T-ALL cell line DND41 was used to 
identify differential binding against the Jurkat cell line (T-ALL vs TAL1-T-ALL) 
(Accession Numbers in Appendix – Supp Tables 7.20 – 7.23).   
 
3.2.5. Processed data visualisation in the UCSC genome browser 
 
Pipeline processed ChIP-seq files from ENA and the pre-processed files from 
ENCODE were then visualised within the UCSC genome browser 
(https://genome.ucsc.edu/). Non-ENCODE BAM files were converted to BIGWIG 
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format through the database ‘Galaxy’ (https://usegalaxy.org/), using the 
‘bamCompare’ option from ‘deepTools’. This allowed for the normalisation of BAM 
files to input control BAM files with the output of a BIGWIG file for visualisation in 
the UCSC genome browser (Ramírez et al., 2014). These files were then uploaded into 
the ‘CyVerse’ server to provide a URL of the BIGWIG files to upload into the UCSC 
genome browser.  
 
All files for regulatory DNA element markers (H3K27ac, DHS and H3K4me3) for 
different cell lines were uploaded into the UCSC genome browser, as well as a file of 
regions identified through DiffBind that included statistically significant differentially 
bound peaks between cell lines tested.  Looping interactions between regulatory 
elements across the TAL1 locus was also visualised through the GeneHancer database. 
GeneHancer is a database that provides data related to enhancers and frames regions 
of enhancer interactions throughout the genome. It specifically integrates data from a 
total of 434, 000 reported enhancers from the ENCODE project, the Ensembl 
regulatory build, VISTA Enhancer browser and the Functional Annotation of the 
Mammalian genome (FANTOM) project (Fishilevich et al., 2017). This database links 
enhancers to genes by using information such as tissue expression correlation between 
genes and eRNAs, transcription factor binding sites, Hi-C data, and expression 
quantitative trait loci variants (eQTLS) and was therefore used for this analysis. 
(Fishilevich et al., 2017). With an additional track from the GTEx database of RNA 
transcripts for thyroid and whole blood cell types.  
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| Table 3.1. List of cell lines tested for consensus peaks in replicate samples using 'DiffBind' 
consensus peak overlap. 
1Cell lines with a percentage overlap of > 70% (green) were used in the following differential binding analysis 
whereas replicate consensus < 70% were excluded (red). Jurkat cell lines were used regardless of percentage 
overlap (yellow). 
 
 
 
 
 
Primary cells/Cell Line Marker Tissue Rep 1 Consensus Rep 2 Total Peaks 
Percentage of 
replicate peak 
overlap1 
CD20RO01778 H3K4me3 B-Cell 21177 35410 20778 77365 45.7 
DND41 H3K4me3 T-ALL  25790  25790 100 
Jurkat H3K4me3 TAL1+ T-ALL 15573 31423 27187 74183 42.4 
MCF7 H3K4me3 Adenocarcinoma 61396 47209 43349 151954 31.1 
SAEC H3K4me3 Lung Epithelial 12026 24776 15439 52241 47.4 
NHEK H3K4me3 Keratinocytes 13413 23971 16045 53429 44.9 
A549 H3K4me3 Lung Cancer  74621  74621 100 
A549v2 H3K4me3 Lung Cancer 23520 39428 32169 95117 41.5 
HMEC H3K4me3 Endothelial Mammary Gland 29578 33548 29484 92610 36.2 
AG04449 H3K4me3 Skin Fibroblast 32524 40704 26667 99895 40.7 
AG04450 H3K4me3 Lung Fibroblast 40488 30358 26667 97513 31.1 
DND41 H3K27ac T-ALL  39585  39585 100 
HMEC H3K27ac Endothelial Mammary Gland 
 57262  57262 100 
Jurkat H3K27ac TAL1+ T-ALL 1504 9195 4485 15184 60.6 
NHEK H3K27ac Keratinocytes  57797  57797 100 
Th2 H3K27ac T-Cell 791 32772 744 34307 95.5 
A549 
 DGF 
Lung Cancer 
 
23273 
 
95564 
 
39452 
 
158289 
 
60.4 
 
CD20RO01778 
 DGF 
B-Cell 
 
57357 
 
89317 
 
104368 
 
251042 
 
35.6 
 
CD20RO01794 
 DGF 
B-Cell 
  
116032 
  
116032 
 
100 
 
SAEC 
 DGF 
Normal Lung 
 
42682 
 
155695 
 
17874 
 
216251 
 
72.0 
 
8988t DGF Pancreatic Cancer  144165  144165 100 
Th1v2 DGF Th1  351905  351905 100 
MonoCD14 DGF Monocytes  159457  159457 100 
Jurkat DGF TAL1+ T-ALL 86560 136177 142477 365214 37.3 
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3.3. Results 
 
 
3.3.1. Differential Binding Analysis of ChIP-seq data between multiple cell lines 
 
The isolation and characterisation of Jurkat T-ALL clonal cell lines relative to a 
parental cell line showed increased proliferation at high passage numbers, as well as 
a decrease in the expression of TAL1 (Chapter 2 - Fig 2.6 and 2.11, respectively). It is 
possible such differences might reflect genetic and/or epigenetic differences between 
these cell lines at the TAL1 locus. In preparation for an analysis of DNA methylation 
and genetic variation across the TAL1 locus, we used a bioinformatic analysis to 
identify putative regulatory elements across the TAL1 locus in Jurkat T-ALL cells.  
 
The combination of DHS, H3K27ac and H3K4me3 provides a map of open chromatin 
and active enhancers and promoters. Using these markers, regulatory elements were 
mapped across the TAL1 locus and were tested for differential binding between cell 
groups stated (Methods: 3.2.4). Firstly, to ensure replicates utilised for the analysis 
were comparable for analysis, they were tested for overlap of consensus peaks with a 
threshold of 70%. This is to ensure that differences between replicates would not 
influence the DBA between cell groups tested. For example, consensus of Th2 cell 
replicates displayed that replicate 1 had 791 different peaks (red circle), replicate 2 had 
744 different peaks (green circle), with 32772 overlapping peaks (blue circle), 
corresponding to a consensus peak overlap of 95% (Fig 3.1). This was done for all cell 
lines tested for each of the regulatory element markers tested. Cell lines with less than 
70% overlap between replicates were excluded from the analysis, except for the Jurkat 
cell line (Table 3.1).  
 
After confirmation of consensus peaks between replicates, a normalised read count of 
peaks and a measure of binding affinity (a measure of read depth at peaks) for each  
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Th2 Consensus Overlaps
791 744
0
0
0 0
32772
| Figure 3.1. Venn diagram of H3K27ac enriched peaks within Th2 cell line replicates (red and green 
circles).  
 
‘DiffBind’ generates a third data set of the overlapping consensus peaks found between the two 
replicates (blue circle). The percentage of peaks overlapped amongst replicates as a quality control 
for the differential binding analysis was taken from this consensus peak analysis. This example 
displays a consensus overlap of 95%, therefore is an example of replicate data used for the analysis. 
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| Figure 3.2. Correlation heatmap based on read counts performed by the R package, DiffBind for H3K27ac 
ChIP-seq data.  
 
Cell line replicates are clustered based on read counts of H3K27ac and relationships are displayed with 
dendrograms, along with the tissue type, factor type (other, immune or lymphocyte), condition (other, T-
cell or B-cell) and replicate number. The distribution of read counts are displayed as a z-score correlation 
histogram (top left). The clustering of non-immune cell lines (HMEC and NHEK) can be seen relative to 
immune cell types (MonoCD14, Jurkat, CD20RO01794, Th1 and Th2), with further clustering of primary T-
helper cells relative to monocytes and the Jurkat cell line.  
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marker tested was conducted. This predicts that the clustering of cell lines will reflect 
their origin and is displayed in a correlation heatmap (Fig 3.2). As an example, for 
H3K27ac, a correlation heatmap was produced to display the relationship between 
samples within the groups designated above as well as a histogram plot of the z-score 
distribution of the data analysed (Fig 3.2 – top left). It is seen that cell types are 
grouped within the correlation heatmap: non-immune cell lines, HMEC and NHEK in 
the top left (Fig 3.2) and that CD4+ T-cells cluster at the right bottom corner (Fig. 3.2). 
All immune cells (MonoCD14, Jurkat and CDRO01794) are identified as unique but 
fall into a larger “immune cell” clade when compared to the non-immune cell lines 
(Fig 3.2 – bottom right). This showed that immune cells have a greater identity in terms 
of shared peaks when compared to non-immune cell lines (Fig 3.2 – top left). Thus, 
this analysis showed that cells were clustered in a way that reflected epithelial/non-
immune and immune cell samples used in this study. This analysis allowed us to 
investigate differential binding affinity (DBA) between and within cell types.  
 
A DBA was conducted for all cell groups to be tested, DiffBind generates a Granges 
Object of differential binding sites between cell groups throughout the entire genome. 
Conducting DBA resulted in over 20,000 differentially bound sites for DHS, H3K27ac 
and H3K4me3, except for the analysis between immune cells and cell lines in 
comparison to other non-immune cell lines for DHS (38 results) (data not shown). 
Firstly, a DBA contrast (threshold FDR 0.05) between lymphocyte cell types (primary 
CD4+ T-cells, B-cell line and Jurkat) and non-immune cell types (as stated in Fig 3.2) 
was conducted (Fig 3.3). This showed the contrast between these cell types and are 
grouped accordingly in the heatmap (Fig 3.3 – top left and bottom right). The absence 
of data within the heatmap (top right and bottom left) indicates an absence of shared 
differential binding sites between the two groups tested (Fig 3.3). This was also done 
for the Jurkat cell line (T-ALL) and primary CD4+ T-cells and the Jurkat cell line and  
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| Figure 3.3. Differential binding analysis (DBA) heatmap based on contrasts of H3K27ac enrichment 
between lymphocyte cell lines (Jurkat, CD20RO01794, Th1 and Th2) and non-immune cell lines 
(HMEC and NHEK). 
 
Cell line replicates are clustered based on differential binding of H3K27ac and displayed as a 
dendrogram (y-axis). A dendrogram also displays relationships of tissue type, factor, condition and 
replicate numbers amongst samples tested. The distribution of the data is displayed as a z-score 
correlation histogram (top left). The contrast analysis has further highlighted trends seen in Fig 3.2, but 
also displays no shared differential binding between immune cell types and other non-immune cell 
types. 
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| Figure 3.4. UCSC Genome browser display of the regulatory element markers, DHS, H3K27ac and H3K4me3 
across the TAL1 locus and with localising regions of differential binding. 
 
 Differential binding analysis was conducted between immune primary cells and cell lines (primary 
MonoCD14, primary Th1 and Th0, Jurkat and B-cell cell line, CD20RO01794) and non-immune cell lines (8988T 
and SAEC)  (I v O - blue) for DHS or lymphocyte cells and cell lines (primary Th1 and 2 cells, Jurkat and B-cell 
cell line, CD20RO01794 (H3K27ac) or CD20RO01778 (H3K4me3) and non-immune cell lines (NHEK and HMEC 
for H3K27ac and MCF7 and SAEC for H3K4me3) (L v O - blue). As well as comparisons of primary CD4+ T-cells 
(Th1 and Th0  for DHS, Th1 and Th2 for H3K27ac and H3K4me3) and the Jurkat cell line (T vs T - purple) and 
the Jurkat cell line and the DND41 (T-ALL) cell line (J vs D – pink) (Table 3.2). Regions identified from the DBA 
within the TAL1 locus were plotted as boxes above each designated regulatory element marker to show the 
site and breadth of differential binding between groups tested. The ideogram of chromosome 1 displays the 
location of the TAL1 locus along the chromosome (red line) and the isoforms of Ref-Seq genes present within 
the locus (TAL1 and STIL) are displayed. Regulatory element markers (DHS, H3K27ac and H3K4me3) display 
read-depth on the y-axis. GeneHancer interactions are displayed as loops (bottom panel) for regulatory 
element interactions. FANTOM TSS Peaks displayed show sites of transcriptional activity for forward and 
reverse strands (red: forward, blue: reverse). Regions are indicated by red numbers for each regulatory 
element marker. Red numbers indicate common regions of differential binding between regulatory element 
markers that map to predicted downstream TSS, H3K27ac and H3K4me3 enriched region (1), TSS, H3K27ac 
and H3K4me3 peak (2), predicted downstream intergenic enhancer from MuTE insertion (3) and the MuTE 
insertion enhancer peak (4).  
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the T-ALL DND41 cell line with the expected correlation of shared bound peaks per 
regulatory element marker (data not shown).  
 
3.3.1.a DBA analysis of DNAse1 Hypersensitivity within the TAL1 locus 
 
Within the TAL1 locus, the DBA analysis identified sites of differential binding for 
H3K27ac, DHS and H3K4me3 between different cell samples (Fig 3.4). For DHS, 
differential binding was identified between immune cells (primary MonoCD14, 
primary Th1 and Th0, Jurkat and B-cell cell line, CD20RO01794) and other non-
immune cell lines (8988T and SAEC) and primary CD4+ T-cells (Th1 and Th0) vs 
Jurkat (Fig. 3.4, DHS: L Vs O, blue bar; T Vs T, purple bar, respectively). These 
differential binding sites map to regions 3 and 4, displaying differential binding at 
intergenic sites upstream of the TAL1 locus (FDR 0.00403 for I vs O and 0.03 and 0.04 
for T vs T, respectively) (Fig 3.4, DHS: 3 and 4 and Table 3.2).  This indicates that this 
DBA is specific to immune cells but may be influenced by the Jurkat cell line as it also 
shows differential binding at this site relative to primary CD4+ T-cells (Fig 3.4 – DHS, 
region 3). One other region of DBA was found downstream the intergenic enhancer 
(MuTE Insertion) between T-cell cell lines and T-ALL (Jurkat), indicating a Jurkat cell-
specific mark (Fig 3.4 – DHS, region 4).  
 
The mapping of the TAL1 region was also done using the ENCODE project DHS data 
for the cell lines, Jurkat, CD20+, CD14+, CD4+ Naïve (T-helper 0), SAEC (normal lung  
epithelial), 8988T (Pancreas Adenocarcinoma) and Th1 (Fig 3.5). A pattern of open 
chromatin marker enrichment was found for the TAL1 region within intragenic 
regions (not identified by DBA) of the gene and the intergenic MuTE insertion region 
(identified by DBA) (regions 1, 2 and 4), however, are much narrower and more 
focused within the intragenic region (Fig 3.5 - second red box). In specifically the 
Jurkat cell line, a large range of read depth of DHS which was found to be statistically 
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significant from DBA (Fig 3.4 – maps to regions 3 and 4), can be seen relative to other 
samples tested from the same laboratory (Jurkat, CD20+, CD14+, CD4+ Naïve and 
SAEC) within the intergenic region highlighted (*), as well as compared to the other 
cell lines tested (other laboratories) (Fig 3.5 – right box) (see also Appendix for all 
replicates – Supp. Fig 7.4). However, within the intragenic region of the TAL1 gene 
that maps to GeneHancer predicted sites (first and second red box – map to regions 1 
and 2 (Fig 3.4)), peaks within the CD14+ (2 samples), CD20+ and 8988T cell lines can 
also be seen in which DBA found no statistical differences between these cell lines (Fig 
3.5, Fig 3.4 – DHS and Table 3.2).  
 
 
| Table 3.2. DBA Analysis of the TAL1 locus. 
 
1 Region: refers to the boxed regions in Fig 3.4 
2 Contrast: Contrasts conducted between immune primary cells and cell lines vs non-immune cell lines (I vs O) 
(DHS) or lymphocyte primary cells and cell lines vs non-immune cell lines (LvsO) (H3K27ac and H3K4me3), 
Marker Region1 Contrast2 
Fold 
Difference3 
p-value FDR 
DHS 
3 TvsT 1.77 0.00133 0.0286 
4 TvsT 2.89 0.00248 0.0462 
4 IvsO 3.23 0.000369 0.00403 
H3K27ac 
1 LvsO 3.19 0.0151 0.0293 
2 LvsO 4.37 0.000688 0.00189 
3 and 4 LvsO 4.87 0.00105 0.00275 
1 TvsT 6.39 6.48E-10 2.25E-09 
2 TvsT 6.26 3.15E-13 1.54E-12 
3 and 4 TvsT 7.52 9.86E-15 5.52E-14 
H3K4me3 
2 LvsO 9.76 0.000101 0.00121 
3 LvsO 5.52 0.00194 0.00978 
4 LvsO 4.64 0.00768 0.0258 
2 TvsT 7.06 7.54E-28 2.34E-25 
3 TvsT 3.01 0.00452 0.0105 
2 JvsD 10.77 4.23E-25 4.08E-23 
3 JvsD 6.66 1.81E-08 1.73E-07 
4 JvsD 5.59 2.00E-05 0.00011 
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primary CD4+ T-cells vs the Jurkat cell line (T vs T) and Jurkat vs DND41 cell line (JvsD) across the TAL1 locus – 
specific cell lines listed in Fig 3.4. 
3 Fold difference: The difference between groups contrasted for analysis in which a positive value means a fold 
increase for immune primary cells and cell lines (IvsO), lymphocyte primary cells and cell lines (LvsO), T-ALL 
Jurkat (TvsT) and Jurkat (JvsD). 
 
 
 
 
| Figure 3.5. DNAse1 hypersensitivity (DHS) read depth displayed in the UCSC genome browser for 
the Jurkat, CD20R017794, MonoCD14, CD4+ Naïve Wb11970640, SAEC, 8988T and Th1 cell lines 
across the TAL1 locus.  
 
Chromosome ideogram of chromosome 1 indicates location of the TAL1 locus indicates location of the 
TAL1 locus indicated by the red line. Ref-Seq genes from the ENCODE Project display isoforms of the 
TAL1 and STIL gene with localised ChIP-seq peaks of the cell lines listed above. Y-axis displays the read 
depth of DHS enrichment and is normalised amongst samples from the same experiment (see also 
Appendix for details and visualisation of all replicates – Appendix Supp. Fig 7.5). GeneHancer database 
looping displays relationships of regulatory elements across the TAL1 locus (Methods: 3.2.5). Red boxes 
highlight areas of DHS enrichment of the Jurkat cell line relative to the other cell lines displayed. DBA 
analysis has identified regions of statistical difference between cell lines at 2 intergenic regions, one of 
which is located at the MuTE insertion (*).   
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3.3.1.b DBA analysis of H3K27ac within the TAL1 locus 
 
DBA was also conducted for H3K27ac enrichment, which in contrast to the DBA 
analysis of DHS, identified two intragenic regions (region 1 and 2) in addition to the 
intergenic region (region 3-4) (Fig 3.4). DBA was conducted between lymphocytes 
(Jurkat, primary Th1 and 2, and B-cell line CD20RO01794) vs other non-immune cell 
lines (NHEK and HMEC) (L vs O – blue box) (FDR 0.0293, 0.002 and 0.003 for LvsO, 
respectively). DBA was also conducted between primary CD4+ T-cells (Th1 and Th2) 
(T vs T – purple box)  (FDR 2.23e-09, 1.54e-12 and 5.52e14, respectively) in contrast to 
Jurkat within two intragenic sites (Fig 3.4, H3K27ac: region 1 and 2) and the intergenic 
site (region 3) spanning the MuTE insertion enhancer for ~7kbs (Fig 3.4, H3K27ac). 
This analysis resulted in both DNA contrasts displaying the same regions of 
differentially bound H3K27ac. Further analysis was conducted between Jurkat and 
the T-ALL cell line, DND41, for DBA of H3K27ac enrichment within the TAL1 locus, 
which identified no statistical differences between these two cell lines. This suggests 
a similar pattern of enrichment of this intragenic site between the T-ALL cell lines 
(DND41 and Jurkat) tested.  
 
Mapping of H3K27ac displayed a higher enrichment of Jurkat H3K27ac across the 
TAL1 region as identified by DBA, specifically highlighted within gene body regions 
and the intergenic region upstream of TAL1 as indicated by the red boxes (Fig 3.6 – 
H3K27ac, Fig 3.4 – map to regions 1 and 2). This display of H3K27ac can be seen to 
map to exonic and intronic regions of the TAL1 gene (over ~15kb), displaying 
characteristics of open chromatin and regulatory element activity, relative to the other 
cell lines displayed (Fig 3.6 – H3K27ac). Three regions of H3K27ac enrichment were 
detected in Jurkat T-ALL samples (also map to Fig 3.4 – regions 1 and 2 and between 
3 and 4). The first of these begun at the 5’ end of the gene and spread through the first 
intron and second exon (Fig 3.6, left red box). This region also co-localised with a  
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| Figure 3.6. H3K27ac and H3K4me3 read depth across the TAL1 locus.  
 
Chromosome ideogram of chromosome 1 indicates location of the TAL1 locus indicated by the red line. Ref-Seq 
genes from the ENCODE Project display isoforms of the TAL1 and STIL gene with localised ChIP-seq peaks of the 
cell lines listed above. Y-axis displays the read depth of H3K27ac and H3K4me3 enrichment and is normalised 
amongst samples from the same experiment, with primary cells and cell line samples indicated on the left-hand 
side (see also Appendix for details and visualisation of all replicates – Supp. Fig 7.4). GeneHancer database 
looping displays predicted interactions between regulatory elements across the TAL1 locus (Methods: 2.3.5). 
Red boxes highlight areas of H3K27ac and H3K4me3 enrichment of the Jurkat cell line relative to the other cell 
lines displayed, DBA regions are highlighted within these boxed regions (*). 
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| Figure 3.7. UCSC genome browser display of the TAL1 locus and mapped GTEx transcripts for thyroid and 
whole blood cell types (green and pink bars, respectively) with peaks of H3K27ac and H3K4me3 and DBA 
analyses between cell type groups tested.  
 
Ref-Seq genes display TAL1 gene isoforms and GTEx transcripts predicted indicate transcription start sites 
(TSSs) for TAL1 isoforms. Likelihood of TSS for the tissues, thyroid and whole blood, is indicated by the height 
of the (green and pink, respectively) where the 5’ end of the transcript (grey line) indicates the location of 
the TSS. Chromosome 1 ideogram displays the location of the TAL1 locus (indicated by red line).  
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broad H3K4me3 signal in Jurkat T-ALL samples, and more localised peaks in other 
cell lines (Fig 3.6 – H3K4me3). Using the GTEx track in the UCSC genome browser 
possible TSSs can be predicted in the context of multiple isoforms for the TAL1 gene  
(https://genome.ucsc.edu/gtex.html, Fig 3.7) and demonstrated transcriptional 
activity within nearby exons for thyroid and whole blood cell types (Fig 3.7, green and 
pink bars, respectively). At the 5’ end of the TAL1 gene, mapping of full isoform 
transcripts that correspond for whole blood and thyroid specific cell types are seen 
(bar height indicates transcripts per kilobase million (TPM)) (Fig 3.7 – full gene 
isoforms 1, 2 and 4 – TPM: 5, 0.5, 0 for thyroid and 1.1, 0, 3.5 for whole blood, 
respectively), suggesting the 5’ region locates the primary promoter of the gene.  
 
A second region of H3K27ac enrichment mapped upstream of the TAL1 gene, but did 
not co-localise with H3K4me3 (Fig 3.6, right red box). This second region also 
corresponds to the location of the MuTE insertion mutation associated with the Jurkat 
T-ALL super enhancer (Mansour et al., 2015) (Fig 3.6 – H3K27ac). These highlighted 
regions of enrichment (*) are also seen to have looping relationships to other elements 
within the region as identified by the GeneHancer looping (Fig 3.6, bottom panel), 
such as the intragenic region within TAL1 and the intergenic region of the Jurkat 
super-enhancer (Fig 3.6 - *). Therefore, a clear relationship between these highlighted 
regions is seen through looping from the TSS of common TAL1 transcripts (GTEx 
transcripts at the 5’ end (Fig 3.7)) to the upstream H3K27ac site (Fig 3.4 - regions 3 and 
4). 
 
3.3.1.c DBA analysis of H3K4me3 within the TAL1 locus 
 
For enrichment of H3K4me3, DBA was conducted and identified the 3 regions of DBA 
(Fig 3.4, H3K4me3 – Regions 2, 3 and 4), specifically displaying differential binding of 
2 intergenic sites (including the Jurkat MuTE enhancer, regions 2 and 3) and one 
intragenic region (region 2) between the two sites identified for H3K27ac (Fig 3.4, 
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H3K4me3). Contrasts between lymphocyte cells and cell lines (primary Th1 and Th2 
and Jurkat) vs other non-immune cell lines (MCF7 and SAEC) (FDR 0.00121, 0.0098 
and 0.03, respectively),  and between Jurkat and DND41 cell lines are found at all three 
sites (Fig 3.4, H3K4me3 - regions 2-4) (FDR 4.08e-23, 1.73e-07 and 0.0011, respectively). 
However, differential binding is found at the intergenic region downstream of the 
MuTE insertion enhancer (region 3) and within the intragenic region (region 2) for T-
cells (Primary Th1 and Th2) and T-ALL (Jurkat) (Fig. 3.4, H3K4me3 - regions 2 and 3) 
(FDR 2.34e-25 and 0.01, respectively). No differential binding of H3K4me3 at the Jurkat 
(MuTE) enhancer between primary CD4+ T-cells vs T-ALL (Jurkat) at this site was 
seen. 
 
The mapping of the promoter marker H3K4me3 was used to confirm the location of 
the active promoter regions relative to the active enhancer regions identified amongst 
the Jurkat cell line and the other cell lines tested (Fig 3.6 and Fig 3.4 -H3K4me3). The 
mapping of H3K4me3 enrichment across the TAL1 region identified a broad range of 
H3K4me3 across the intragenic region of the TAL1 gene (first red box) (Fig 3.6 – 
H3K4me3) which maps across region 2 for H3K4me3 DBA (Fig 3.4, H3K4me3 – region 
2). This region has a broad range of read depth for H3K4me3 across ~10kb which is 
not seen for the cell lines, DND41, primary cells MonoCD14+, CD20ORO01778 (B-cell), 
A549 (lung epithelial cancer), primary Th1 and Th2 (Fig 3.6 – H3K4me3). Within this 
region, a narrow peak of H3K4me3 can be seen for all cell lines (except DND41) which 
has displayed a putative promoter site (Rivera-Reyes et al., 2016), which also maps to 
the 5’ end of the GTEx transcripts for TSS location of TAL1 isoforms for thyroid and 
whole blood tissue types (Fig 3.7 – full gene transcripts 1, 2, and 4). A contrast can be 
seen with enhancer markers being restricted to the intergenic region of TAL1 in this 
analysis relative to the findings of the MuTE super-enhancer stretched across from the 
intergenic Jurkat enhancer into the first intronic regions of the TAL1 gene  (Mansour 
et al., 2014).  
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The enrichment of H3K4me3 in combination with predicted isoform transcripts that 
are not at this site (upstream), suggest that the DBA found that the intragenic region 
may be a weak promoter as suggested by the TPM scores of 0.5 and 0 for isoform 3 
and 1.1 and 0 for isoform 5 for thyroid and whole blood cell types that map to this site 
(Fig 3.7 – isoforms 3 and 5). The mapping of H3K4me3 also displays limited H3K4me3 
enrichment within the MuTE insertion region where the intergenic Jurkat enhancer is 
located, confirming that this region is a putative enhancer site due to minimal 
H3K4me3 enrichment relative to the enrichment of H3K27ac and DHS at the same site 
(Fig 3.4 and 3.6 – right box). DBA between primary T-cells and DND41 compared to 
Jurkat indicated statistically increased H4K4me3 enrichment (Table 3.2), however in 
combination with relative H3K4me3 from other cell lines that lack H3K4me3 at this 
site and relative increases in Jurkat H3K27ac and DHS, this statistical increase is due 
to regulatory element activity at this site, whereas other cell lines exhibit no signs of 
regulatory element activity (Fig 3.6 and Fig 3.4 – H3K4me3). Therefore, expected 
patterns of high H3K27ac and DHS relative to low H3K4me3 indicates region 3 and 4 
(Fig 3.4, H3K4me3 and Fig 3.6, H4K3me3 – two right boxes) are putative enhancer 
sites.  
 
All the patterns displayed amongst the three regulatory elements markers, H3K27ac, 
DHS and H3K4me3, displayed statistically significant increases in fold change for 
lymphocyte primary cells and cell lines (which includes Jurkat) and for Jurkat (T vs T 
and J vs D) for all the stated markers (Fig 3.4 and Table 3.2). This indicates that the 
Jurkat cell line may have affected the results and influenced the immune or 
lymphocyte specific signature relative to other non-immune cells lines. Each site 
mapped had a statistical difference that was lower than a threshold FDR of 0.05, 
(default from ‘DiffBind’) with an increased fold difference of 1.77 to 10.77 for immune 
primary cells/cell lines  or lymphocyte primary cells/cell lines (compared to non-
immune cell lines), and Jurkat (compared to primary CD4+ T-cells and the DND41 cell 
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line) (Table 3.2). For H3K27ac and H3K4me3 enrichment, differential binding between 
T-cell cells and Jurkat as well as Jurkat and DND41 are more significant relative to 
other regions of DBA found (Table 3.2 - FDR). Overall, the binding profile of 
regulatory markers, DHS, H3K27ac and H3K4me3 show differential binding within 
the TAL1 locus that is specific for the Jurkat cell line.  
 
3.4. Conclusion 
 
Overall, the bioinformatics pipeline and analysis conducted allowed for the mapping 
of intragenic and intergenic regions within TAL1, to display the regulatory landscape 
through markers of H3K27ac, DHS and H3K4me3. The four regions found were 
between the first and second exon of the TAL1 gene (Fig 3.4 - regions 1 and 2) and 
upstream in the intergenic region, mapping to an intergenic enhancer downstream of 
the Jurkat MuTE super-enhancer site (Fig 3.4 – regions 3 and 4). It was found that these 
regions have differential binding between lymphocytic groups and other non-
immune cell types which was narrowed down between primary T-cells in comparison 
to the Jurkat cell line and the T-ALL cell line, DND41 and Jurkat. These sites 
specifically mapped to the putative enhancer region (MuTE enhancer) established in 
literature within the TAL1 locus, however also displayed a possible Jurkat T-ALL 
specific region of promoter enrichment within the intragenic region of TAL1, in 
contrast to other studies stating this region is a part of the MuTE putative super 
enhancer (Mansour et al., 2014). This analysis aided in the understanding of the 
regulatory element landscape of the TAL1 locus and can be used to map other 
epigenetic markers, such as DNA methylation, to help target testing of differential 
DNA methylation at regulatory sites between Jurkat clonal populations established in 
Chapter 2.  
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Chapter	4 -	DNA	methylation	and	
genetic	variation	across	the	TAL1	
locus	
 
4.1. Introduction  
 
4.1.1. DNA methylation  
 
DNA methylation and histone subunit methylation and acetylation modulate patterns 
of gene expression across the genome without the alteration of a DNA sequence 
(Moore et al., 2013). DNA methylation involves the transfer of a methyl group onto 
the second cytosine base of a CpG dinucleotide, which are concentrated in clusters 
within CpG islands (Kulis and Esteller, 2010).  CpG islands are regions of DNA that 
have a higher density of CpG dinucleotide sequences than the rest of the genome, 
however they are typically unmethylated (Bird et al., 1995). These regions are 
evolutionarily conserved within humans, promoting the regulation of gene expression 
through association with chromatin structure and TF binding, specifically at 
promoters and enhancers (Moore et al., 2013).  
 
At promoters, DNA methylation leads to the silencing of the targeted gene but DNA 
methylation at intragenic and intergenic enhancers  can have varying effects on gene 
expression (Sharifi-Zarchi et al., 2017). It is believed that intragenic DNA methylation 
inhibits cryptic or intragenic enhancer-driven transcription enabling efficient 
transcription from the unmethylated promoter  (Sharifi-Zarchi et al., 2017). Loss of 
intragenic enhancer methylation increases eRNA transcription, which may cause 
interference with elongating RNA Pol II activity from the promoter of the gene in 
which it is located,  and can also enable gene transcription at neighbouring gene(s) 
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(Cinghu et al., 2017). Therefore, DNA methylation within the gene body is complex 
and dynamic.  
 
4.1.1.a. Methylation-Sensitive Restriction Endonuclease (MSRE) assay 
 
A MSRE assay allows for the rapid detection of DNA methylation within multiple 
amplicons simultaneously (Melnikov et al., 2005). It is a simple method that relies on 
the digestion of genomic DNA (gDNA) by methylation sensitive restriction 
endonucleases (Pandey et al., 2016). Although bisulphite-based methods are 
considered the benchmark in the analysis of DNA methylation, these methods have 
several limitations that are due to the technically demanding parameters that need to 
be met and the cost of sequencing technologies (Pandey et al., 2016). However, MSRE 
assays using qPCR can be used for rapid and simultaneous detection of DNA 
methylation that allows for high-level multiplexing, minimal assay optimisation, and 
a low concentration of gDNA needed for each assay (Pandey et al., 2016).  
 
Through the use of commercially available restriction endonucleases, the MSRE assay 
can be used in a cost-effective way. In the absence of DNA methylation, methylation-
sensitive restriction endonucleases will cleave the DNA and the subsequent qPCR 
amplification will detect high cycle threshold values (CT) due to decreased 
amplification from the limited starting product (Hashimoto et al., 2007). If a CpG 
dinucleotide site is methylated, the methylation-sensitive restriction endonuclease 
cannot cleave the DNA template, resulting in a high yield during the qPCR, with 
lower CT values (Hashimoto et al., 2007). The digestion of a DNA template by a 
methylation-sensitive restriction endonuclease is compared to digestion by an 
isoschizomer that digests both methylated and unmethylated DNA with equal 
efficiency (Hashimoto et al., 2007). The methylation-sensitive endonuclease HpaII and 
its isoschizomer MspI both cut at the sequence, CCGG, with methylation at the CpG 
dinucleotide inhibiting cleavage by HpaII but not MspI. The difference in CT values 
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of amplicons from gDNA digested with HpaII or MspI can be quantified and used as 
an assessment of methylation status at that site (Hashimoto et al., 2007).  
 
The aim of this investigation is to use a quantitative MSRE assay to assess the 
dynamics of DNA methylation at the TAL1 locus within regulatory sites identified in 
Chapter 3 (Fig 3.4) in the different Jurkat clonal cell lines. Reduced representation 
bisulphite sequencing (RRBS) and Illumina HumanMethylation450 array (Methyl450) 
data from the ENCODE project and the Cancer Cell Line Encyclopaedia (CCLE) will 
be used to define expected patterns of DNA methylation within the TAL1 locus and 
will be compared to results obtained using the MSRE assay.  
 
4.1.2. Nanopore sequencing  
 
Oxford Nanopore Technologies’ MinION sequencer is being utilised as a compact and 
powerful device for long-read sequencing, particularly for long PCR amplicons 
(thousands to ten thousands of base pairs) (Leggett and Clark, 2017; Orsini et al., 2018). 
Nanopore sequencing is done at a single-molecule level by detecting an electric 
current of single-stranded DNA as it passes through a protein channel (nanopore) 
(Wei et al., 2018). Benefits from using nanopore technology involve sequencing that is 
focused towards long reads that achieve highly contiguous assembly and identifying 
structural variation within samples (Bowden et al., 2019). The accessibility of the 
MinION Nanopore system, and its ability to read long sequences, made it an ideal 
choice for sequencing PCR-generated amplicons of 2kb or longer that covered much 
of the TAL1 locus. Through the generation of libraries of TAL1 amplicons from the 
Jurkat parental and clonal cell lines, it was possible to test whether differences seen 
within the phenotypic, transcriptional and epigenetic landscape of TAL1 in these cell 
lines was correlated with genetic variation.  
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The aims of this chapter are to assess the dynamics of DNA methylation at the TAL1 
locus within regulatory sites identified within Chapter 3 and use the MinION 
nanopore sequencer for TAL1 regions to test whether genetic differences exist between 
the Jurkat parental and clonal cell lines (established in Chapter 2).  
 
4.2. Methods  
 
4.2.1. Bioinformatic analysis of the DNA methylation landscape across TAL1 
 
To identify sites of differential DNA methylation within the TAL1 region, data 
supplied from the ENCODE project was used to identify targets for the MSRE assay. 
These data sets are from the HAIB RRBS and HAIB Methyl450 array data conducted 
by the Myers Lab within the HudsonAlpha Institute (Varley et al., 2013). This data 
was displayed together with the location of putative regulatory elements identified in 
Chapter 3 (Chapter 3 - Fig 3.4). RRBS is an approach for large-scale high-resolution 
DNA methylation analysis through bisulphite conversion and sequencing of  MspI 
digested small CG rich sequences to represent the whole genome (Meissner et al., 
2005). The  Methyl450 bead array data provides high-throughput DNA methylation 
quantification through bisulphite conversion and whole-genome amplification across 
>450, 000 methylation sites  (Dedeurwaerder et al., 2014). The FANTOM5 track was 
also used to map mRNA transcriptional activity from Cap Analysis of Gene 
Expression sequencing (CAGE-seq) (Noguchi et al., 2017). 
 
Based on the intersection of sites of putative regulatory elements and the sites of DNA 
methylation, targets were identified for MSRE analysis (Table 4.1). Primers were 
designed to target these sites by using the UCSC genome browser to retrieve the DNA 
sequence from seven broad regions of interest. The MspI/HpaII recognition sequence 
‘CCGG’ were identified within each of these seven broad regions. Amplicons between 
150-250bp which contained a CCGG sequence located in the middle of the sequence 
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were selected and primers designed using the Primer 3 program 
(http://bioinfo.ut.ee/primer3-0.4.0/), ensuring the CCGG sequences were not within 
the primer sequences. Nineteen primer sets were identified and verified within the 
UCSC genome browser using the ‘In-silico PCR’ tool to validate the region of interest 
to be tested for the MSRE analysis (https://genome.ucsc.edu/cgi-bin/hgPcr). Five of the 
19 primer sets were utilised to target exonic, the two Jurkat intragenic sites (Chapter 
3 - Fig 3.4), the intergenic H3K27ac enriched site downstream of the MuTe insertion 
and the Jurkat enhancer region (MuTE Insertion) of the TAL1 gene (Table 4.1).  
 
| Table 4.1. List of MSRE primers designed to target CpG dinucleotide sites within the TAL1 
locus. 
Primer 
Name 
Coordinates Forward Primer (5’-3’) Reverse Primer (5’-3’) Target Region 
MSRE_1 
Chr1:47,685,696-
47,685,857 
AGGCGGAGGATCTCATTCTT CTAATCTCCAGGTCCCCACA Exonic 
MSRE_2 
Chr1:47,694,782-
47,694,979 
CTGTCCTGAGCCTTCCTCAC AAAAAGGGGGAAAGCAAAGA 
Downstream TSS 
Peaks, H3K27ac and 
H3K4me3 enrichment 
MSRE_3 
Chr1:47,695,312-
47,695,481 
GAACATTTTCGAACCCTCCA CTATTCGCCTTTCCCAACAC 
Co-localised TSS 
Peaks, H3K27ac and 
H3K4me3 peak 
MSRE_4 
Chr1:47,701,431-
47,701,582 
GGTTCTCCCTAAACCCCAAA ATAAACTCGGCTGCTCATCA 
Downstream 
intergenic H3K27ac 
and DHS Peak  
MSRE_5 
Chr1:47,705,095-
47,705,268 
CGCATGTGCATTCTCTCTGT TGCCTTGCTTCTATGGGGTA 
Jurkat (MuTe) 
enhancer 
1Primer amplicon sequences in Appendix – 7.3.2.a 
 
DNA methylation within CpG Islands of the TAL1 locus was mapped using data 
supplied from the Cancer Cell Line Encyclopedia (CCLE) (Ghandi et al., 2019). TAL1-
specific regions were retrieved from the CCLE database for T-ALL-specific and 
leukaemia cell lines out of the 1457 cell lines available 
(https://portals.broadinstitute.org/ccle/data). The data file 
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Cell_lines_annotations_20181226.txt was downloaded to identify T-ALL and 
leukaemia cell lines studied by the CCLE and the data file 
CCLE_RRBS_cgi_CpG_clusters_20181119.txt was used to retrieve percentages of 
methylation at the two clusters of CpG islands identified within the TAL1 gene 
(chr1:47,690,440 – 47,691,404 and chr1: 47,690,503 – 47,693,585) (Fig 4.5). These regions 
were displayed in the UCSC genome browser by uploading a BED file that included 
the coordinates of the two clusters of CpG islands within TAL1.  The cell line data that 
was used included: Jurkat (T-ALL), PEER (T-ALL), HL60 (acute myeloid leukaemia), 
K562 (chronic myelogenous leukaemia), MOLM-13 (acute myeloid leukaemia), 
ALLSIL (T-ALL), KASUMI-2 (B-ALL), DND41 (T-ALL), HPBALL (T-ALL), PF382 (T-
ALL), RPMI8402 (T-ALL), P12-ICHIKAWA (T-ALL), RCHACV (B-ALL) and MOLT-
3 (T-ALL). Data was plotted in the web tool ‘Methylation plotter’ according to the 
formatting rules described by Mallona et al. (2014). This provided a methylation 
profile heatmap, a summary of the categorised groups based on cell type, a 
dendrogram to cluster identified groups, and statistical testing using a Kruskal-Wallis 
test to assess differences between the groups 
(http://maplab.imppc.org/methylation_plotter/). This analysis provided an 
understanding of DNA methylation patterns within intragenic CpG islands in 
multiple leukaemia cell lines within the TAL1 gene.  
 
4.2.2. gDNA isolation of Jurkat Clonal Populations  
 
Jurkat clonal populations were grown under the same conditions presented in 
Chapter 2 (0.1% FBS starvation in 1% PSF RPMI 1640 media for 24 hours and 5% FBS 
1% PSF in RPMI 1640 media for 72 hours within 96 round-bottom well plates). Clonal 
populations P0, C11 and C4 were used for the MSRE assay based on their differential 
expression of the TAL1 gene (high, moderate and low, respectively) at passages 1 and 
9 (Table 4.2). Passages 1 and 9 were used as they displayed significant differences 
between clonal populations in the phenotyping and gene expression analysis 
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conducted in Chapter 2. The cell line, A549 (lung epithelial cancer), was also used to 
compare differences of methylation status as predicted by UCSC RBBS and Methyl450 
data between Jurkat at the exonic and intragenic H3K27ac and H3K4me3 peak region 
within the TAL1 gene (Primers MSRE_1 and MSRE_3).  
 
The cell line populations were harvested and gDNA isolation was conducted per the 
Bioline ISOLATE II Genomic DNA kit protocol 
(https://www.bioline.com/us/downloads/dl/file/id/873/isolate_ii_genomic_dna_kit_p
roduct_manual.pdf). The concentration of isolated gDNA was checked using the 
Qubit 2.0 Fluorometer using the Qubit dsDNA BR assay kit (ThermoFisher) as stated 
by the Qubit 2.0 Fluorometer protocol.  
 
| Table 4.2. Averaged duplicates for TAL1 gene expression (Chapter 2) for Jurkat clonal and 
parental cell lines at passage 1 and 9 and arranged based on relative TAL1 expression2. 
 
Passage 1 Passage 9 
Cell Line TAL1 Cell Line TAL1 
P01 1.428 P0 1.772 
C9 0.882 P00 1.518 
C3 0.789 C10 1.282 
C2 0.750 C5 0.969 
C11 0.748 C3 0.891 
P00 0.700 C9 0.666 
C1 0.628 C1 0.593 
C8 0.600 C11 0.579 
C10 0.396 C2 0.567 
C4 0.351 C6 0.502 
C6 0.222 C8 0.501 
C5 0.127 C4 (9) 0.399 
 
1Boxed parental and clonal cell lines were utilised for MSRE assay due to consistent TAL1 expression ranging 
from high (P0), moderate (C11) and low (C4) between passage 1 and 9 relative to other clonal cell lines.  
2Heatmap displays red as high expression, white as moderate expression and blue as low expression of TAL1 
(relative fold change).  
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4.2.3. MSRE Protocol  
 
Commercial restriction endonucleases that are used for MSRE assays include 
methylation-sensitive (HpaII) and methylation-insensitive (MspI) (Tran et al., 2010). 
These endonucleases determine methylation at CpG dinucleotides as they cleave at 
CCGG recognition sites (Tran et al., 2010). The use of both a methylation-sensitive and 
methylation-insensitive endonucleases allows for the comparison of a reference 
control sample (methylation-insensitive endonuclease) that will cleave at methylation 
sites regardless of methylation status, therefore limiting false positive results due to 
polymorphic variation at restriction sites and incomplete digestion by endonucleases 
(Tran et al., 2010).  
 
Duplicate digestions for HpaII, MspI and mock digestions were done for gDNA 
samples (P0, C11 and C4 at passage 1 and 9), with triplicate qPCR assays done for each 
duplicate digestion (n=6 per cell line and passage) (Table 4.3).  
 
| Table 4.3. Parameters used for gDNA digestion with endonucleases HpaII, MspI and mock 
digested gDNA. 
 
Digestions were conducted in the following reaction: 1 x CutSmart Buffer (New 
England BioLabs), 1 µL of 5U/µL HpaII and MspI (New England BioLabs), 150ng of 
gDNA, in a total volume of 15µL. Digestions were incubated at 37°C for 1 hour 
followed by a 95°C heat inactivation for 15 minutes using the Applied Biosystems 
Veriti Thermal Cycler. The digested gDNA was stored at -20°C until required for use.  
gDNA Concentration (ng) 150ng (10ng/µL) 
Enzyme Concentration 
(Units) 
5U – MspI and HpaII 
Reaction Volume (µL) 15µL 
Reaction Length (Hours) 1 
Heat Inactivation 95°C - 15 minutes 
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MSRE qPCR analysis of the digested gDNA was done using 10ng of gDNA, 1 x 
SensiFAST SYBR Green No-ROX Kit from a 2x stock (Bioline), forward and reverse 
primers at a final concentration of 0.4µM in a total final volume of 10µL. The reaction 
was run using the Applied Biosystems 7500 Fast Real-Time PCR system with cycling 
conditions: 95oC for 5 minutes, followed by 40 cycles of 95oC for 10 seconds, 62oC for 
10 seconds and 72oC for 30 seconds.  
 
4.2.4. MSRE assay analysis 
 
The MSRE assay was analysed by comparing the dCT values generated from gDNA 
digested with HpaII or MspI (positive control) and the mock digested DNA (negative 
control), i.e. dCT HpaII (HpaII - Mock Digestion) and dCT MspI (MspI - Mock 
Digestion). This was done per digest and primer set and averaged for the triplicate 
values per digest (n=6 per duplicate digests). The data distribution of dCT HpaII and 
dCT MspI for each primer set was tested for statistical significance using a two-tailed 
Wilcoxon Signed-Rank test 
(https://www.socscistatistics.com/tests/signedranks/default2.aspx) that is a statistical 
test for non-parametric data for differences of paired values of unequal variance 
(Nahm, 2016). Statistically significant differences (p<0.05) between dCT MspI and dCT 
HpaII were followed-up for further analysis using box plot outliers.  
 
To assign methylation status to each amplified region, a boxplot analysis of outliers 
was conducted. This was done according to the method described in Chapter 2.2.6. 
Lower inner and outer fences for dCT MspI digested gDNA per region were 
calculated per region and used as thresholds to determine the distribution of 
unmethylated values (dCT MspI). If dCT HpaII values fell above the lower inner fence 
this was deemed unmethylated, values between inner and outer fences (mild outlier) 
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were deemed partial/low DNA methylation, and high methylation was seen when 
values fell lower than the lower outer fence (extreme outlier).  
 
Statistical correlations of the MSRE dCT HpaII data was also tested using the 
Spearman’s Rho correlation test 
(https://www.socscistatistics.com/tests/spearman/default.aspx) for correlations 
between passages 1 and 9 per region tested, per cell line population and for CFSE and 
TAL1 gene expression results from Chapter 2.  
 
4.2.5. Amplicon generation  
 
Due to the advantage of nanopore sequencing conducting long-reads, a targeted 
whole-gene approach was undertaken to generate amplicons using PCR (Orsini et al., 
2018). Due to the error-rate of nanopore technologies, PCR amplification of targeted 
regions can ensure high-level read depth at targeted sites and compensate for this 
limitation (Orsini et al., 2018). Primers were designed to target chr1:47,691,795-
47,705,959 across the TAL1 locus that mapped to regulatory sites and DNA 
methylation sites identified in Chapter 3 and 4. 
 
The UCSC genome browser was used to identify regions for MinION Nanopore 
Sequencing by mapping regions within the TAL1 locus that span sequences targeted 
by the MSRE assay amplicons. Using the UCSC genome browser, DNA sequences for 
these regions were extracted using the ‘View’ and ‘Get DNA’ options 
(https://genome.ucsc.edu/) (Appendix – section 7.3.2.b). The DNA sequence for each 
region was  copied into the Primer3 database (http://bioinfo.ut.ee/primer3-0.4.0/) with 
the following parameters: Temperature minimum: 59°C, Temperature Optimal: 60°C, 
Temperature maximum: 61°C for a product size of 1500 – 4000bp. Primers were 
selected to generate overlapping amplicons (~200bp) and amplicons tested and 
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selected using the UCSC genome browser ‘In-Silico PCR’ option 
(https://genome.ucsc.edu/cgi-bin/hgPcr_) (Table 4.4).  
 
|Table 4.4. Primers designed for MinION Nanopore sequencing for targeted regions across 
the TAL1 locus. 
Primer 
Name Coordinates Forward Primer (5’-3’) Reverse Primer (5’-3’) 
Seq_1 Chr1:47,691,795-47,694,488 CAGAGACTGAGGGCCAAAAG CTCGAGTGGGCCCTGAT 
Seq_2 Chr1:47,694,309-47,697,743 ACCCAGCCTCTGGTCTCTCT AGAGGTCTTCGCTCCCTTTC 
Seq_3 Chr1:47,697,580-47,701,354 CGCGCATTTCTGTATATTGC CCCAGTTCCAGACTCCAGAC 
Seq_4 Chr1: 47,699,942 – 47,702,280 AGGAAACAGCTGGACCAAGG AGTAGTAGGCCTGGGGTGAG 
Seq_5 Chr1:47,701,548-47,704,837 GCCATGCATGCACTCTGATG AGGGCTCCAGGGTATGCTAA 
Seq_6 Chr1:47,703,476-47,705,959 GGCTCATCTCACCCAGTCAC CTGCCTCTCCTTCTCACTGC 
1Amplicon sequence information in Appendix – section 7.3.2.b 
 
The primers were tested for the appropriate annealing temperature using the New 
England BioLabs Tm calculator (https://tmcalculator.neb.com/#!/main) for the Q5 
High-Fidelity DNA polymerase (New England BioLabs) at a final primer 
concentration of 0.5µM. All annealing temperatures were noted and used to conduct 
the generation of TAL1 amplicons.  
 
Amplicons were generated using the Q5 High-Fidelity DNA polymerase (New 
England BioLabs) protocol (https://www.nebiolabs.com.au/protocols/2013/12/13/pcr-
using-q5-high-fidelity-dna-polymerase-m0491). gDNA was isolated as described 
(Methods: 4.2.2). All reactions were assembled on ice and quickly transferred to a pre-
heated Applied Biosystems Veriti Thermocycler at 98°C. A touch-down PCR was used 
to increase the specificity and sensitivity of the PCR amplification. The touch-down 
PCR technique increases the initial annealing temperature above that of the predicted 
primer annealing temperature and decreases the annealing temperature over multiple 
cycles (Korbie and Mattick, 2008).  
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In some cases, successful PCR required the addition of 10% dimethylsulfoxide 
(DMSO). The following reaction was set up dependent on the amplicon: 5x Q5 
Reaction buffer (New England BioLabs) at a 1x concentration, 10mM dNTPs at a final 
concentration of 0.2mM (Bioline), forward and reverse primers at a final concentration 
of 0.5µM each (Sigma-Aldrich), 75ng of gDNA, 0.5µL of Q5 High-Fidelity Polymerase 
(20 units/mL) (New England BioLabs), DMSO (as required, 10%) in a final volume of 
50µL. The PCR amplification was then run as described in Table 4.5.  
 
 
| Table 4.5. PCR cycling conditions for TAL1 amplicons using the Q5 High-Fidelity polymerase.  
Step Temperature (°C) Time 
Initial Denaturation 98 2 minutes 
10 cycles 98 10 seconds 
(TAP + 10°C) or (TAP + 10°C) -5°C 
1°C decrease per cycle 
10 seconds 
72 40 seconds/kb 
25 cycles 98 10 seconds 
TAP or TAP -5°C 10 seconds 
72 40 sec/kb 
Final Extension 72 2 minutes 
Hold 10 - 
*TAP: predicted annealing temperature as calculated by https://tmcalculator.neb.com/#!/main. 
 
Amplification of amplicons was verified using a 1.2% agarose gel stained with SYBR 
Safe DNA gel stain (ThermoFisher Scientific) in 1x Tris-borate-EDTA (TBE) buffer 
within an electrophoresis tank (BioRad). Samples were loaded with 5x DNA loading 
buffer (Bioline) at a 1x concentration and run with the Hyperladder 1kb (Bioline).  
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4.2.6. Nanopore library preparation and sequencing  
 
After confirmation of the amplification of targeted TAL1 regions, library preparation 
was conducted. First, concentrations of gDNA from the amplicons generated was 
measured using the Qubit 2.0 Fluorometer and Qubit 2.0 BR assay kit (ThermoFisher 
Scientific) (as per manufacturers’ instructions – Chapter 2). Amplicons were combined 
into cell line-specific pools at a concentration of 0.2 pM for each amplicon and made 
up to 100µL with 1x Tris-EDTA (TE) buffer (10mM Tris-HCl, pH 8.0, 1mM EDTA). 
The gDNA concentration for each amplicon pool was measured using the Qubit 2.0 
fluorometer and then purified using the Monarch DNA Cleanup and Gel Extraction 
Kit (New England BioLabs), eluted in 40µL and measured for gDNA concentration 
again (pools were between 0.6-1.2µg in total). Next, to prepare the amplicons for 
ligation of the sequencing barcodes, end repair of the amplicons was conducted using 
the NEBNext Ultra II End Repair/dA-Tailing Module (New England BioLabs). The 
reagents were mixed in the following order: 3µL of NEBNext Ultra II End Prep 
Enzyme mix, 7µL of NEBNext Ultra II End Prep Reaction buffer, 50µL of DNA (made 
up with TE for a of maximum gDNA amount of 1µg) for a total volume of 60µL. 
Reaction was run in an Applied Biosystems Veriti Thermocycler with the cycling 
conditions: 20°C for 30 minutes, 65°C for 30 minutes and held at 4°C.  
 
After end repair, a column purification was conducted (Monarch DNA Cleanup and 
Gel extraction kit) before ligation of barcode adaptors. Using the Blunt/TA ligase 
Master Mix (New England BioLabs) and the Nanopore PCR Barcoding Expansion Kit 
(Oxford Nanopore Technologies), ligation was conducted at a ratio of 5:1 (adaptors : 
fragments) with 12µL of purified End Prep DNA (300ng), 8µL of barcode adaptors and 
20µL of Blunt/TA Ligase Master Mix (in this order). Reaction was mixed gently, and 
contents of the tube were spun down. Bead purification was done using 60µL of 
resuspended Agencourt AMPure XP DNA purification beads (Beckham Coulter) and 
mixed thoroughly. Reactions were incubated on a rotator mixer for 5 minutes at room 
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temperature, spun down and pelleted using the DynaMag-2 Magnetic Particle 
Concentrator (Invitrogen). Supernatant was discarded after pelleting and beads were 
washed using 200µL of 70% ethanol (Sigma-Aldrich) (freshly made) and without 
disturbing the pellet, ethanol was removed and the washing with ethanol was 
repeated. The sample tube was briefly centrifuged and placed on the magnet and 
residual ethanol was evaporated and left to dry at 37°C with lid open. Pellet was 
resuspended in 25µL of ddH2O, incubated for 2 minutes at room temperature, and 
placed on a magnet to pellet beads (eluate to be clear and colourless). Then 15µL of 
eluate was retrieved and quantified using the Qubit 2.0 fluorometer. The library was 
then diluted to 10ng/µL with ddH20 or TE Buffer. 
 
Barcoded DNA was amplified as follows: 5x Long Amp Reaction buffer (New 
England BioLabs), final concentration of 0.3mM dNTPS (New England BioLabs), PCR 
barcode primers at a final concentration of 0.4µM (BC01-BC06) (Oxford Nanopore 
Technologies), 2µL of Long Amp Taq polymerase (5U in total) (New England 
BioLabs), 20ng adapter ligated template in a final volume of 50µL. The PCR reaction 
was run with the following cycling conditions: Initial denaturation: for 3 minutes at 
95°C, denaturation for 15 seconds at 95°C and annealing for 15 seconds at 62°C and 
extension for 50 seconds/kb at 65°C (15 cycles), extension for 10 minutes at 65°C and 
held at 4°C. Barcoded amplicons were quantified using the Qubit 2.0 Fluorometer and 
run on a 1.2% agarose E-Gel with SYBR Safe DNA gel stain to confirm amplification 
of pooled amplicons. Barcoded templates were pooled in equimolar ratios (in most 
cases, a maximum amount of approximately 400ng of gDNA per primer set, with each 
library containing 6 primers) and purified using the Agencourt AMPure XP DNA 
purification beads (as stated above). An end repair step was not done as the Long 
Amp polymerase adds an overhanging A base (New England Biolabs). Next, adaptor 
ligation was conducted using 60µL of gDNA sample from previous step, 25µL of 
thawed Ligation Buffer (Oxford Nanopore Technologies), 10µL of NEBNext Quick T4 
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DNA Ligase (New England BioLabs) and 5µL of Adaptor Mix (Oxford Nanopore 
Technologies) and incubated for 10 minutes at room temperature. We next conducted 
the AMPure XP bead purification, however used 250µL of Short Fragment Buffer 
(Oxford Nanopore Technologies) to wash the beads. Beads were pelleted again, 
supernatant was discarded and repeated and allowed to dry for 30 seconds. Next, 
15µL of Elution Buffer was used (Oxford Nanopore Technologies) and incubated for 
10 minutes at room temperature, beads were pelleted, and the eluate was retained in 
a clean 1.5mL centrifuge tube. Ligated DNA was assessed for concentration using the 
Qubit 2.0 Fluorometer. DNA library was loaded at a concentration of 50 fmol. 
 
After library preparation, priming of the MinION flow cell was done using the Flow 
Cell Priming Kit (Oxford Nanopore Technologies) and conducted as per 
manufacturers’ instructions. The MinION sequencer was run for 16 hours before 
termination of the run and extraction of the data using the MinIT companion (Oxford 
Nanopore Technologies) that conducts base-calling of the data through the Guppy 
algorithm and outputs FAST5 and FASTQ files for analysis.  
 
4.2.7. Nanopore Sequencing Analysis 
 
FASTQ files generated from MinION Nanopore sequencing of Jurkat populations P0, 
C4 and C11 across the TAL1 locus required processing before conducting genetic 
variant analysis. Using the Python package, ‘qcat’ 
(https://github.com/nanoporetech/qcat), FASTQ files were combined into a single 
FASTQ file, trimmed and demultiplexed to remove adaptors and sorted into the 
barcoded samples (P0, C11 and C4 at passage 1 and 9) (EPI2ME algorithm for 
demultiplexing (ONT))(Deshpande et al., 2019). Next, the Python package ‘Minimap2’ 
was used for alignment of long reads of DNA (specific for nanopore sequencing) 
against a reference genome (Li, 2018). This resulted in an aligned SAM file to be 
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converted to a BAM file for analysis. Using ‘Samtools’ within Python, SAM files were 
converted to BAM files and sorted by coordinate (as conducted in Chapter 3 Methods 
– 3.2.3). BAM files processed and sorted were then tested for quality metrics and read 
length distributions using the European Galaxy database option ‘Nanoplot’ (Theuns 
et al., 2018). All command lines can be found in Appendix – 7.4.3. 
 
Also within the ‘Samtools’ package, the ‘Bcftools’ component can be used to compute 
the genotype likelihood of samples, call variants and provide statistics of variants in 
a binary variant call format (BCF) (Li, 2011; Li et al., 2009). ‘Bcftools’ also operates 
faster than other variant calling programs and is able to generate multi-way pileups, 
producing genotype likelihoods (mpileup). BCF files were converted to VCF files and 
analysed for sequence variants (Danecek and McCarthy, 2017). This identified genetic 
variants that differed from the reference genome (Human Genome Assembly 
GRCh37/hg19) with metrics of genotyping, allele depth (unfiltered number of reads 
per allele), depth of coverage (filtered depth of reads per allele), SP (Phred-scaled 
strand bias p-value) and allelic depth per strand (ADF (Forward) and ADR (Reverse)) 
within a VCF File format as described by the Broad Institute 
(https://gatkforums.broadinstitute.org/gatk/discussion/1268/what-is-a-vcf-and-how-
should-i-interpret-it). VCF files were analysed per sample to identify single-
nucleotide variants (SNVs) within the Jurkat cell lines and were narrowed down based 
on a threshold of < 60 for Phred-scaled strand bias p-value (SP). SP was used as it 
ensures that genetic variants identified have an equal amount of read depth on both 
strands to ensure correct evaluation of the alleles counted per strand as described by 
the Broad Institute 
(https://software.broadinstitute.org/gatk/documentation/article?id=6925). The 
identified SNVs were verified visually using the Integrative Genome Viewer (IGV). 
Sorted BAM files were loaded onto IGV, as was the VCF file that contained the 
genotyping information from the mpileup from ‘Bcftools’. This allowed for a direct 
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comparison of ‘Bcftools’ genotyping calls with aligned Nanopore sequencing data. 
These sites were also mapped with the 1000 Genomes Project Phase 3 single-
nucleotide polymorphisms (SNPs) (from the IGV server) to identify common and rare 
variants (The 1000 Genomes Project Consortium, 2015; Zheng-Bradley and Flicek, 
2017). The Genome Aggregation Database (gnomAD) by the Broad Institute was also 
used to retrieve known variants for the TAL1 locus 
(https://gnomad.broadinstitute.org/) (Karczewski et al., 2019) (Table 4.9). A 
normalised BIGWIG track for DHS within the Jurkat cell line (ENCODE data) that 
identifies open chromatin at regulatory DNA sequences was also included to assist in 
localising variants that reside within the regulatory landscape of TAL1. All command 
lines can be found in Appendix – 7.4.3.  
 
We then tested the linkage disequilibrium (LD) of identified SNPs that co-localise 
Jurkat SNVs using the NCI LDLink  (https://ldlink.nci.nih.gov/) database. Using the 
‘LDProxy’ option, genome-wide association studies (GWAS) SNPs were entered and 
downloaded as a .csv file to identify if SNPs identified to map Jurkat SNVs are proxy 
SNPs with a LD correlation of r2 > 0.8 (Carlson et al., 2004; Teo et al., 2009). Proxy SNPs 
in LD were analysed for Utah Residents from North and West Europe (CEU) 
population groups only. The r2  measure was used as it represents allelic frequency of 
pairwise LD SNPs more accurately than D’ values which are also used for LD analysis 
(VanLiere and Rosenberg, 2008).  
 
A set of criteria was placed to predict SNV functional relevance within regulatory 
elements. SNVs were displayed in the UCSC genome browser to show co-localisation 
of predicted TF binding sites (TFBS) from the JASPAR 2020 database track as 
validation for possible functional applications of co-localising Jurkat SNVs with TF 
binding (Khan et al., 2018b), as well as the Genomic Evolutionary Rate Profiling 
(GERP) to map highly conserved regions of the genome. This identified two SNVs that 
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may have functional relevance for regulatory element dysfunction within all Jurkat 
cell lines and were further tested through predictive analysis of 810 TF binding 
profiles within the JASPAR 2020 data base (http://jaspar.genereg.net/). The reference 
allele and alternative allele for the two SNVs were tested and displayed differential 
binding profiles at the SNV site and 12-bp upstream and downstream to mimic TF 
binding at sites from 6-12bp (Tuğrul et al., 2015).  
 
4.3. Results 
 
4.3.1. MSRE Optimisation 
 
To ensure the MSRE assay was reproducible and quantitative, the following 
conditions were optimised: gDNA concentration, HpaII and MspI endonuclease 
concentration, reaction volume and reaction time for digestion with MspI and HpaII 
and the qPCR cycling parameters were also optimised for this assay.  
 
Initially, the following digestion conditions were tested based on protocols from 
literature (Table 4.6) (Hashimoto et al., 2007; Holemon et al., 2007; Oakes et al., 2006).  
 
 
| Table 4.6. Digestion optimisation conditions with endonucleases HpaII and MspI for Jurkat 
cell line gDNA. 
 
MSRE Optimising Conditions 
gDNA Concentration (ng) 300 (20ng/μL) 150ng (10ng/μl) 
Enzyme Concentration (Units) 5 
Reaction Volume (μL) 15 
Reaction Length (Hours)1 1 
Other2 15 min 95°C Heat Inactivation 
1 New England Biolabs recommend a one hour digest for a gDNA concentration of 1μg 
(https://www.nebiolabs.com.au/protocols/2012/12/07/optimizing-restriction-endonuclease-reactions). 
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2 New England BioLabs suggest a heat inactivation step to inhibit STAR activity of endonucleases such as HpaII, 
which is inactivated at 80°C, whereas MspI cannot be heat inactivated.  
 
 
 
 
 
 
The very low amplicon yield associated with a starting digestion of 150ng of gDNA 
and a total of 10ng in the qPCR reaction (Fig 4.1, red arrow) indicated the optimal 
condition for digestion of gDNA by MspI. However, despite defining optimal 
digestion of gDNA with MspI, qPCR CT values displayed a large variation amongst 
all HpaII, MspI and Mock digested samples (Standard Deviation > 1) (data not shown).  
 
To improve the sensitivity of the assay we next tested different concentrations of 
primers (0.2 and 0.4µM final concentrations) and used a 3-step qPCR method (Table 
4.7) that is reported to be more accurate when compared to the standard 2-step PCR 
(Fast qPCR) (Hilscher, 2005).  
 
| Figure 4.1 Digested gDNA with endonucleases HpaII, MspI and mock digested at digestion 
concentrations of 150ng and 300ng and qPCR gDNA concentration with 10ng or 20ng.  
 
Red arrow indicates a low yield of amplicon product at 150ng of digested gDNA and 10ng of 
digested gDNA in the qPCR reaction. E-Gel 1Kb Plus DNA ladder (ThermoFisher Scientific) was 
used to measure amplicon size from 100 – 15000bp. 
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| Table 4.7. Previous 2-step qPCR cycling conditions changed to the 3-step qPCR cycling 
conditions for a more sensitive MSRE assay. 
 
Previous 2-step qPCR Cycling Conditions 
Cycle Temperature (°C) Time Step 
1 95 2 min 
Polymerase 
activation 
2-40 95 3 sec Denaturation 
 60 30 sec 
Annealing and 
Extension 
Changed to 3-step qPCR cycling Conditions 
1 95 5 min 
Polymerase 
Activation 
2-40 95 10 sec Denaturation 
 62 10 sec Annealing 
 72 30 sec Extension 
 
 
The 3-Step qPCR method was tested with a starting amount of 150ng of digested 
gDNA with 1.25, 2.5, 5, 10 and 20ng of gDNA in a qPCR reaction and 0.2µM or 0.4µM 
final primer concentrations. Differences between 0.2µM and 0.4µM were 
distinguished by the melt curve analysis which that displayed a single melt peak at  
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0.2µM primer 10ng gDNA 0.4µM primer 10ng gDNA
0.4µM primer 1.25ng gDNA 0.4µM primer 5ng gDNA 0.4µM primer 20ng gDNA
| Figure 4.2. (A-B) Melt Curve plot of duplicate amplicons generated through MSRE optimisation. 
 
Optimisation for MSRE primer 2 (Table 4.1) 10ng of MspI digested gDNA (150ng) within the qPCR 
reaction at a final primer concentration of 0.4μM and 0.2μM, respectively. (C-E). Melt curve plot of 
duplicate amplicons generate through MSRE optimisation for MSRE primer 2 at 1.25, 5 and 20ng of 
MspI digested gDNA (150ng) within the qPCR reaction with a final primer concentration of 0.4μM 
(respectively). Derivative reporter (negative first derivative of normalised fluorescence (Rn) by the 
reporter) on the x-axis and temperature on the y-axis. A single peak indicates the ‘melting’ of a single 
amplicon product after qPCR MSRE analysis. 
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| Figure 4.3. (A-E) MSRE Primer Efficiencies.  
 
Scatter plots of triplicate CT values (y-axis) against log sample quantity (Dilution factor 2) (x-axis) for MSRE 
primers, MSRE_1, MSRE_2, MSRE_3, MSRE_4 and MSRE_5, respectively (10ng of mock digested gDNA with a 
final primer concentration of 0.4μM in reaction). The slope equation of the standard curve (light blue line) is 
displayed (red) which was used to test the primer efficiency (black) per primer set (Methods 4.2.3.b.). 
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0.4µM, whereas multiple melt peaks are seen at 0.2µM (Fig 4.2A,B) (Melt curve cycling 
as stated in Chapter 2 Methods: 2.2.10). It is clear that multiple peaks appear at lower 
concentrations of gDNA using a final concentration of 0.4µM primers (Fig 4.2C and 
D) and that variability between replicates at 20ng of gDNA was also displayed (Fig 
4.2E). Therefore, the following MSRE assay was conducted with 10ng of digested 
gDNA using a final concentration of 0.4µM for the primers (Fig 4.2B). 
 
Having established gDNA digestion and amplification conditions, we next tested the 
amplification efficiency for each primer set (Table 4.1). Primers at a final concentration 
of 0.4µM per reaction were tested with mock digested gDNA with 1:1 serial dilutions 
of 2.5 to 0.156 ng, confirming each primer pair was amplified at between 90-110% 
efficiency (Fig. 4.3) (Rogers-Broadway and Karteris, 2015).  
 
4.3.2. The DNA methylation landscape of TAL1 
 
The prediction of DNA methylation sites across the TAL1 locus was done through the 
use of ENCODE supplied data for RRBS and Methyl450 bead array data (Methods: 
4.2.1). Methylation data was mapped across the TAL1 locus along with markers for 
active regulatory DNA: H3K27ac, DHS and H3K4me3 (Fig 4.4). The combined 
analysis of DNA methylation and histone methylation and acetylation identified five 
regions for MSRE analysis (Fig 4.4, pink vertical lines, MSRE_1-5). These regions 
targeted the 3’ exon (Fig 4.4, MSRE_1), two intragenic sites (Fig. 4.4, MSRE_2 and 3), 
an intergenic site immediately downstream of the MuTE insertion (Fig 4.4, MSRE_4) 
and the Jurkat MuTE insertion and intergenic enhancer (Fig. 4.4, MSRE_5).  
 
In Chapter 3, sites of intragenic and intergenic histone acetylation and methylation 
and the relative transcripts from the predicted TSS were utilised to identify DNA 
methylation for MSRE analysis. Specifically, MSRE_2-5 match DBA peaks of DHS, 
H3K27ac and H3K4me3 (Fig 4.4, Jurkat - *). Within the two intragenic sites (Fig 4.4, 
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MSRE_2 and 3) that are downstream of the exon, GTEx transcripts are displayed for 
full isoforms of the TAL1 gene within thyroid and whole blood cell types (Fig 4.4, TSS 
peaks, red box). H3K27ac and DHS DBA peaks at the two intergenic sites that map 
enriched H3K27ac and DHS downstream of the MuTE insertion (Fig 4.4, MSRE_4) and 
the Jurkat MuTE insertion and intergenic enhancer (Fig 4.4, MSRE_5) were also used 
for the MSRE analysis.  
 
Using the RRBS and Methyl450 data, patterns of  partial or low methylation 
(blue/purple and green bars) of the TAL1 locus in Jurkat T-ALL cells was seen in 
comparison to the A549 cell line (methylated) (Fig 4.4 – RRBS and Methyl450, 
respectively), except at the 3’ exon (Fig 4.4, MSRE_1) which is methylated for both 
Jurkat and A549 (Fig. 4.4, RRBS, Methyl450, Jurkat and A549 – red/orange bars). 
Therefore, the combination of regulatory element markers using DBA from Chapter 3 
in conjunction with RRBS and Methyl450 data has allowed for the targeting of MSRE 
sites 1 to 5 (Fig 4.4, MSRE Primers).  
 
Using RRBS data from the CCLE (Ghandi et al., 2019), DNA methylation across the 
CpG island in TAL1 was also assessed (Fig 4.5A). Using data from 14 different cell 
lines, comprised of T-ALL (Fig. 4.5B, Green bars - Peer, MOLT3, Jurkat, RPMI6402, 
HPBALL, ALLSIL, DND41, PF382, P12ICHIKAWA), myeloid leukaemia (Fig. 4.5B, 
purple bars -  HL60, MOLM, K562) and B-ALL (Fig 4.5B, orange bars - RCHAV, 
KASUMI), the percent methylation of each cell line was plotted using hierarchical 
clustering (Fig 4.5B). Relative to the other cell lines tested, the T-ALL Jurkat cell line 
was hypomethylated at the CpG islands and was similar to Peer, MOLT3, HL60 and 
MOLM cell lines (Fig 4.5B), and coincides with literature describing hypomethylation 
within CpG sites within TAL1 in late cortical T-ALL (Haider et al., 2018) (Fig 4.5B – 
cluster 1, green bars) (Haider et al., 2018). However, other T-ALL cell lines such as 
RPMI8402, HPBALL, DND41 and ALLSIL displayed a hypermethylation pattern 
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across both CpG islands (Fig 4.5B, cluster 2, 0.8-1). The myeloid leukaemia cell lines 
and B-ALL cell lines tend to group together within their respective groupings and  
 
 
 
 
 
 
 
 
 
 
 
 
| Figure 4.4. Identification of MSRE Target Regions.  
 
Highlighted MSRE primer targets localised with methylation sites identified by HAIB RRBS and HAIB Methyl450 
bead array data supplied by ENCODE through the UCSC genome browser. HAIB RRBS data displays DNA 
Methylation of cell lines, K562, H1-hESC, GM12878, A549 and Jurkat. RRBS DNA methylation displays 
unmethylated (blue), partial methylation (purple) and methylation (orange). HAIB Methyl450 displays cell lines, 
GM12878, K562, H1-hESC, A549 and 2 replicates of the Jurkat cell line. Methyl450 displays unmethylated 
(green), partial methylation (yellow) and methylation (red). These DNA methylation markers are mapped to 
Jurkat regulatory elements identified in Chapter 3 using DBA (H3K27ac, H3K4me3 and DHS), as well as the Jurkat 
enhancer (MuTE Insertion) (*). Chromosome 1 ideogram displays location of the TAL1 region (red line) and Ref-
Seq genes display isoforms of the genes, TAL1 and STIL. GeneHancer looping supplied from ENCODE is also 
shown with FANTOM5 mRNA transcript sites (red: forward strand, blue: reverse strand), red box indicates 
common transcript sites from GTEx data of thyroid and whole blood cell types 
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| Figure 4.5. Display of CCLE tested CpG Island sites within the TAL1 gene and percent methylation. 
 
A.TAL1 regions (CpG 1 and 2) with localisation of Ref-Seq genes for TAL1, regulatory ChIP-seq (H3K27ac and 
H3K4me3) and DHS markers, FANTOM5 mRNA transcript sites (red: forward strand, blue: reverse strand) and 
GeneHancer looping within the UCSC genome browser. B. Hierarchical clustering heatmap of CCLE RRBS data 
for DNA methylation at TAL1 CpG islands 1 and 2 (left and right, respectively) for cell lines Peer, MOLT3, Jurkat, 
HL60, MOLM, RPMI6402, HPBALL, K562, ALLSIL, DND41, PF382, RCHAV, KASUMI and P12ICHIKAWA. 
Clustering dendrogram displays the grouping of T-ALL (green), myeloid leukaemia (purple) and B-ALL (orange) 
cell lines based on DNA methylation percentage. Clustering dendrogram identifies methylation trends of 
tested cell lines into 3 clusters, cluster 1: hypomethylation/partial (0-0.5), cluster 2: partial/hypermethylation 
(0.8-1) and cluster 3: partial methylation (0.3-0.6). Kruskal-Wallis statistical testing displays no significant 
difference between groups (p < 0.05) (see also Appendix – Supp. Table 7.27). Scale of DNA methylation 
percentage is indicated in the heatmap legend (top left). 
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have shown hypomethylation or moderate methylation across these CpG sites, 
respectively (Fig 4.5B – purple and orange groups). Although no statistically 
significant differences were found between the different cell line groups for DNA 
methylation at the TAL1 CpG islands (Appendix - Supp. Table 7.27), it was apparent 
that T-ALL methylation is heterogeneous (Fig 4.5B), and that in the context of Jurkat-
specific T-ALL, intragenic CpG Islands within TAL1 are hypomethylated. 
 
4.3.3. MSRE assay on Jurkat parental and clonal cell lines (P0, C11 and C4) for regions across the 
TAL1 locus 
 
With this understanding of the predicted DNA methylation landscape across TAL1, 
an MSRE assay was done using DNA extracted from the Jurkat parental (P0) and 
clonal cell lines C11 and C4 as these cell lines exhibited high, moderate and low levels 
of TAL1 expression (Table 4.2). These Jurkat cell lines were tested at MSRE sites 2-5, 
which represented two intragenic (Fig 4.4, MSRE_2 and 3) as well as two 5’ intergenic 
sites (Fig 4.4, MSRE_4 and 5). In addition, validation of the MSRE assay against 
published methylation data sets was done using Jurkat and A549 cell lines (Fig. 4.4, 
MSRE_1 and 3).  
 
Using a boxplot outlier analysis, the dCT for MspI – Mock (dCT MspI) and HpaII – 
Mock (dCT HpaII) were displayed as averages of each replicate digest (Fig 4.6A and 
B - P0, C11, C4, passage numbers 1 and 9, n=12). Since dCT MspI values represented 
digested (i.e. unmethylated) MSRE amplicons, and the mock digested control 
represented undigested amplicons (i.e. methylated), the values for dCT MspI (CT 
MspI – CT mock) must be well above zero. Based on this rationale, an MSRE site was 
identified as methylated if the dCT HpaII values (CT HpaII – CT mock) clustered 
around zero. The assigning of methylated/not methylated to the MSRE amplicons was 
formalised by using outlier analysis of a box plot: lower inner and outer fences were 
calculated for each MSRE dCT MspI dataset. The dCT HpaII values were plotted and, 
relative to the MspI data, were defined as mild outliers when mapped between the  
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inner and outer fences; and defined as extreme outliers when mapped below the lower 
outer fence. In this way, MSRE amplicons could be identified as not methylated (above 
inner fence), low/partial methylation (values between inner and outer fences) and 
high methylation (below outer fence).  
 
The box plot analysis displayed the distribution of data of the positive control i.e. the 
expected CT value for an unmethylated samples (dCT MspI) relative to the dCT values 
of each sample per region (dCT HpaII). 
 
We first analysed the two intragenic MSRE sites (Fig 4.4, MSRE_2 and 3), which map 
to intragenic TSS sites (GTEx transcript) and peaks of H3K4me3 and H3K27ac (Fig 
4.4). dCT HpaII values are mainly distributed between the unmethylated and partial 
methylated states (Fig 4.6A, MSRE_2: CT MspI boxplots shown in blue, CT HpaII 
values show as red points; inner and outer lower fences indicated as black lines). This 
region is downstream of DBA identified H3K27ac and H3K4me3 intragenic 
enrichment based on Chapter 3 DBA (Chapter 3 - Fig 3.6) and GTEx transcripts from 
thyroid and whole blood cell types identified that major TAL1 isoform transcripts (full 
| Figure 4.6. MSRE Analysis of the TAL1 locus in Jurkat Cell Lines.  
 
(Previous Page). Location of MSRE primers 1-5 (MSRE_1-5) relative to H3K27ac, DHS, H3K4me3 and the 
longest isoform transcript identified by GTEx for thyroid and whole blood cell types (green and pink bars, 
respectively. (A) Methylation status of the intragenic (MSRE_2 and 3) and 5’ extragenic (MSRE_4 and 5) 
using Jurkat cell lines P0, C11 and C4. Boxplots show results of dCT MspI (dCTM) with results of dCT 
HpaII shown as scattered data points (dCTH) (B) Validation of the MSRE assay using Jurkat (P0) and A549 
gDNA samples (MSRE_1 and 3). Boxplot inner and outer lower fences calculated from the dCT MspI 
datasets (n=12 in each case) are shown as black lines: unmethylated data falls above lower inner fence 
(top line), partial methylated samples between the inner and outer fences, and high methylation 
samples below the lower outer fence. X-axis displays region tested corresponding to the targeted 
regions highlighted (top panel) and y-axis displays HpaII dCT values. 
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transcripts) are upstream of this site (Chapter 3 - Fig 3.7). Inspection of the HpaII data 
points showed the parental and clonal cell line 11 shifted from unmethylated at 
passage 1 to partial methylation at passage 9 whereas the opposite was seen for cell 
line C4 (Table 4.8).  
 
However, this is different for the second intragenic site that maps H3K27ac and 
H3K4me3 and TSS transcripts (MSRE_3) that co-localise within an active regulatory 
element peak. In this case, the distribution dCT HpaII values (Fig. 4.6, MSRE_3, dCT 
HpaII) falls within the partially methylated and high methylation status (Fig4.6A, 
MSRE_3: dCT MspI shown in yellow, CT HpaII values show as green data points; 
inner and outer lower fences indicated as black lines). Therefore, inspection of the dCT 
HpaII data points displayed the parental cell line shifting from a partially methylated 
state to a high methylation state at passage 1 (Table 4.8 – P0). The opposite is seen for 
clonal cell line 4 where the methylation state changes from high methylation to 
partially methylated between passage 1 and 9, whereas clonal cell line 11 remains 
partially methylated between passages (Table 4.8 – C11 and C4). Therefore, despite 
the relative proximity of the MSRE_2 and MSRE_3 regions to each other (Fig 4.4), the 
changes in DNA methylation between MSRE_2 and MSRE_3 were evident, shifting 
from an overall unmethylated state to a partial/methylated state. Thus, a dynamic shift 
of DNA methylation occurs at these sites, particularly at MSRE_3, and these sites are 
localised to intragenic peaks of H4K3me3 and H3K27ac.   
 
Next, we analysed the methylation status of the two intergenic MSRE sites, which 
include the MuTE insertion enhancer (Fig 4.4, MSRE_5), and a downstream site that is 
defined by increased H3K27ac and DHS in Jurkat T-cells (Fig 4.4, MSRE_4). At the 
intergenic H3K27ac and DHS enriched region downstream of the MuTE insertion 
(MSRE_4), dCT HpaII values mainly fell within the partially methylated and 
unmethylated states (Fig 4.6A, MSRE_4: dCT MspI shown in purple, dCT HpaII 
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values shown as light blue data points; inner and outer lower fences  indicated as black 
lines). Prior DBA of this site indicated the presence of a Jurkat specific H3K27ac and 
DHS enriched region that does not co-localise with the MuTE insertion (Chapter 3 – 
Fig 3.4). At this site, partial methylation was seen amongst all clonal cell lines, except 
clonal cell line 11 at passage 1 (Table 4.8). This indicated an overall stable state of DNA 
methylation across cell lines and passages at this intergenic H3K27ac and DHS 
enriched site.  
 
In contrast, the MuTE insertion enhancer (MSRE_5) displayed dCT values that fell 
within the unmethylated state for all cell lines at both passages (Fig 4.6A, MSRE_5: 
dCT MspI shown in pink, dCT HpaII values are shown as light green data points; 
inner and outer lower fences indicated as black lines). This site localises with the MuTE 
insertion mutation that introduces MYB binding motifs and harbours TAL1 CRC 
binding activity (Mansour et al., 2014). In addition, DBA identified the differential 
binding at this region as statistically significant for the Jurkat cell line, relative to other 
cell lines tested in Chapter 3 (Fig 3.4). The stable unmethylated state seen between all 
cell lines and passages (passage 1 and 9 correlation tested using Spearman’s Rho test, 
p < 0.05) suggested that this enhancer was active in all Jurkat cell lines, in comparison 
to the putative downstream intergenic enhancer (Fig 4.6 - MSRE_5 Vs MSRE_4). This 
result also validated the MSRE assay by identifying low DNA methylation that agreed 
with the function of this super-enhancer site within T-ALL.   
 
In order to compare the DNA methylation status of the TAL1 locus presented here to 
published methylation data from cell lines in other laboratories, comparisons of 
differential methylation were tested using the A549 cell line (lung epithelial cancer) 
and the Jurkat parental cell line (P0) at the exonic and intragenic  H3K27ac and 
H3K4me3 peak site (MSRE_1 and 3) to HAIB RRBS and HAIB Methyl450 data (Fig 
4.6B). This showed different results to those seen within the ENCODE HAIB RRBS 
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and Methyl450 data for the exonic site and intragenic peak site for A549 and Jurkat 
(Fig 4.5 and 4.6B – MSRE_1 and 3). In our MSRE assay, both the A549 and the Jurkat 
cell line DNA was unmethylated at the exonic site (Fig 4.6B - MSRE_1: dCT MspI 
shown in blue, dCT HpaII values shown as red data points; inner and outer lower 
fences indicated as black lines), whereas the ENCODE data displayed DNA 
methylation at this site for both cell lines (Fig 4.4 – MSRE_1 – red/orange methylated 
sites). Dynamic methylation was seen at the intragenic site that colocalised with 
H3K27ac and H3K4me3 enrichment (Fig 4.6B - MSRE_3: CT MspI shown in yellow, 
dCT HpaII values shown as green data points; inner and outer lower fences indicated 
as black lines) for A549 and Jurkat within the MSRE assay, whereas this is 
unmethylated for the Jurkat cell line and methylated for the A549 cell line within the 
ENCODE data (Fig 4.4 – MSRE_3 – green/blue for unmethylated sites and red/orange 
for methylated sites). Therefore, while our MSRE assay was consistent with an active, 
unmethylated enhancer at the MuTE site (Fig. 4.6, MSRE_5), there was variation 
between our results and those done in other laboratories, suggesting variation in cell 
lines and DNA methylation between laboratories.    
 
| Table 4.8. DNA methylation statuses of Jurkat parental and clonal cell lines (P0, C11 and C4) 
as found by the MSRE assay for MSRE regions 2-5 and TAL1 expression at passages 1 and 9.  
 Region 2 3 4 5 
TAL1 
Expression 
Pa
ss
ag
e 
1 P0 Unmethylated Partial Partial Unmethylated 1.43 
C11 Unmethylated Partial Unmethylated Unmethylated 0.75 
C4 Partial High  Partial Unmethylated 0.35 
Pa
ss
ag
e 
9 P0 Partial High  Partial Unmethylated 1.77 
C11 Partial Partial Partial Unmethylated 0.58 
C4 Unmethylated Partial Partial Unmethylated 0.40 
1 Methylation status was determined by boxplot outlier tests (Methods: 4.2.4) (Fig 4.6A). 
2TAL1 fold change relative to the Jurkat parental P0 at passage 1 as found in Chapter 2.  
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Overall, the results obtained from the MSRE assay for each cell line and passage, 
suggested an association with TAL1 expression despite no statistical correlations (data 
not shown). MSRE_3 (co-localised with TSS peaks and H3K27ac and H3K4me3 
enrichment) exhibited the most dynamic DNA methylation across the regions tested, 
specifically for the Jurkat parental at passage 1 and 9 (Fig 4.6 and Table 4.8 – P0 
passage 1 and 9). It was seen that a state of partial methylation shifted to high 
methylation at this site and this coincided with increased TAL1 expression (Table 4.8 
– 1.43 to 1.77, relative fold expression), and was also seen for MSRE_2 (downstream 
of TSS Peaks and H3K27ac and H3K4me3 peak enrichment) shifting from an 
unmethylated state to a partially methylated state (Table 4.8 – region 2). In clonal cell 
line 11, within the downstream enriched DHS and H3K27ac intergenic site (MSRE_4), 
a shift from an unmethylated state to a partially methylated state was observed and 
this coincided with decreased TAL1 expression (Table 4.8 – 0.75 to 0.58, relative fold 
expression). However, clonal cell line 4 did not exhibit a correlation between DNA 
methylation status and TAL1 expression, with constant expression of TAL1 between 
passages, despite changes in methylation status between passage 1 and 9 (Table 4.8 – 
region 2 and 3).  
 
 
Using bioinformatics analysis, reduced HAIB representation bisulphite sequencing 
(RRBS), and HAIB Methylation450 array (Methyl450) data supplied from the 
ENCODE project, sites of DNA methylation within the TAL1 locus were identified. 
Sites were identified that have the same or different patterns of DNA methylation for 
cell lines, such as A549 (lung epithelial cancer) and the Jurkat cell line. These sites have 
provided target regions for analysis of DNA methylation using the methylation-
sensitive restriction endonuclease (MSRE) assay, as well as DNA sequencing using 
Nanopore sequencing of the Jurkat cell lines P0, C11 and C4 at passages 1 and 9.  
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4.3.4. Amplicon Generation Optimisation for Nanopore Sequencing  
 
The initial cycling conditions suggested by New England BioLabs (Appendix – Supp. 
Table 7.28) were tested with all primers made for amplicon generation testing between 
different combinations of 5x Q5 High GC Enhancer at a 1x concentration, 50-200ng of 
gDNA, changes to the predicted annealing temperature (TAP) (2°C + TAP) and testing 
between 25µL and 50µL reactions. Each combination of the conditions tested provided 
no results when run on a 1.2% agarose gel stained with SYBR Safe Gel stain (data not 
shown). The GC content of the amplicons to be generated were then tested using the 
BiologicsCorp GC content calculator 
(https://www.biologicscorp.com/tools/GCContent) and provided a line graph to 
display the distribution of GC content across each amplicon (30bp window) 
(Appendix – Example shown in Supp. Fig 7.6). 
 
After understanding the GC content of the amplicons to be generated, a new approach 
for the cycling conditions was taken place through the use of a touch-down PCR 
technique (Korbie and Mattick, 2008). A majority of primers approached GC content 
of 75-100% in areas of the amplicon to be generated (example – Supp. Fig 7.6). 
Therefore, as recommended by Korbie and Mattick (2008), 10% DMSO was used for 
amplicons with a GC-content > 60% in combination with the touch-down PCR 
technique with 75ng of gDNA with an annealing temperature of 10°C + TAP and (10°C 
+ TAP) - 5°C (Initial annealing) and TAP and TAP - 5°C (second annealing temperature) 
with an extension time of 40 seconds/kb (Methods: 4.2.5). It was found that these 
conditions produced amplicons at the predicted size (2-4kb) for four out of the six 
primers for cycling conditions at 5°C below the TAP  (initial annealing temperature: 
(10°C + TAP) - 5°C and second annealing temperature: TAP - 5°C) (Fig 4.7A). The 
remaining two primers exhibited secondary PCR products at 10% DMSO, due to 
decreasing the melting point of the primers used (Lorenz, 2012). Therefore, conditions 
were tested for the remaining two primers at 0% and 5% DMSO, with secondary PCR 
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products and reduced amplification at 5% DMSO at the TAP (Fig 4.7B – 5% DMSO). At 
0% DMSO, increased single products at the predicted size were generated and 
therefore used for Jurkat cell line amplicon generation (Fig 4.7B - 0% DMSO). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After the sequencing run was completed, the MinION interface provided metrics on 
the quality, read lengths, cumulative output of the sequenced data and summary of 
channel pores used throughout the run of all the samples tested as a pool. This 
confirmed that the overall quality of the sequenced data had a q-score of 10 and 
approximately 100% of pores were used during the sequencing run (data not shown). 
10037
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| Figure 4.7. (A-B). Optimisation of PCR amplicons (Seq_1 - Seq_6) with 75ng of gDNA using the touch-
down PCR cycling conditions. 
 
(Methods: 2.5.4). A. Amplicon primers Seq_1 and Seq_4 to Seq_6 under conditions of 10% DMSO with 
the TAP-5°C touch-down PCR cycling conditions . B. Amplicon primers Seq_2 and Seq_3 optimised with 
0% and 5% DMSO at the predicted annealing temperature (TAP). At 5% DMSO, primers generated more 
secondary PCR products in comparison to 0% DMSO and therefore was used for Jurkat cell line amplicon 
generation.  
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The quality of the data after processing and aligning (Methods: 4.2.7) (Aligned BAM 
files) was further validated per sample using Nanoplot within the Galaxy European 
database (https://usegalaxy.eu/). This provided similar metrics per sample and 
visualisation of  the read quality displayed with a q-score > 7.5 (minimum 7 as stated 
by Theuns et al., (2018)) and a read length metric of 0-4kb (as expected for the 
amplicons generated) (Fig 4.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
| Figure 4.8. Example of the metrics provided by European Galaxy database 'Nanoplot' for nanopore 
sequencing data.  
 
The density plot displays the relationship between average read quality (y-axis) and the average read 
lengths of the sequences for sequencing of the Jurkat cell line amplicons, P0 at passage 1, across the 
TAL1 locus. Density plot displays the correlation and concentration of values for average read quality 
across a q-score range of 7.5-12.5 and the average read length at two points around 0-1500bp and 2000-
3500bp (range of amplicon sizes). Histogram plots along the right and top side of the plot display the 
scale of average read quality and read lengths individually to display the distribution of data 
(respectively). 
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The sequencing data was processed and assessed for genetic variants (Single 
nucleotide variants (SNVs)) using the ‘Bcftools’ mpileup file generated (Methods: 
4.2.7). This identified genetic variants that differed from the reference genome 
(Human Genome Assembly GRCh37/hg19).  Initially, between 20 to 27 genetic 
variants were called using ‘Bcftools’ per Jurkat cell line at each passage. Using the SP 
metric, genetic variants found per sample were narrowed down to 8-16 SNVs. A 
threshold of 60 was set (as stated by the Broad Institute) to remove a majority of false 
positive variants, however false positive variants can still be found within variants 
with a SP of < 60.  
 
4.3.5. Nanopore sequencing of the Jurkat parental and clonal cell lines across TAL1 
 
The Integrative Genomics Viewer (IGV) identifies variants using  algorithms similar 
to the commonly used Genome Analysis Tooklit (GATK, Thorvaldsdóttir et al., 2013). 
Therefore, IGV was used to visually validate filtered SNVs identified by ‘Bcftools’ and 
provide allele frequencies of the called variants as well as highlight mismatched reads, 
highlight low quality reads and sort, group and colour alignments based on different 
parameters (read strand, base pair etc.). IGV also can map known GWAS and common 
SNPs from the 1000 Genomes Project, which in conjunction with the gnomAD 
database (Karczewski et al., 2019) was used to validate SNVs and other alleles in Jurkat 
cell line DNA across the TAL1 locus (Example shown in Fig 4.9- i).  Through using 
IGV, SNVs detected by ‘Bcftools’ were confirmed for 9 variants across all Jurkat cell 
lines, and one variant for clonal cell line 4 at passage 1 and 9 (Table 4.9). Five of the 
SNVs identified in Jurkat cell lines corresponded to known GWAS and common SNPs 
from the 1000 Genomes Project and the gnomAD database (Table 4.9, Fig 4.9 – i, see 
also Fig 4.10B). False-positive calling of insertions and deletions (indels) was seen 
using ‘Bcftool’ indel calling procedures, therefore IGV was used to manually find  
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Gene |
DHS
1000 GP’s SNP
Read Depth 83975 57903
Sequencing 
Alignment
Sequence
i
ii
| Figure 4.9. IGV detection of a SNV and 12-bp insertion after Nanopore Sequencing of TAL1. 
 
Top: The TAL1 (Ref-seq) regulatory landscape using DNase1 Hypersensitivity data for Jurkat from the ENCODE 
project as displayed in the UCSC genome browser. i). Heterozygous 1000 Genomes Project SNP rs741958 at 
chr1: 47,692,281 in the Jurkat parental cell line (P0). Read-depth of sequencing is displayed (a total of 83975 
reads that includes forward and reverse strands) with C: 56% and T: 43%. Alignment of nanopore sequencing 
is visualised in IGV with corresponding colours to read strands (red: forward, blue: reverse), with near-equal 
reads each strand for each allele ii). The 12-bp heterozygous MuTE insertion (chr1: 47,704,968), symbolised 
by purple marker with the insertion size displayed. Read depth of sequencing run is shown (57903) with 
alignment visualising of strands (red: forward, blue: reverse) and co-localising reference genome sequence 
relative to the insertion site. Approximately 50% of reads were assigned the insertion. Although most 
insertions were 12-bp in length, some sequencing-dependent artefacts of shorter or longer reads were also 
detected. 
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indels amongst Jurkat samples (Fig 4.9-ii). Indels were verified based on read depth 
and number of reads for each indel. Through manual screening of Jurkat samples 
using IGV, the 12-bp heterozygote insertion (predicted MuTE Insertion) was identified  
(Fig 4.9-ii purple bars, 50% of reads were assigned to the insertion) as stated in 
literature (Table 4.9 –Insertion) (Mansour et al., 2014). 
 
Bioinformatic and MSRE analysis of the TAL1 locus in Jurkat T-cells (Chapters 3 and 
4) identified three regulatory regions as defined by peaks of H3K27ac and/or 
H3K4me3 and sites of DNA methylation (Fig. 4.10A, red boxes). After confirmation of 
Jurkat cell line SNVs and the 12-bp insertion using IGV, each was mapped to the TAL1 
locus: six variants mapped to introns within the TAL1 gene and flanked the MSRE 
sites MSRE_2 and MSRE_3 (Fig 4.10A, leftmost red box), while five genetic variants 
mapped to an intergenic region upstream of TAL1 that also included the MuTE 12-bp 
insertion mutation and MSRE_5 (Fig. 4.10A, rightmost red box) No genetic variants 
mapped to the region that included MSRE_4 (Fig. 4.10A, middle red box).  
 
After mapping the Jurkat SNVs within these regulatory regions, we next mapped co-
localising genome-wide association studies (GWAS) and common SNPs from the 1000 
Genomes Project and the gnomAD database (Karczewski et al., 2019; The 1000 
Genomes Project Consortium, 2015; Zheng-Bradley and Flicek, 2017). It was found 
that 5 of the SNVs identified here localised with published SNPs (Fig 4.10B). 
Specifically, SNV1 and SNV2 mapped to GWAS SNPs rs741958 and rs2250380 that are 
associated with coronary artery calcified atherosclerotic plaques within African-
Americans with type-2 diabetes (Divers et al., 2017); SNV4 mapped to rs11211480 that 
is associated with variation in human blood cell traits for complex disease (Astle et al., 
2016); SNV8 and SNV9 mapped to published SNPs rs6701381 and rs11211482 that 
have not been reported in any GWAS study.  
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| Figure 4.10. Mapping of Jurkat cell line genetic variants within the TAL1 locus identified using nanopore 
sequencing and co-localising published SNPS.  
 
A. Location of Jurkat cell line genetic variants identified through ‘Bcftools’ and IGV as vertical lines across the 
TAL1 landscape relative to regulatory element markers, H3K27ac and H3K4me3, MSRE primers and 
corresponding differential binding sites identified in Chapter 3 (red boxes). Chromosome ideogram of the TAL1 
locus and the Ref-Seq isoforms for TAL1 are displayed.  Vertical lines show the location of Jurkat cell line SNVs 
and Indels identified: dark green (1-9) – SNV found in all Jurkat cell lines tested, red (12) – Jurkat MuTE insertion 
identified in all Jurkat cell lines tested, dark purple (11) – SNV identified in C4 at passage 1 and 9 - numbers 
correspond to Table 4.9). GERP scoring across the TAL1 locus displayed mammalian evolutionary conservation 
where positive scores (positive bar) display conserved bases and negative scores (negative bar) display 
evolutionary neutral bases. B. Zoomed-in view of the two regulatory regions that include Jurkat genetic 
variants identified in this study. 'rs’ numbers identify published SNPs from the 1000 Genomes Project and the 
GnomAD database and co-localise with SNVs 1, 2, 4, 8 and 9 (see also Table 4.9).  
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| Table 4.9. Called genotypes for finalised Jurkat cell line SNVs and Indels with a list of co-
localising GWAS/common SNPs from 1000 Genomes Project and gnomAD database and their 
alternative allele and allele frequencies. 
Jurkat Cell Line 
SNV Coordinate (Chrom 
1) 
SNV Genotype 
Co-localising 
GWAS1/common 
SNP2 
SNP Alternative 
Allele – Allele3 
Frequencies 
All cell lines 
SNV1 - 47,692,281 
Heterozygote 
rs741958 T – 0.88 
SNV2 - 47,692,786 
rs2250380 
(also gnomAD 
identified SNP) 
C – 0.88 
SNV3 - 47,693,116 - - 
SNV4 - 47,693,220 rs11211480 G – 0.28 
SNV5 - 47,695,997 
Homozygote (Alt) 
- - 
SNV6 - 47,697,125 - - 
SNV7 - 47,703,613 
Heterozygote 
- - 
SNV8 - 47,704,240 rs6701381 G – 0.34 
SNV9 - 47,704,674 rs11211482 T – 0.38 
C4 Passage 1 
and 9 
SNV10 - 47,705,764 Heterozygote - - 
All cell lines Insertion – 47,704,968 
12-bp 
heterozygote 
insertion 
(predicted MuTE 
insertion) 
- - 
1GWAS-associated SNPs from the 1000 Genomes Project – rs2250380 also found within the gnomAD database 
2Common SNPs from the 1000 Genomes Project 
3Allele frequencies calculated from 1000 Genomes Project data 
4All SNPs were identified as eQTLs from the GTEx database. 
 
 
We next used the published SNPs that map to Jurkat SNVs to understand the genetic 
structure of the TAL1 intragenic (SNV1, SNV2 and SNV4) and intergenic (SNV8 and 
9) regions.   
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Linkage disequilibrium (LD) is the non-random association of alleles on the same 
chromosome (two or more loci) within a population (Slatkin, 2008). The human 
genome includes an average of 4 million SNPs and are identified through GWAS to 
map haplotype blocks across the genome (Corradin et al., 2014). A haplotype block is 
a genomic locus that is bound by common points of recombination and SNPs that fall 
within these blocks are seen to be in high LD (Wall and Pritchard, 2003). To identify 
haplotypes across the TAL1 locus the NCBI LDLink database (Methods: 4.2.7) was 
used to find the 5 SNPs that co-localised with Jurkat SNVs 1, 2, 4, 8 & 9 (Fig 4.10B and 
Appendix – Supp. Table 7.29). It was found that LD extended across and between 
intragenic and intergenic regions, particularly seen with SNV9 (rs6701381) having 
high LD with SNV8/rs11211482 (r2=0.88), SNV4/rs11211480 (r2=0.81), and 
SNV2/rs2250380 (r2=0.81) (Fig 4.11 – rs6701381). This analysis showed that all Jurkat 
SNVs 1, 2, 4, 8 & 9 are in high LD within a haplotype block. We also concluded that 
the remaining Jurkat SNVs that did not map to published SNPs, were novel mutations 
within this haplotype block.  
 
Having mapped the location of the Jurkat SNVs to two regulatory regions (Fig 4.10B) 
and identified patterns of LD across the TAL1 locus (Fig 4.11), we next considered the 
possible functional relevance of the Jurkat SNVs in the context of regulatory elements 
such as promoters and enhancers. To do this, criteria that identify Jurkat SNVs 
predicted to have possible regulatory function were defined as: location within a 
regulatory element marker peak (H3K27ac and/or H3K4me3), predicted TF binding 
site(s) within 10bp upstream and downstream of the SNV, and Genomic Evolutionary 
Rate Profiling (GERP) localisation (Fig 4.12 and Appendix – Supp. Fig 7.7 to 7.16).  
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After selection of SNVs based on these criteria, two SNVs (SNV3 and SNV5) within 
the intragenic region that do not map to published SNPs were identified. Specifically, 
SNV3 maps in the centre of a peak of H3K27ac and lower relative levels of H3K4me3, 
within a region of GERP identified high conservation with predicted binding of TFs, 
ZNF143, PKNOX2, TGIF1, TGFI2, NFE2 and NFE2 within 10bp (Fig 4.12 and 
Appendix – Supp. Fig 7.14). SNV5 also maps within a H3K27ac peak and H3K4me3,  
| Figure 4.11. Linkage disequilibrium patterns of co-localising published SNPs with Jurkat SNVs identified 
through Nanopore Sequencing within the TAL1 locus. 
 
Display of linkage disequilibrium (LD) patterns within intragenic and intergenic TAL1 regions isolated from 
Fig 4.12 and zoomed in to display co-localising published SNPs with Jurkat SNVs. SNPs are shown to map to 
the associated variant and display the reference and alternative alleles for each SNV (all SNVs display 
heterozygous alternative alleles). LD correlation coefficient r2, displays relationships of the co-localising SNPs 
within high LD (r2>0.8). rs741958 has high LD with rs2250380 (r2=0.94), rs2250380 also has high LD with 
rs6701381 (r2=0.81), and rs6701381 has high LD with rs11211482 and rs11211480 (r2=0.88 and 0.81, 
respectively).  
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with high predicted evolutionary conservation and predicted binding of TFs, EMOES 
and TBX21 (Fig 4.12 and Appendix – Supp Fig. 7.12). This suggested that the TAL1 
locus in the Jurkat cell lines included two rare variants/mutations that may play a role 
in regulatory element activity based on these criteria (Fig 4.12).  
 
Having identified two possible regulatory SNVs, we next conducted a deeper 
predictive analysis of TF binding by using the JASPAR 2020 database (Khan et al., 
2018b).  Possible differences in TF binding to motifs that included alternate alleles of 
the two SNVs mutations were investigated by using 810 TF profiles for Homo Sapiens 
and within a range 12bp upstream and downstream of each variant allele, based on 
TF binding occurring across 6-12bp (Tuğrul et al., 2015). A comparison between TF 
| Figure 4.12. Prediction of Jurkat SNV functional relevance within regulatory elements. 
 
The prediction analysis is based on the criteria of co-localising regulatory marker enrichment (H3K27ac and 
H3K4me3), predicted transcription factor binding from the JASPAR 2020 database within 10bp upstream and 
downstream of SNV and mapping of Genomic Evolutionary Rate Profiling (GERP) regions of conservation 
amongst mammalian species. (see also Appendix – Supp. Fig 7.7-7.16 for mapping of these criteria per SNV). 
JASPAR 2020 predicted sites display scoring of TF binging probability within a minimum p-value of <10-4 (as 
stated by the JASPAR 2020 track in the UCSC genome browser). GERP scoring at each SNV, displays mammalian 
evolutionary conservation where positive scores (positive bar) display conserved bases and negative scores 
(negative bar) display evolutionary neutrally conserved bases.  
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binding of the reference allele and the alternative allele for SNV3 and SNV5 was 
conducted. SNV3 displayed 27 predicted binding profiles for the reference allele, in 
comparison to 36 binding profiles with the alternative allele (G>A heterozygote) 
(Appendix – Supp. Table 7.30). In particular, predicted binding of TFs, MYB and 
NKX2-2 which are involved in T-ALL processes such as the TAL1 CRC and early 
cortical T-ALL (respectively)(Sanda et al., 2012; Van Vlierberghe and Ferrando, 2012) 
were identified within the reference G-allele analysis, but were absent for the alternate 
A-allele (Appendix – Supp. Table 7.30). Other TFs, such as SOX and HOXA proteins, 
were identified only for the alternate-A allele, and these TFs are associated with 
transcriptional regulation of embryonic and HSCs, respectively (Dou et al., 2016; 
Kamachi and Kondoh, 2013). For SNV5, predicted binding of the reference allele 
showed 30 TF binding profiles in comparison to 80 binding profiles for the 
homozygote alternative allele (G>A homozygote) (Appendix – Supp. Table 7.31). Of 
note, TFs GATA5, GATA2 and GATA3 were predicted to bind to a sequence that 
included the reference G-allele but were predicted to interact with increased affinity 
when tested with the alternate A-allele (e.g. GATA2: binding score of 4.45 to 5.10 and 
GATA3: 4.7 to 5.116) (Appendix – Supp. Table 7.31). The GATA3 TF is involved in 
TAL1 CRC function (Sanda et al., 2012), and similar to SNV3, the predicted binding of 
HOXA proteins was also seen with  the alternate A-allele for SNV5.  
 
4.4. Conclusion  
 
A bioinformatics analysis using ENCODE supplied RRBS and Methyl450 data, 
mapped DNA methylation across the TAL1 locus for the Jurkat cell line, as well as 
other leukaemia cell lines. This analysis showed that the TAL1 locus was 
hypomethylated in Jurkat T-ALL cells and was consistent with published literature. 
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The MSRE assay was used to test the methylation landscape amongst Jurkat 
populations (P0, C11 and C4) at passages 1 and 9. Differential DNA methylation was 
seen between the different MSRE sites (exonic, two H3K27ac and H3K4me3 enriched 
sites, downstream intergenic H3K27ac and DHS site and the MuTE insertion enhancer 
site). Analysis of the intragenic MSRE sites that co-localised with TSS peaks, H3K27ac 
and H3K4me3 showed some Jurkat populations displaying high methylation 
dependent on passage (C4 and P0), while the intergenic Jurkat (MuTE) enhancer 
showed all Jurkat populations were unmethylated at this site for all passages, as 
expected for tumorigenic TAL1 overexpression. Trends were seen between DNA 
methylation status within the parental cell line, specifically, intragenic methylation 
increased as TAL1 expression increased, whereas clonal cell line 11 showed that DNA 
methylation increased at the downstream intergenic H3K27ac and DHS peak with a 
decrease of TAL1 expression at passage 1 and 9 (Table 4.8, MSRE_2). This identified 
two regions of potential dynamic DNA methylation that were associated with changes 
in gene expression patterns between Jurkat cell lines and passages, and which might 
be consistent with the presence of an intragenic enhancer (King et al., 2016; Mansour 
et al., 2014), particularly for MSRE_3. Therefore, an investigation into possible genetic 
differences across the TAL1 locus between these Jurkat cell lines could determine why 
differences in the phenotype, transcription of TAL1 and the DNA methylation profile 
within the TAL1 locus are seen. To do this, a Nanopore sequencing experiment was 
conducted for parental and clonal populations P0, C11 and C4 at passages 1 and 9.  
 
 
The sequencing of the TAL1 locus identified genetic variants within Jurkat parental 
and clonal cell lines, P0, C11 and C4, at sites of dynamic DNA methylation (MSRE_2 
and 3) and intragenic sites enriched for H3K27ac and H3K4me3 as well as an 
intergenic site enriched for H3K27ac. Five of these variants identified also mapped 
with publicly available GWAS and common SNP data from the 1000 Genomes Project 
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and the gnomAD database, allowing us to conduct a predictive analysis of 
recombination patterns between these SNPs. These SNPS were found to be in high LD 
with each other, suggesting they all fall within one haplotype block that extended 
between intragenic and intergenic regions. The genetic variants were further analysed 
for their specific mapping to regulatory element markers, highly conserved regions 
and potential TF binding. This identified two SNVs that met these criteria, SNV3 and 
SNV5, which were further analysed using the JASPAR database for predicted binding 
of TFs when comparing the reference and alternative allele within the sequence. For 
both SNVs, the presence of the alternative allele is correlated with a difference in the 
predicted number, identity and affinity of TFs binding to motifs that include these 
alleles. However, SNV3 was seen to no longer contain MYB and NKX2-2 binding 
motifs after alteration of the allele but introduced SOX and HOXA protein binding. 
The alternative allele for SNV5 was associated with increased predicted TF binding 
such as for the key TAL1 CRC protein GATA3 and other HOXA proteins as well. 
Therefore, these two SNVs present in all cell lines may be novel variants that are 
predicted to be associated with regulatory elements within the TAL1 locus but are not 
Jurkat cell-line specific.  
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Chapter	5 -	Discussion	and	Future	
Directions	
 
5.1. Hypothesis  
 
The hypothesis of this thesis proposed that the expression of the gene encoding the 
transcription factor TAL1 was associated with the proliferation of the Jurkat late 
cortical T-ALL cell line. Specifically, we tested whether differences in the proliferation 
of Jurkat T-ALL clonal cell lines reflected differences in TAL1 transcription, and 
whether such differences were accompanied by epigenetic and/or  genetic differences 
between the different cell lines and at varying passage numbers of culture.  
 
5.2. Summary of Results  
 
5.2.1. Phenotypic and Transcriptional Profiles of Jurkat parental and clonal cell lines 
 
In this thesis we have shown that Jurkat clonal populations have differential 
proliferative abilities that are typically higher than the original parental population 
(Chapter 2 – Fig 2.7). Differential proliferation was statistically significant between 
clonal and parental populations, as clonal cell lines tended to show higher rates of 
proliferation with increasing time in continuous culture (Chapter 2 – Fig 2.7 and Table 
2.3). This was expected as Ben-David et al. (2018) and Zhao et al. (2012) reported 
continual passaging altered the proliferative qualities of cancer cells and stem cells 
respectively. We also tested the expression of TAL1, GATA3, RUNX1 and MYB (all the 
members of the TAL1 CRC), which showed a general trend of decreasing expression 
of TAL1 in the clonal cell lines relative to the parental cell lines, with the parental cell 
lines falling within the TAL1+ expression group (Chapter 2 – Table 2.5). This was not 
expected as both parental cell lines displayed a lower median proliferative value 
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relative to the isolated clonal populations, with the majority of clonal cell lines falling 
within the extreme proliferation group (Chapter 2 – Table 2.5). Contrary to our 
proposed hypothesis, these results showed an inverse relationship between TAL1 
expression and proliferation (Chapter 2 – Fig 2.7 and Table 2.5) (Litzow and Ferrando, 
2015). Ben-David et al. (2018) also demonstrated difficulty in establishing a clear link 
between differential drug responses of cancer cell lines tested and proliferation rate. 
This suggests that proliferation of Jurkat T-ALL cells may not be as tightly controlled 
by the TAL1 CRC as expected. Overall, in agreement with earlier studies by Ben-
David et al. (2018) and Martin-Pardillos et al. (2019), we have demonstrated 
phenotypic and transcriptional heterogeneity between Jurkat clonal populations and 
the original parental populations they were derived from, showing decreased TAL1 
expression associated with hyper-proliferative clonal populations. 
 
5.2.2. The understanding of the intergenic MuTE insertion enhancer within Jurkat cell lines 
 
Using publicly available data from the ENCODE consortium (Chapter 3 – Fig 3.4), we 
next confirmed the location of the powerful TAL1 Jurkat super-enhancer that maps to 
a predicted MuTE insertion (Mansour et al., 2014; Tan et al., 2019), with H3K27ac 
enrichment symbolising this super-enhancer and spreading into the downstream 
TAL1 gene. This in silico analysis of an active super-enhancer agreed with our in vitro 
analysis of this region which revealed stable DNA hypomethylation for all Jurkat cell 
lines, and supported the idea that the MuTE intergenic enhancer increases TAL1 
expression when hypomethylated (Chapter 4 – Table 4.8) (Ehrlich et al., 2016; 
Rauscher et al., 2015). The Mansour et al. (2014) study also shows that the MuTE super-
enhancer is essential for Jurkat T-ALL cell viability as deletion of this region using 
CRISPR/Cas9 gene editing failed to produce any viable cells. Our identification of the 
12-bp heterozygous insertion at the MuTE site through nanopore sequencing in all cell 
lines tested would support the idea that this insertion is important for Jurkat T-ALL 
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cell viability. Overall, confirming the location, activity and importance of the MuTE 
insertion amongst Jurkat cell lines.  
 
5.2.3. The intragenic landscape of TAL1 within Jurkat parental and clonal cell lines  
 
Through bioinformatic analysis, two intragenic sites were identified within the first 
two introns of TAL1 that map to statistically significant H3K27ac enrichment between 
the Jurkat cell line relative to other non-immune cell lines and primary T-cells but not 
to the DND41 cell line (non-TAL1 T-ALL cell line) (Chapter 3 – Fig 3.4). This predictive 
analysis agrees with the findings by Mansour et al. (2014), who show that the 
heterozygous somatic mutation within the non-coding intergenic region of TAL1, 
creates a super-enhancer with H3K27ac enrichment breadth extending into the first 
introns of the TAL1 gene within Jurkat cell lines.  In addition, active promoter marker 
H3K4me3 enrichment also mapped to this intragenic region and was statistically 
significant for the Jurkat cell line but was not assessed within the Mansour et al. (2014) 
study. This suggested putative promoter activity (Calo and Wysocka, 2013) (Chapter 
3 – Fig 3.4) however, mapped RNA-seq transcripts from the GTEx database for thyroid 
and whole-blood cell types suggested that the main promoter activity was at the 5’ 
end of the TAL1 gene as stated by Patel et al. (2014) (Chapter 3 – Fig 3.7). Therefore, 
we conclude the existence of an intragenic regulatory element at this site within the 
Jurkat cell line. 
 
We have argued that the presence of H3K27ac and H3K4me3 enrichment and the 
evidence of weak transcriptional activity at this intragenic site has suggested the 
presence of an intragenic regulatory DNA element. We analysed the methylation 
status of this site using the MSRE assay (MSRE_2 and MSRE_3). DNA methylation at 
MSRE_3 which maps to the intragenic H3K27ac and H3K4me3 enriched peak 
displayed high DNA methylation within the P0 cell line despite DNA methylation at 
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CpG sites elsewhere within TAL1 displaying DNA hypomethylation (Chapter 4 – Fig 
4.7 and Table 4.6) (Haider et al., 2018; Vandiver et al., 2015). The high DNA 
methylation of this site in Jurkat parental populations contrasts with reduced 
methylation in clonal cell lines 11 and 4, and suggested this region showed dynamic 
DNA methylation (Chapter 4 – Table 4.8). The higher levels of TAL1 gene expression 
in the parental cell line would be consistent with high intragenic methylation being 
associated with high levels of gene transcription (Neri et al., 2017; Rauscher et al., 
2015). We would argue that this intragenic region is an intragenic enhancer, with high 
methylation inhibiting intragenic enhancer-associated transcription that would 
otherwise inhibit TAL1 expression (Cinghu et al., 2017; Varley et al., 2013) (Chapter 4 
– Table 4.8). Dynamically methylated regions that map to regulatory elements have 
been found to be at tissue-specific regions associated with key cell identity genes that 
require dynamic switching that results in cell-to-cell heterogeneity (Song et al., 2019). 
TAL1 is known to be involved in HSC tissue-specificity, therefore aligns with why 
DNA methylation would be dynamic at this region and lead to heterogeneity within 
T-ALL as seen between the Jurkat cell lines (Sanda et al., 2012; Song et al., 2019).  
 
Finally, MinION nanopore sequencing identified nine SNVs that mapped within the 
TAL1 locus at DBA identified intragenic and intergenic sites common amongst all 
Jurkat cell lines (P0, C11 and C4 at passage 1 and 9), except for an additional 
heterozygote variant within the clonal cell line 4 at passage 1 and 9 (Chapter 4 – Table 
4.9 - SNV10). Though Jurkat cell line mutations were expected due to the known 
instability of the cell line as stated by Gioia et al. (2018), our hypothesis also proposed 
cell-line specific SNVs, which was only seen for clonal cell line 4 upstream of the 
intergenic MuTE insertion. Five out of the 10 SNVs identified co-localised with 
published SNPs from the 1000 Genomes Project in which the five SNPs were in high 
LD with one another, suggesting a predicted haplotype block that all Jurkat SNVs 
mapped within for intragenic and intergenic regions of TAL1. Specifically, the 
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predicted TAL1 intragenic enhancer identified by DBA and dynamic DNA 
methylation mapped two novel SNVs (SNV3 and SNV5) flanking MSRE_3 which 
were predicted for association with regulatory elements through predicted TF binding 
and high evolutionary conservation at these sites (Chapter 4 – Fig 4.12). TF binding 
motif analysis of SNV3 and SNV5 (12-bp upstream and downstream) identified 
differences in the predicted TF binding profiles when comparing the reference allele 
and the alternative alleles for each SNV within a 24-bp sequence. This agrees with our 
hypothesis that genetic variants in cancer cells map to regulatory DNA elements of 
TAL1, consistent with increasing evidence identifying functional SNVs in the non-
coding segments of the genome (Scacheri and Scacheri, 2015). SNV3 and SNV5 
investigations into the predicted binding of TFs at the reference and alternative allele 
displayed increased differences in the number and affinity of TF binding for the 
alternative allele, such as HOXA and SOX TFs (Appendix – Table 7.30 and 7.31). 
HOXA and SOX proteins are known for their association to embryogenic and HSC 
transcriptional activity (Dou et al., 2016; Kamachi and Kondoh, 2013), in which HOXA 
TFs are also known as master TFs within T-ALL, and are associated with HSC 
differentiation inhibition when overexpressed, similar to aberrant TAL1-mediated T-
ALL programs (Bond et al., 2016; Tan et al., 2019). Overall, this has displayed the 
possible introduction and increased affinity of TFs that aberrantly bind at the 
predicted intragenic enhancer of TAL1 with possible relevance to T-ALL.  
 
Thus, we have demonstrated evidence that the intragenic region of the TAL1 locus is 
a modulated intragenic enhancer when considering predicted regulatory activity 
within this site using DBA, through the dynamic DNA methylation profile identified 
by the MSRE assay, the correlation of increased DNA methylation at this intragenic 
site and increased TAL1 expression and the mapping of potential regulatory-
associated SNVs for all the Jurkat cell lines at this site. 
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5.3. Future Directions 
 
 
In Chapter 2, it was difficult to see the distinct differences between proliferation of 
each individual clonal population and a clear correlation with gene expression of 
TAL1 CRC genes. Consequently, relationships between proliferation and gene 
expression of late cortical TAL1 CRC genes may not be apparent due to only focusing 
on a small subset of possible genes (TAL1 CRC) that may be partly involved or not 
involved in TAL1-mediated T-ALL (Girardi et al., 2017; Van Vlierberghe and 
Ferrando, 2012). In addition, conducting serum starvation and serum re-introduction 
as a treatment to initiate proliferation may not have drawn out the differences between 
the clonal populations to a point of statistical significance and was not reflected within 
the TAL1 CRC gene expression assay statistically as well. Therefore as a future 
direction, other treatments that can draw out more significant differences between 
clonal cell lines may be conducted such as T-ALL-specific microenvironment stimuli 
such as Interleukin 7 (IL7) and Sonic hedgehog (SHH) signalling is known to induce 
survival and proliferation within T-ALL cell types in vivo through NOTCH1 pathways 
(a gene involved in all T-ALL subtypes) and cortico-medullary subtypes such as 
TAL1-mediated T-ALL, respectively (Passaro et al., 2016). This may draw out 
statistical differences between Jurkat clonal cell lines that is more related to in vivo 
processes within the microenvironment. The analysis into proliferation can also be 
tested for relative gene expression with a larger set of genes involved in late cortical 
T-ALL proliferation and activity such as late-cortical T-ALL specific genes LMO1, 
LMO2, TAL2 and other T-ALL general genes such as NOTCH1, CDKN2A and CDKN1B 
(Chapter 1 – Table 1.1), which are involved in cell cycle regulatory functions for a more 
specific gene approach (Girardi et al., 2017; Van Vlierberghe and Ferrando, 2012). 
However, genome-wide RNA-seq would be the benchmark technique to map 
transcripts that show a significant difference in expression within hyperproliferative 
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clonal cell lines and be correlated to proliferative phenotypes for a more large-scale 
robust analysis. This has been a common technique utilised for identifying 
proliferation-informative cancer types through screening thousands of genes to 
develop a proliferation-specific gene signature (Ramaker et al., 2017; Waldman et al., 
2013). 
 
The analysis conducted in Chapter 3 confirmed the location and specificity of the 
MuTE insertion super-enhancer within the Jurkat cell line, however it is not known 
whether the other enhancer elements found within the analysis are a part or work in 
conjunction with the enhancer found at this site, such as the intergenic H3K27ac peak 
downstream of the MuTE insertion enhancer (Chapter 3 - Fig 3.4 - intergenic 
downstream enhancer peak). These elements identified across the TAL1 locus can then 
be further stratified by utilising the H3K4me2 marker to define “hyperacetylated 
chromatin domains” (HCDs) in conjunction with the active regulatory element 
marker, H3K27ac. These regions distinctly confirm and stratify super-enhancers that 
align more closely with cell type-specific activity and coordination of enhancer 
elements as a cohesive unit, as opposed to other super-enhancers that don’t map 
H3K4me2 and may not function differently from typical enhancers (Fox et al., 2019). 
Furthermore, due to this bioinformatic analysis being predictive and utilising data 
from other studies, a display of regulatory element markers within our Jurkat clonal 
populations was not assessed and therefore may not truly reflect the actual 
functioning of regulatory elements within TAL1 and the relevant isoforms within 
these clonal populations. Using ChIP-seq analysis of H3K27ac and H3K4me3 can be 
utilised within a differential binding analysis to statistically assess the activity of 
regulatory elements across the TAL1 locus between clonal populations and the 
parental cell line (Brown, 2011; Steinhauser et al., 2016). Whilst utilising the RNA-seq 
technique can aid in identifying where isoform transcripts originate from within the 
TAL1 locus to ensure the proper localisation of the TSS for the Jurkat cell lines used 
  
144 
within the project (Sarantopoulou et al., 2019; Zhang et al., 2017a). This will confirm if 
whether the intragenic region identified is a true promoter for TAL1 within the Jurkat 
cell line (Chapter 3 – Fig 3.7).  
 
In Chapter 4, the MSRE assay provided a focus of broad patterns of dynamic DNA 
methylation within TAL1, it has provided a cost-effective model to be used to assess 
other genes involved in TAL1-mediated pathogenesis such as the TAL1 CRC and 
other late cortical T-ALL related genes such as LMO1, LMO2, NOTCH1 and TAL2 
(Melnikov et al., 2005; Van Vlierberghe and Ferrando, 2012). Due to the results of this 
analysis displaying dynamic and stable DNA methylation patterns within just TAL1 
between Jurkat cell lines, similar patterns specific to T-ALL are likely to be throughout 
entire Jurkat genomes. The MSRE assay allows for predictive testing before 
conducting quantitative costly-assays for DNA methylation such as RRBS, which 
would be the next step for assessing whole-genome DNA methylation patterns 
between Jurkat clonal cell lines tested in the context of late cortical T-ALL 
heterogeneity (Meissner et al., 2005). Other possible future directions would 
investigate whether the predicted intragenic enhancer site is a part of the MuTE 
insertion super-enhancer and test the relationship of super-enhancer activity and 
DNA methylation as conducted by Heyn et al. (2016). This may illuminate if super-
enhancer activity at the MuTE insertion site may be conducted and modulated 
through individual enhancer elements or if the multiple subunits work as a cohesive 
unit, a phenomenon which is still unknown (Jia et al., 2019).  
 
Finally, future directions using techniques such as ChIP-seq for H3K27ac and 
H3K4me3 enrichment and DNase-seq for DHS,  can be used to assess the individual 
activity patterns of the regulatory elements identified between the different Jurkat 
clonal populations between passages 1 and 9, particularly the variability within C11 
and the low proliferative and TAL1 expression within C4 (Chapter 2 – Table 2.3 and 
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Table 2.5). These techniques could also be used to assess TF binding of TAL1 CRC TFs 
as well such as TAL1, GATA3, RUNX1 and MYB, specifically for these sites and assess 
the functionality of the Jurkat SNVs directly across TAL1 for TF binding affinity. Long-
read nanopore sequencing can also be utilised to confirm the haplotype block which 
was predicted using published SNPs amongst late cortical T-ALL Jurkat cell lines, as 
it provides better distinction of haplotypes and the allele-specific expression that may 
co-localise with the regulatory elements identified in Chapter 3 (Ebler et al., 2019; 
Mantere et al., 2019). This analysis has also provided a workflow of testing gene-
specific genetic variants between clonal populations that can be applied to many other 
TAL1-T-ALL related genes such as the TAL1 CRC. This may be in particular interest 
for C4 that falls within the GATA3+ gene group for assessing if GATA3 epigenetic 
variability and genetic variants that map GATA3 are the reason for the relatively low 
proliferative abilities of the clonal cell line 4 relative to the other clonal cell lines 
between passages (Chapter 2 – Table 2.3 and Table 2.5). The heterogeneity presented 
between Jurkat clonal cell lines can also be assessed between single cells within each 
population to confirm whether cell populations within each clonal cell line harbour or 
contain the same transcriptional, epigenetic and genetic basis as this study was based 
on the average trends seen between whole populations. Techniques such as single-cell 
RNA sequencing or DNA sequencing can be used to assess these differences between 
single cells within each clonal cell line for whole genome profiles (Goldman et al., 
2019; Singh et al., 2019; Sun et al., 2019). This technique has the ability to correlate and 
differentiate sequences within a given cell across proteomic, epigenomic, 
transcriptomic and genetic levels, adding depth into the analysis of intra-tumoural 
heterogeneity amongst Jurkat clonal cell lines (Goldman et al., 2019; Sun et al., 2019) 
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5.5. Conclusion 
 
In conclusion, this thesis has provided a cost-effective model to generate a resource of 
clonal cell lines and provides evidence of potential mechanisms of heterogeneity 
displayed amongst the cell lines, specifically in the context of the TAL1 locus. These 
cell lines can be exploited to further assess heterogeneity within populations in a cost-
effective way and do functional testing to test other cancer hallmark phenotypes, such 
as the differentiation block within T-ALL, as well as test a variety of other genes that 
elaborate on the TAL1 CRC and its role in TAL1-mediated T-ALL. We have also 
established a rationale for testing DNA methylation across different T-ALL related 
loci that map within intragenic and intergenic enhancers, for a deeper understanding 
of the malleability of cancer genomes and its role in heterogeneity. This thesis has also 
provided evidence of novel Jurkat specific SNVs within the clonal populations that 
can be further tested for their relevance in the functionality of the regulatory elements, 
epigenetic sites and TF binding in late cortical T-ALL. Not only have we shown 
evidence for TAL1 being a gene target that displays clonal cell line heterogeneity 
through identifying dynamic DNA methylation patterns at these sites, but this gene-
specific approach can also be applied to the rest of the genome to understand the basis 
of late cortical T-ALL and other cancers.  
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Chapter	7 -	Appendix	
 
7.1 – Chapter 2: Supplementary Figures, Tables and Command Lines 
 
7.1.1 Supplementary Figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.1.2 Supplementary Tables 
 
| Table 7.1. Kruskal-Wallis Post-Hoc Dunn Test, further adjusted by Holm FWER method 
between all Jurkat cell lines at passage 1 for averaged proliferation index 
Cell lines C1 C10 C11 C2 C3 C4 C5 C6 C8 C9 P0 
C10 1 
          
C11 1 1 
         
C2 1 1 1 
        
C3 1 1 1 1 
       
C4 1 1 1 1 1 
      
C5 1 1 1 1 1 1 
     
| Figure 7.1. Flow cytometry histogram plots of CFSE stained Jurkat Clone 2 at cell concentration 
of 2x104/well 48-hour growth in 10% FBS 1% PSF in RPMI 1640 with 0.5μM of CFSE.  
 Gates were established based on the negative control (no CFSE stained sample) and display the 
percentage of cells within the total population that fall within the fluorescence of the negative 
control (41.9). Cell count is demonstrated on the x-axis and CFSE fluorescence intensity is plotted 
logarithmically along the y-axis. 
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C6 1 1 1 1 1 1 1 
    
C8 1 1 1 1 1 1 1 1 
   
C9 1 1 1 1 1 1 1 1 1 
  
P0 1 1 1 1 1 1 1 1 0.53442 1 
 
P00 1 1 1 1 1 1 1 1 1 1 1 
 
| Table 7.2. Kruskal-Wallis Post-Hoc Dunn Test, further adjusted by Benjamini-Hochberg FDR 
method between all Jurkat cell lines at passage 1 averaged proliferation index 
Cell 
lines 
C1 C10 C11 C2 C3 C4 C5 C6 C8 C9 P0 
C10 0.6
72
62 
          
C11 0.8
30
65 
0.581
4 
         
C2 0.6
43
1 
0.987
25 
0.581
4 
        
C3 0.6
57 
0.987
25 
0.581
4 
0.987
25 
       
C4 0.9
87
25 
0.595
75 
0.949
72 
0.593
72 
0.593
72 
      
C5 0.9
55
77 
0.593
72 
0.978
94 
0.593
72 
0.593
72 
0.987
25 
     
C6 0.9
78
94 
0.593
72 
0.955
77 
0.593
72 
0.593
72 
0.987
25 
0.987
25 
    
C8 0.5
55
5 
0.781
02 
0.403
71 
0.797
61 
0.783
41 
0.447
64 
0.423
97 
0.433
7 
   
C9 0.6
57 
0.987
25 
0.581
4 
0.987
25 
1 0.593
72 
0.593
72 
0.593
72 
0.783
41 
  
P0 0.5
45
45 
0.244
18 
0.595
75 
0.244
18 
0.244
18 
0.581
4 
0.593
72 
0.593
72 
0.095
17 
0.244
18 
 
P00 0.6
43
1 
0.422
86 
0.846
23 
0.417
08 
0.417
08 
0.723
28 
0.771
03 
0.745
11 
0.244
18 
0.417
08 
0.793
41 
 
 
 
| Table 7.3. Kruskal-Wallis Post-Hoc Dunn Test, further adjusted by Holm FWER method 
between all Jurkat cell lines at passage 5 averaged proliferation index 
Cell lines C1 C10 C11 C2 C3 C4 C5 C6 C8 C9 P0 
C10 1 
          
C11 1 1 
         
C2 1 1 1 
        
C3 1 1 1 1 
       
C4 1 1 1 1 1 
      
C5 1 1 1 1 1 1 
     
C6 1 1 1 1 1 1 1 
    
C8 1 0.66594 0.30783 1 1 1 1 1 
   
C9 1 1 1 1 1 1 1 1 1 
  
P0 1 1 1 1 1 1 1 1 1 1 
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P00 1 1 1 1 1 1 1 1 1 1 1 
 
 
| Table 7.4. Kruskal-Wallis Post-Hoc Dunn Test, further adjusted by Benjamini-Hochberg FDR 
method between all Jurkat cell lines at passage 5 averaged proliferation index 
Cell 
line
s 
C1 C10 C11 C2 C3 C4 C5 C6 C8 C9 P0 
C10 0.50383 
          
C11 0.41814 
0.8597
1 
         
C2 0.70201 
0.7208
9 
0.6486
8 
        
C3 0.89006 
0.4265
3 
0.3313
7 
0.6486
8 
       
C4 0.63775 
0.2179
1 
0.1605
3 
0.3632
1 
0.6814
6 
      
C5 0.6063 0.21791 
0.1605
3 
0.3313
7 
0.6486
8 
0.9601
5 
     
C6 0.89006 
0.4265
3 
0.3313
7 
0.6486
8 1 
0.6814
6 
0.6486
8 
    
C8 0.41814 
0.1385
2 
0.1385
2 
0.2179
1 
0.4634
5 
0.7208
9 
0.7646
5 
0.4634
5 
   
C9 0.80874 
0.6486
8 0.5617 
0.8597
1 
0.7208
9 
0.4508
9 
0.4265
3 
0.7208
9 
0.2750
6 
  
P0 0.63775 
0.8597
1 
0.7208
9 
0.8597
1 0.5322 
0.2750
6 
0.2652
8 0.5322 
0.1605
3 
0.7208
9 
 
P00 0.64868 
0.2371
7 
0.1719
5 
0.3972
9 
0.7020
1 
0.9601
5 
0.9317
4 
0.7020
1 
0.7208
9 
0.4634
5 
0.3016
8 
 
| Table 7.5. Kruskal-Wallis Post-Hoc Dunn Test, further adjusted by Holm FWER method 
between all Jurkat cell lines at passage 9 averaged proliferation index 
Cell lines C1 C10 C11 C2 C3 C4 C5 C6 C8 C9 P0 
C10 1 
          
C11 1 1 
         
C2 1 1 1 
        
C3 1 1 1 1 
       
C4 1 1 1 1 1 
      
C5 1 1 1 1 1 1 
     
C6 1 1 1 1 1 1 1 
    
C8 1 1 1 1 1 1 1 1 
   
C9 1 1 1 1 1 1 1 1 1 
  
P0 1 1 1 1 1 1 1 1 1 0.95643 
 
P00 1 1 0.95643 1 1 1 1 1 1 0.45638 1 
 
| Table 7.6. Kruskal-Wallis Post-Hoc Dunn Test, further adjusted by Benjamini-Hochberg FDR 
method between all Jurkat cell lines at passage 9 averaged proliferation index 
Cell lines C1 C10 C11 C2 C3 C4 C5 C6 C8 C9 P0 
C10 0.83647           
C11 0.74378 0.83647          
C2 0.67463 0.5756 0.46361         
C3 0.46361 0.37266 0.2857 0.74378        
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C4 0.37266 0.2857 0.21775 0.67463 0.83647       
C5 0.69432 0.60567 0.46361 0.94784 0.73509 0.66994      
C6 0.86664 0.76012 0.6911 0.73509 0.56097 0.45595 0.74378     
C8 0.6063 0.46361 0.37266 0.86664 0.83647 0.73509 0.83647 0.67463    
C9 0.67463 0.74378 0.83647 0.37266 0.21775 0.18891 0.37266 0.60567 0.31211   
P0 0.37163 0.27692 0.20387 0.65376 0.83647 0.93381 0.60779 0.39294 0.7109 0.16802  
P00 0.27889 0.20387 0.16802 0.54664 0.73509 0.83647 0.5041 0.34073 0.60779 0.15613 0.83647 
 
 
| Table 7.7. List of primers sets for qPCR analysis of genes TAL1, GATA3, MYB and RUNX1 
Gene Forward Primer 5’-3’ Reverse Primer 5’-3’ 
TAL1 ccccctatgagatggagatt aaaggccccgttcacatt 
GATA3 ctctctgctcttcgctaccc gcgacgactctgcaattct 
MYB tggaccaaagaagaagatcaga tctcccctttaagtgcttgg 
RUNX1 actcggctgagctgagaaatg gacttgcggtgggtttgtg 
 
7.1.2.a qPCR primer sets and amplicon sequences (Methods: 2.2.9) 
 
TAL1 
 
Exon 4-5 (Intron 4) 
 
841 ccccctatga gatggagatt actgatggtc cccacaccaa agttgtgcgg cgtatcttca 
      901 ccaacagccg ggagcgatgg cggcagcaga atgtgaacgg ggcctttgcc gagctccgca 
 
  >chr1:47685767-47689702 3936bp CCCCCTATGAGATGGAGATT 
AAAGGCCCCGTTCACATT 
CCCCCTATGAGATGGAGATTactgatggtgagtctgccccaccccaccgt 
tgtacctgcccctcacgctggttagagccctctggaggagggaacatctg 
ggactactccgtaggtatctcacaaagatgggcgggccactttccaaacc 
caaactgccgaagcccttcaccctgcagctgagctagggctaagtaaagt 
cctggatggggctagcaggaccacactcacagtcctgcaaagaggaggca 
tgggagagagacacataatggcgcttagcccaaacctctggagttagttc 
ccaaacctttggagttagttccagtccccagtccgggctccattcctaca 
ctttggcaaggatcccaagtgggcgcagaatcacacagtgtcccccgatc 
ccccattctaggcactgaccctcagggattccctgcacttcctcccaagt 
cttccttagagtctggagtctgcttcctccctgcaatggagtcatcaagg 
gttttctccgaggtccctacacagtaggctccccttgtctcccgttaaca 
cattctgggcttagacctggagttcccttcctgacatcatggattctacc 
ttgccccctggattccccgagaagggccttggcactgctcctttgaggta 
cttgaatattccctgaacttgcaggggtggtttggacaaatgggagattt 
ggaagaccctcgccatctttccaaggttgaccttgtatagtagattggtc 
ccagcaccaggggtaggagagcaggcacttcagagctgagggactttgag 
ccagacccagatgcccccagaacttcagcttggctgtggcctggggctcc 
tgtaggaaggctgcccaaggcctcagagcaaggctgggatttatgctcca 
aactggtgggaggaatatgagtatggagctggagcctctggagtggagcc 
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ctctgtggtgttctggagaggagcggggctgggatctgcacaacagaaaa 
gacttcaaaagacccaagcagcctggggcacaggtgtgcagggctgagag 
gcaggggtgccttctgctagattagagaggagttctctagtctaagagag 
gtgggtgtaccaaacaggaagaagacaggaccagccctgaagttccccag 
ggatgaggcattttctacaataggcagaagaggcagagcataggggcgag 
ggtttgtggggtgtgcaggagtgtagggcagtcattatccataagtgttg 
gcaatatttaccgagcacctactcagtgctggccagagagaggcagagga 
caccaggaggggtagacagactcaggaaagaggaaggtgaggagaggggg 
tggttctctggaataaaaccagagaggaataggcagacatgtaggcgaag 
ggtagggtatgagtgtgcaggatgtgtctaggggacactgaaattagaga 
ttgaacccaaaaagagtccatagaagtagaactaatgcaagatctagagt 
taggacttgatgtggattcctgttgctgaattgctactaccatgtattgg 
acacctactatgtgccatggactatgtgtgcttgatttctgtttattcct 
taccacaagctcatgagggcaatattattgtttacatctcacagataagg 
aaattgaggctgagagaggttacccagcttgatcaaggtcacacagctaa 
gtcctgggtcacacagctaagtcctggaccaccctcataacactggtctt 
aagctttggaataagtcctgaccacttccccaccatctccccttctggat 
gtagtctagctccagctgtgacagcagtcataagtaccccctccccaact 
aggagctccctcaagatcaccagcattagccatggtggagggactgtcct 
ccctatgtcactgctgagggatgctctctgtctggcctggaggcctgaaa 
gcagcaagtaatttcctcagaggccgcccagggtagaactgccctgcagt 
tgtgctgtgtttttcccaggctgggtctggcctttggcaaacagtcagct 
gggctagggcctgctatggtttggaaaggcagcttcagaggtaccatggg 
caggggatggtgatccttcccattaaaagtgtgtgtgtgtgaacacccac 
acatgcatgtgcatgcctgtgtgcgtgtaggagagagaaagagatgatca 
ggcagtaagtgtggcatggatgagctgattcacagactgaccactgaggt 
gaggtctgcttccatcccagcctcagtctccttagctataaaatgggcag 
tgggacttaggtgaggtcttagctcttctcctctacctcggttttcacac 
tctgaggtctggttccaggggttactagaagagggaaaataaatatccta 
ggactggcagttccttcagtgctcagagcttcctggactatgtgaccctg 
gcttgtgcctcgatgttagggagagaagcagtctcctcagcccagaagtt 
caagagcactagtaggacccttcactgtcttcccctggctttacaaatcc 
ccagtgagtcttgaacacagcacagtgctttgcacaccataagtgcccta 
gacatgtgtgctggtatctgccactgctccataagtctttatacatggaa 
tgttagtgactattgggccaagccatagtcagtggattgtagacatgagg 
agactgaggcagccttcagaagcctgcctagagctataggccatggctgt 
gcatagctgtgtcttcacttctctcctgggtatgagagcccttctgcatc 
gatctctgctctcccctccattccccacctgccaccatgatgggtcagtt 
agcagacattttctaagcccctactctgtgctttccatcacccttaggat 
aaagtccccccgccttactgcaaggccctgtggagtctggaccctgccta 
ctctgatcttgtgcacaggactccagccagcctggcttcaggccttgtct 
agtgcagggcctgtgcattcccttggcttggatactcttcttcctctccc 
cttcttgtgcctggctgtttcttcacagcctcagacaagccttcccagcc 
actggagctaaacatggagcttcttttcattacaattcagccctggtttg 
tttgttttttaatattcgtttccccattaacatgtaagctccatgagggc 
aggcactcaatttagttcaccattattcctcagtgcctagcacagtgcct 
ggttgttagcaaaaaactgatacatggataataatagctaacatttattg 
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actgctaagctgaggcaggcattgtcttaagttctttacctgtgttaggt 
actagacccatgtaacaactcatgacttagtagtattacctccattttgc 
aggtgatgaagccaaggcacttcacaagtttttatgtcacttgcccagag 
tcattcatttaggtaggggtagtcaaataggaatggagtctgtctcctta 
gacatagctgtaaggcctcttggcacaagtgaatggatgaatgaataaca 
tacggtccctgtcctcaaatatatcacagcccagggagggagacaagcac 
agaaacataagtaatgatcaagagtgatggaactccagggattgcggtat 
cgtggtggttggttacatctgtctggaggggttgaggaagttcccataga 
tgaggaagcacaggaacttgaatttgaagggtggatgttttctaagtaaa 
aggaaagtaggcattctaggcttcccaagtttcccaatgtatggagatgc 
ctttggggaaggaatctcaagcccattctcctaactcttgtcctcctaat 
ctccaggtccccacaccaaagttgtgcggcgtatcttcaccaacagccgg 
gagcgatggcggcagcagAATGTGAACGGGGCCTTT 
 
RUNX1 
 
Primers taken from: Challen, G.A, and Goodell, M.A. (2010). Runx1 isoforms show 
differential expression patterns during hematopoietic development but have similar 
functional effects in adult hematopoietic stem cells. Exp Hematol 38, 403-416. 
 
GATA3 
 
Exon 1 1…204 à 191…291 
ADDITIONAL OLIGOS 
                    start  len      tm     gc%   any    3' seq  
 
 1 LEFT PRIMER          3   20   59.33   60.00  2.00  0.00 ctctctgctcttcgctaccc 
   RIGHT PRIMER       108   19   59.13   52.63  4.00  2.00 gcgacgactctgcaattct 
   PRODUCT SIZE: 106, PAIR ANY COMPL: 5.00, PAIR 3' COMPL: 0.00 
 
 
 
  
>chr10:8096833+8097333 501bp CTCTCTGCTCTTCGCTACCC GCGACGACTCTGCAATTCT 
CTCTCTGCTCTTCGCTACCCaggttggtactggtgacttttttttttttt 
aagtttgattttttgcccccaaccacttgggaggacctaaatcaatttta 
aaaactcaactctcctcttttggaggttttctaggggctgagaggacggt 
cccgggaccggtgtccccgagggagggacttgccctccaagtcgtaacag 
tcagccctgggacttgccctccaagttgctcagccagccccggctcccgc 
gagccgggctgcagggacgtccccgagagccctgcgggctccgcggccgt 
gtccccgcgctcccgtgcgggtctcgggtgcgctgggcgggcgggcggcg 
cgaggggaggttgtgccactccagcaactcaggggctcatccaggtctcc 
cattctctcccttgcaggtgacccgaggagggactccgcctccgagcggc 
tgaggaccccggtgcagaggagcctggctcgcAGAATTGCAGAGTCGTCG 
C 
 
MYB 
 
Exon 4: 413…505 à 481…591 
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OLIGO            start  len      tm     gc%   any    3' seq  
LEFT PRIMER          2   22   58.91   40.91  5.00  3.00 tggaccaaagaagaagatcaga 
RIGHT PRIMER        94   20   59.31   50.00  5.00  0.00 tctcccctttaagtgcttgg 
SEQUENCE SIZE: 110 
INCLUDED REGION SIZE: 110 
 
PRODUCT SIZE: 93, PAIR ANY COMPL: 4.00, PAIR 3' COMPL: 0.00 
 
    1 ttggaccaaagaagaagatcagagagtgatagagcttgtacagaaatacggtccgaaacg 
       >>>>>>>>>>>>>>>>>>>>>>                                      
 
   61 ttggtctgttattgccaagcacttaaaggggagaattggaaaacaatgta 
                    <<<<<<<<<<<<<<<<<<<<    
 
 
 
  
>chr6:135510998+135511333 336bp TGGACCAAAGAAGAAGATCAGA 
TCTCCCCTTTAAGTGCTTGG 
TGGACCAAAGAAGAAGATCAGAgagtaagttctttcttcattggtgtgtg 
actcataattaagaatattcccaaaatgctaatattttcctatttgagga 
agcaggtaaaatgggcaaacaggaagtagaggactctattcccatatttc 
cagtgaatgaaagcaaattttggaaattttctaaagatcttgtaacactg 
aagaatgattatactgactcattacataactttaaaacataggttatttt 
tgtgtgtttatctgaaggtgatagagcttgtacagaaatacggtccgaaa 
cgttggtctgttattgCCAAGCACTTAAAGGGGAGA  
 
 
 
| Table 7.8. Friedman Test results for averaged gene expression of TAL1 CRC genes at 
passages 1, 5 and 9 (p<0.05). 
Genes TAL1 GATA3 RUNX1 MYB 
p-value 
(p<0.05) 
0.01685 0.00525 0.00483 0.2778 
Significance Yes Yes Yes Yes 
 
| Table 7.9. Wilcoxon Rank Sum Two-Tailed Test as Post-Hoc for Friedman test (Table 7.8) 
between passages 1 and 5, 1 and 9 and 1 and 5 for averaged TAL1 CRC gene expression 
TAL1 CRC Genes 
p-value (p<0.05) TAL1 GATA3 RUNX1 MYB 
P1 vs P5 0.0151 0.0151 0.0048* 0.012* 
P1 vs P9 0.18 0.88 0.04* 0.238 
P1 vs P5 0.006* 0.008* 0.24 0.05 
 
 
1Significant p-values indicated by asterisk (*) 
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| Table 7.10. Kruskal-Wallis Dunn Post-Hoc test p-values further adjusted by the Holm FWER 
method for TAL1 gene expression between gene expression groups 
Gene Expression 
Groups 
GATA3+ RUNX1+ MYB+ 
RUNX1+ MYB+ 0.625854 
 
TAL1+ 0.057444 0.057444 
 
 
| Table 7.11. Kruskal-Wallis Dunn Post-Hoc test p-values further adjusted by the Benjamini-
Hochberg FDR method for TAL1 gene expression between gene expression groups 
Gene Expression 
Groups 
GATA3+ RUNX1+ MYB+ 
RUNX1+ MYB+ 0.625854 
 
TAL1+ 0.029888 0.029888 
 
 
| Table 7.12. Kruskal-Wallis Dunn Post-Hoc test p-values further adjusted by the Holm FWER 
method for GATA3 gene expression between gene expression groups 
Gene Expression 
Groups 
GATA3+ RUNX1+ MYB+ 
RUNX1+ MYB+ 0.018685 
 
TAL1+ 0.127682 0.390284 
 
 
 
| Table 7.13. Kruskal-Wallis Dunn Post-Hoc test p-values further adjusted by the Benjamini-
Hochberg FDR method for GATA3 gene expression between gene expression groups 
Gene Expression Groups GATA3+ RUNX1+ MYB+ 
RUNX1+ MYB+ 0.018685 
 
TAL1+ 0.095761 0.390284 
 
| Table 7.14. Spearman’s Rho Correlation test p-values for the GATA3+ group and gene 
expression of TAL1 CRC genes 
GATA3+ Group MYB TAL1 RUNX1 
GATA3 0.00026 0.00385 3e-05 
RUNX1 3e-05 0.02082  
TAL1 0.0149   
 
| Table 7.15. Spearman’s Rho Correlation test p-values for the TAL1+ group and gene 
expression of TAL1 CRC genes 
TAL1+ Group MYB TAL1 RUNX1 
GATA3 0.0053 0.0004 0.001 
RUNX1 0.004 0.0003  
TAL1 0.00061   
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| Table 7.16. Spearman’s Rho Correlation test p-values for the RUNX1/MYB+ group and gene 
expression of TAL1 CRC genes 
RUNX1/MYB+ Group MYB TAL1 RUNX1 
GATA3 0.00014 0.00087 0.00381 
RUNX1 0.00247 0.0023  
TAL1 6e-05   
 
 
| Table 7.17. Spearman’s Rho Correlation test p-values for all Jurkat parental and clonal cell 
lines and gene expression of TAL1 CRC genes 
All Cell lines MYB TAL1 RUNX1 
GATA3 5.699e-05 0.0003 1.35e-6 
RUNX1 6.58e-08 8.84e-7  
TAL1 3.2e-07   
 
 
| Table 7.18. Spearman's Rho Correlation test p-values for proliferation index (PI) correlation 
to TAL1 CRC gene expression over all passages, passage 1, 5 and 9 for all Jurkat parental and 
clonal cell lines 
PI Correlation All Passages Passage 1 Passage 5 Passage 9 
TAL1 0.47 0.30 0.45 0.61 
GATA3 0.27 0.94 0.65 0.86 
RUNX1 0.74 0.46 0.65 0.85 
MYB 0.82 0.51 0.94 0.81 
 
| Table 7.19. Spearman's Rho Correlation test p-values for proliferation index (PI) correlation 
to TAL1 CRC gene expression for all passages for gene expression groups 
PI Correlation GATA3+ TAL1+ RUNX1/MYB+ 
TAL1 0.14 0.2 0.83 
GATA3 0.14 0.2 0.51 
RUNX1 0.23 0.49 0.54 
MYB 0.28 0.36 0.37 
 
 
7.1.2.b Pheatmap Command Line – R programming language 
 
library(pheatmap) 
 
# Create test matrix 
T <- data.matrix(datafile., rownames=1) 
TALL <- data.matrix(datafile) 
 
colnames(TALL) = colnames(TALL) 
rownames(TALL) = rownames(TALL) 
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#Gene Signature, euclidean distance 
pheatmap(TALL, scale = "row", clustering_distance_rows = "euclidean", 
clustering_distance_cols = "euclidean") 
 
#Gene Score, no clustering, raw data 
pheatmap(TALL, cluster_row = FALSE, cluster_cols = FALSE) 
 
7.1.2.c GSALightning Command Line – R Programming language 
 
#GSALightning: Ultra-fast Permutation-based Gene Set Analysis 
library(devtools)  
# if not yet installed run: install_github("billyhw/GSALightning") 
library(GSALightning) 
 
#example data 
data(expression) 
data(sampleInfo) 
data(targetGenes) 
 
 
#write targetgenes as a list with unique elements for individual  
#genes or groups of genes  
 
l <- list(TAL1 = c('TAL1'), GATA3 = c('GATA3'), RUNX1 = c('RUNX1'),  
          MYB = c('MYB')) 
 
#input your data 
#Use unaveraged data with unique ID names for each replicate 
sampleInfo <- ALLGSA 
targetGenes <- l 
expression <- as.matrix(ALLPGSAExpression, rownames.force = 1, 
colnames(ALLPGSAExpression)) 
 
#remove genes with 0 variance 
expression <-  expression[apply(expression,1,sd) != 0,] 
 
#run permutations 
#try all three methods (methods = 'maxmean' OR 'mean' OR 'absmean') 
#set "nperm = X" by calculating n/0.05 x 2, where n = the number of geneSets in your data. 
#set "minsize = x, maxsize = x" to the minimum and maximum number of genes in your 
geneSets. 
GSALightmax <- GSALight(eset = expression, fac = factor(sampleInfo$TN), gs = targetGenes, 
nperm = 160, method = 'maxmean', restandardize = FALSE, minsize = 1, maxsize = 6, 
rmGSGenes = 'gene', verbose = FALSE) 
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#view statistical results 
head(GSALight) 
 
#Investigate distribution of results 
hist(GSALightmax[,'p-value:up-regulated in Control'], main=NULL, xlab='p-value') 
 
#restandardise results  
GSALightResultsReStand <- GSALight(eset = expression, fac = factor(sampleInfo$TN), gs = 
targetGenes,  
                                          nperm = 160, method = 'maxmean', restandardize = TRUE, minsize = 
1,  
                                          maxsize = 6, rmGSGenes = 'gene', verbose = FALSE) 
 
#Investigate distribution of restandardised results 
hist(GSALightResultsReStand[,'p-value:up-regulated in Control'], main=NULL, xlab='p-value') 
 
#Export all results as .csv files  
write.csv(GSALightmax, file = "ALL P MaxMean Permutation Statistics.csv") 
write.csv(GSALightMean, file = "Mean Permutation Statistics.csv") 
write.csv(GSALight, file = "ALLP AbsMean Permutation Statistics.csv") 
write.csv(GSALightResultsReStandMaxMean, file = "Restandardised MaxMean Permutation 
Statistics.csv") 
write.csv(GSALightResultsReStandMean, file = "Restandardised Mean Permutation 
Statistics.csv") 
write.csv(GSALightResultsReStand, file = "ALL P Restandardised AbsMean Permutation 
Statistics.csv") 
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7.2 – Chapter 3: Supplementary Figures, Tables and Command Lines 
 
7.2.1 Supplementary Figures 
 
 
 
 
 
 
 
 
Figure 7.2. Example of the quality score across all bases for Illumina 1.9 sequencing of Jurkat 
H3K27ac replicate 1 (GEO Accession: GSM1431908) using the FastQC program (Method:3.2.2).  
Position in read per base pair (bp) along the x-axis and Phred score along y-axis. Green region 
indicates satisfactory quality (> 25) and orange and red regions indicate low quality of the 
sequencing experiment (< 25 and <20). Median is indicated by red line. Quality reads for all ChIP-
seq files downloaded and tested are in Supplementary Table 7.3.2.  
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| Figure 7.3. Example of MACS2 outputs of Illumina 1.9 ChIP-seq data peak model analysis and cross-correlation 
analysis from the Jurkat H3K27ac replicate 1 data (GEO Accession: GSM1431908).  
A. Display of peak model analysis of ChIP-seq data quality through the positional information and reads from both 
strands, ensuring accurately mapped locations of peaks within the data. Percentage of reads for both forward 
and reverse tags are displayed on the y-axis and distance of tags from the centre of a peak is shown on the x-axis. 
B. A cross-correlation plot displaying a single peak for fragment-lengths relative to read-length, ensuring 
correlation of tags to the sequencing reads. Y-axis displays correlation of tags and x-axis displays lag between the 
forward and reverse tags. List of data used and run through MACS2 can be found in Supplementary Table 7.3.1. 
MACS2 peak model plot and cross correlation analysis was seen to be similar for all files tested. 
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| Figure 7.4. H3K27ac read depth across the TAL1 locus for all replicates for cell lines, Jurkat, DND41, 
HMEC and NHEK, and primary cell lines Th1, Th2, CD20+ B-cells and MonoCD14+. 
Chromosome ideogram of chromosome 1 indicates location of the TAL1 locus indicated by the red line. 
Ref-Seq genes from the ENCODE Project display isoforms of the TAL1 and STIL gene with localised ChIP-
seq peaks of the cell lines listed above. Y-axis displays the read depth of H3K27ac enrichment and is 
normalised amongst samples from the same experiment, with primary cells and cell line samples 
indicated on the left-hand side (see also Appendix for details and visualisation of all replicates). 
GeneHancer database looping displays predicted interactions between regulatory elements across the 
TAL1 locus (Methods: 2.3.5). Red boxes highlight areas of H3K27ac and H3K4me3 enrichment of the 
Jurkat cell line relative to the other cell lines displayed. 
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| Figure 7.5. DNAse1 hypersensitivity (DHS) read depth displayed in the UCSC genome browser for the all 
replicates of Jurkat, CD20R017794, MonoCD14, CD4+ Naïve Wb11970640, SAEC, 8988T and Th1 cell lines 
across the TAL1 locus.  
Chromosome ideogram of chromosome 1 indicates location of the TAL1 locus indicates location of the TAL1 
locus indicated by the red line. Ref-Seq genes from the ENCODE Project display isoforms of the TAL1 and STIL 
gene with localised ChIP-seq peaks of the cell lines listed above. Y-axis displays the read depth of DHS 
enrichment and is normalised amongst samples from the same experiment (see also Appendix for details and 
visualisation of all replicates). GeneHancer database looping displays relationships of regulatory elements 
across the TAL1 locus (Methods: 2.3.5).  
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7.2.2 Supplementary Tables 
 
| Table 7.20. List of DNAse1 Hypersensitivity files downloaded from the ENCODE project used 
for differential binding analysis 
DNAse1 Hypersensitivity 
Cell Line Tissue File Type Replicate ENCODE? Lab GEO Accession 
8988t Pancreas adenocarcinoma .bam 1 Y Duke University GSM816667 
8988t Pancreas adenocarcinoma .bam 2 Y Duke University GSM816667 
8988t Pancreas adenocarcinoma .narrowPeak Combined Y Duke University GSM816667 
Adult CD4 Th0 CD4 Th0 .bam 2 Y Duke University GSM1008572 
Adult CD4 Th0 CD4 Th0 .bam 1 Y Duke University GSM1008572 
Adult CD4 Th0 CD4 Th0 .narrowPeak Combined Y Duke University GSM1008572 
CD20RO01794 B Cells .bam 2 Y Duke University GSM1008588 
CD20RO01794 B Cells .bam 1 Y Duke University GSM1008588 
CD20RO01794 B Cells .narrowPeak Combined Y Duke University GSM1008588 
Jurkat T-ALL .bam 1 Y University of Washington GSM736501 
Jurkat T-ALL .bam 2 Y University of Washington GSM736501 
Jurkat T-ALL .broadPeak 1 Y University of Washington GSM736501 
Jurkat T-ALL .broadPeak 2 Y University of Washington GSM736501 
MonoCD14 Monocyte .bam 1 Y Duke University GSM1008582 
MonoCD14 Monocyte .bam 2 Y Duke University GSM1008582 
MonoCD14 Monocyte .narrowPeak Combined Y Duke University GSM1008582 
SAEC Normal Lung Epithelial .bam 1 Y University of Washington GSM736617 
SAEC Normal Lung Epithelial .bam 2 Y University of Washington GSM736617 
SAEC Normal Lung Epithelial .narrowPeak 1 Y University of Washington GSM736617 
SAEC Normal Lung Epithelial .narrowPeak 2 Y University of Washington GSM736617 
Th1 v2 Th1 .bam 1 Y University of Washington GSM646569 
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Th1 v2 Th1 .bam 2 Y University of Washington GSM646569 
Th1 v2 Th1 .broadPeak 1 Y University of Washington GSM646569 
Th1 v2 Th1 .broadPeak 2 Y University of Washington GSM646569 
 
 
| Table 7.21. List of H3K27ac ChIP-seq data from the ENCODE Project and other studies (GEO 
Accession and SRA accession) 
H3K27ac ChIP-Seq 
Cell Line Tissue File Type Replicate ENCODE? Lab GEO/SRA Accession 
CD20RO01794 B Cells .bam 1 Y Broad GSM1003459 
CD20RO01794 B Cells .bam 2 Y Broad GSM1003459 
CD20RO01794 B Cells .broadPeak Combined Y Broad GSM1003459 
DND41 T-ALL .bam 1 Y Broad GSM1003462 
DND41 T-ALL .bam 2 Y Broad GSM1003462 
DND41 T-ALL .broadPeak Combined Y Broad GSM1003462 
HMEC Dermal Endothelim .bam 1 Y Broad GSM733660 
HMEC Dermal Endothelim .bam 2 Y Broad GSM733660 
HMEC Dermal Endothelim .broadPeak Combined Y Broad GSM733660 
NHEK Keratinocytes .bam 1 Y Broad GSM733674 
NHEK Keratinocytes .bam 2 Y Broad GSM733674 
NHEK Keratinocytes .bam 3 Y Broad GSM733674 
NHEK Keratinocytes .broadPeak Combined Y Broad GSM733674 
Jurkat T-ALL .fastq 1 N HVB, Genetics and Genomics Sciences GSM1431908 
Jurkat T-ALL .fastq 2 N HVB, Genetics and Genomics Sciences GSM1431909 
Th2 Th2 .fastq 1 N Aalto University, Finland SRR873431 
Th2 Th2 .fastq 2 N Aalto University, Finland SRR873435 
Th1 Th1 .fastq 1 N Aalto University, Finland SRR873432 
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Th1 Th1 .fastq 2 N Aalto University, Finland SRR873434 
 
 
| Table 7.22. List of H3K4me3 ChIP-seq data from the ENCODE Project and other studies (GEO 
Accession and SRA Accession) 
H3K4me3 ChIP-Seq 
Cell Line Tissue File Type Replicate ENCODE? Lab GEO/SRA Accession 
Jurkat T-ALL .bam 1 Y University of Washington GSM945267 
Jurkat T-ALL .bam 2 Y University of Washington GSM945267 
Jurkat T-ALL .broadPeak Combined Y University of Washington GSM945267 
SAEC Normal Lung .bam 1 Y University of Washington GSM945199 
SAEC Normal Lung .bam 2 Y University of Washington GSM945199 
SAEC Normal Lung .broadPeak 1 Y University of Washington GSM945199 
SAEC Normal Lung .broadPeak 2 Y University of Washington GSM945199 
CD20RO01794 B Cells .bam 3 Y University of Washington GSM945198 
CD20RO01778 B Cells .bam 1 Y University of Washington GSM945229 
CD20RO01778 B Cells .broadPeak 2 Y University of Washington GSM945229 
CD20RO01778 B Cells .broadPeak 3 Y University of Washington GSM945229 
MCF7 Mammary Gland .bam 1 Y University of Washington GSM945269 
MCF7 Mammary Gland .bam 2 Y University of Washington GSM945269 
MCF7 Mammary Gland .broadPeak 1 Y University of Washington GSM945269 
MCF7 Mammary Gland .broadPeak 2 Y University of Washington GSM945269 
Dnd41 T-ALL .bam 1 Y University of Washington GSM1003468 
Dnd41 T-ALL .bam 2 Y University of Washington GSM1003468 
Dnd41 T-ALL .broadPeak Combined Y University of Washington GSM1003468 
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Th1 Th1 .fastq 1 Y Aalto University, Finland SRR873613 
Th2 Th2 .fastq 1 Y Aalto University, Finland SRR873615 
 
| Table 7.23. List of Input Files for ENCODE and other studies ChIP-seq data (GEO Accession 
and SRA Accession) 
Input Files for ChIP-seq 
Cell Line Tissue File Type 
Replica
te 
ENCOD
E? Lab 
GEO/SRA 
Accession 
Dnd41 T-ALL .bam 1 Y Broad GSM1003558 
Dnd41 T-ALL .bam 2 Y Broad  
HMEC Dermal Endothelim .bam 1 Y Broad GSM733668 
HMEC Dermal Endothelim .bam 2 Y Broad GSM733668 
NHEK Keratinocytes .bam 1 Y Broad GSM733740 
NHEK Keratinocytes .bam 2 Y Broad GSM733740 
CD20RO01
778 B Cell .bam 1 Y University of Washington GSM945197 
Jurkat v2 T-ALL .fastq 1 N HVB, Genetics and Genomics Sciences SRR1509752 
Th1 Th1 .fastq 1 Y Aalto University, Finland SRR873613 
Th2 Th2 .fastq 1 v Aalto University, Finland SRR873615 
Jurkat T-ALL .bam 1 Y University of Washington GSM945268 
SAEC Normal Lung .bam 1 Y University of Washington GSM945314 
CD20RO01
794 B Cells .bam 3 Y University of Washington GSM945195 
MCF7 Mammary Gland .bam 1 Y University of Washington GSM945274 
 
 
| Table 7.24. Phred Scores of ChIP-seq data for the cell line, Jurkat and primary cell lines, Th0, 
Th1 and Th2 for H3K27ac, H3K4me3 and Inputs from FastQC and after FastP trimming. 
Cell Type/Line Factor Replicate FastQC FastP 
Jurkat H3K27ac 1 >32 - 
Jurkat H3K27ac 2 >32 - 
Jurkat Input 1 >38 - 
Th0 H3K4me3 1 21-24 22-25 
Th0 Input 1 >26 - 
Th0 H3K27ac 1 >32 - 
Th1 H3K4me3 1 17-23 25 
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Th1 H3K27ac 1 >30 - 
Th1 H3K27ac 2 >30 - 
Th1 Input 1 >30 - 
Th1 Input 2 >30 - 
Th2 H3K4me3 1 19-25 25 
Th2 H3K27ac 1 >30 - 
Th2 H3K27ac 2 >30 - 
Th2 Input 1 >30 - 
Th2 Input 2 >30 - 
1Primary cell lines and the Jurkat cell lines used are derived from Table () and tested using the FastQC program 
and Fastp (Supplementary Code: 7.3.3.a). 
 
 
 
| Table 7.25. Example of the top 50 results from DiffBind Differential Binding Analysis Granges 
Object for primary T-cells (Th0 and Th1) and the Jurkat cell line for DNAse1 Hypersensitivity 
(Cell lines from Table 7.20-23). 
 seqnames start end width Conc Conc_T.Cell Conc_T.ALL Fold p.value FDR 
1 chr2 5800122 5802122 2001 6.21 2.72 9.42 -6.7 1.51E-54 4.86E-49 
2 chr15 25008707 25010707 2001 5.99 2.77 9.16 -6.4 5.86E-45 9.43E-40 
3 chr2 59640062 59642062 2001 5 2.48 8.08 -5.6 2.35E-42 2.52E-37 
4 chr8 130179473 130181473 2001 6.72 3.3 9.91 -6.61 3.44E-41 2.77E-36 
5 chr7 133716225 133718225 2001 5.65 3.6 8.62 -5.02 7.76E-40 5.00E-35 
6 chr8 68879953 68881953 2001 6.45 3.75 9.56 -5.82 1.78E-38 9.56E-34 
7 chr8 130191098 130193098 2001 5.85 3.33 8.93 -5.6 3.07E-37 1.41E-32 
8 chr10 2927289 2929289 2001 5.83 3.65 8.83 -5.19 1.53E-36 6.15E-32 
9 chr3 32667457 32669457 2001 4.95 2.82 7.94 -5.12 1.72E-36 6.15E-32 
10 chr12 11950970 11952970 2001 6.25 4.06 9.26 -5.21 2.87E-36 8.71E-32 
11 chr2 182274990 182276990 2001 5.41 3.08 8.44 -5.36 2.97E-36 8.71E-32 
12 chr13 63570473 63572473 2001 5.6 2.82 8.72 -5.9 7.36E-36 1.97E-31 
13 chr1 245540753 245542753 2001 6.13 4.07 9.1 -5.03 1.46E-35 3.61E-31 
14 chr3 18004789 18006789 2001 6.13 3.75 9.17 -5.42 1.68E-35 3.85E-31 
15 chr10 45240790 45242790 2001 5.54 2.95 8.62 -5.67 6.63E-35 1.42E-30 
16 chr21 19815181 19817181 2001 5.92 3.05 9.06 -6.01 5.21E-34 1.05E-29 
17 chr3 117862996 117864996 2001 5.68 2.48 8.86 -6.37 8.60E-34 1.63E-29 
18 chr16 34794174 34796174 2001 6.28 3.06 9.46 -6.4 1.08E-33 1.94E-29 
19 chr8 130427019 130429019 2001 6.39 3.84 9.47 -5.63 1.95E-33 3.30E-29 
20 chr14 53691496 53694404 2909 6.3 3.47 9.43 -5.96 5.56E-33 8.95E-29 
21 chr11 92494436 92496436 2001 5.94 3 9.09 -6.09 9.88E-33 1.52E-28 
22 chr8 85676331 85678331 2001 5.53 2.8 8.65 -5.85 1.28E-32 1.87E-28 
23 chr4 142833219 142836335 3117 5.88 3.89 8.82 -4.93 2.02E-32 2.83E-28 
24 chr9 93737402 93739402 2001 6.51 3.46 9.67 -6.2 7.14E-32 9.58E-28 
25 chr14 26312206 26314206 2001 5.42 2.54 8.55 -6.01 1.19E-31 1.53E-27 
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26 chr1 31949069 31951069 2001 5.44 2.88 8.52 -5.65 1.34E-31 1.66E-27 
27 chr11 16358469 16360469 2001 4.57 2.66 7.49 -4.83 2.01E-31 2.40E-27 
28 chr15 86625030 86627030 2001 6.09 3.79 9.12 -5.33 3.89E-31 4.47E-27 
29 chr6 7344576 7346576 2001 5 3.19 7.9 -4.71 4.03E-31 4.47E-27 
30 chr6 47219564 47221564 2001 5.23 3.52 8.08 -4.56 5.93E-31 6.36E-27 
31 chr8 105879304 105881304 2001 5.95 2.97 9.1 -6.13 9.89E-31 1.03E-26 
32 chr16 88644554 88646554 2001 5.81 4.3 8.59 -4.29 1.13E-30 1.13E-26 
33 chr20 15026936 15028936 2001 5.69 2.76 8.83 -6.07 1.65E-30 1.61E-26 
34 chr3 18059502 18061502 2001 4.82 3.26 7.62 -4.36 2.74E-30 2.59E-26 
35 chr3 18023441 18025441 2001 5.96 3.31 9.06 -5.76 2.98E-30 2.73E-26 
36 chr6 14462591 14466197 3607 5.62 4.19 8.36 -4.16 3.05E-30 2.73E-26 
37 chr11 104209396 104213028 3633 5.97 3.8 8.97 -5.17 5.39E-30 4.69E-26 
38 chr3 18126796 18130734 3939 6.25 4.43 9.15 -4.72 5.71E-30 4.84E-26 
39 chr15 56969960 56971960 2001 5.41 2.87 8.49 -5.62 7.79E-30 6.43E-26 
40 chr7 92380738 92385495 4758 7.18 5.06 10.16 -5.11 9.69E-30 7.80E-26 
41 chr2 66561018 66563018 2001 5.36 3.23 8.35 -5.12 1.38E-29 1.08E-25 
42 chr1 38353178 38355178 2001 5.64 3.32 8.68 -5.35 1.40E-29 1.08E-25 
43 chr13 105461803 105463803 2001 4.83 3.02 7.73 -4.71 1.44E-29 1.08E-25 
44 chr3 108473746 108477456 3711 5.95 4.35 8.77 -4.42 1.60E-29 1.17E-25 
45 chr15 93831197 93834357 3161 6.24 4.14 9.23 -5.09 1.86E-29 1.33E-25 
46 chr7 56977661 56981018 3358 3.45 0.98 6.51 -5.53 1.93E-29 1.35E-25 
47 chr2 124609933 124611933 2001 3.77 2.16 6.59 -4.43 2.25E-29 1.54E-25 
48 chr8 130252550 130254550 2001 5.66 3.46 8.66 -5.2 3.82E-29 2.56E-25 
49 chr6 135665372 135668977 3606 5.59 4.06 8.37 -4.31 4.58E-29 3.01E-25 
50 chr13 77342780 77344780 2001 5.28 3.31 8.23 -4.92 5.01E-29 3.23E-25 
 
 
7.2.3 Chapter 3 - Command Lines Used 
 
7.2.3.a FastP Code - Python 
 
#Create an environment  
$ conda create --name FastP 
 
# To activate this environment, use 
$ conda activate FastP 
 
# Install FastP Package  
$ conda install -c bioconda fastp 
 
# Run code to trim files 
$ fastp -i untrimmedfile.fastq -o trimmedfile.fastq 
 
# Will produce a .html file and .json file -> Need to re-name the .html file to save  
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7.2.3.b Bowtie2 Code – Python 
 
#Create an environment  
$ conda create --name Bowtie2 
 
# To activate this environment, use 
$ conda activate Bowtie2 
 
# Install FastP Package  
$ conda install -c bioconda bowtie2 
 
# Run code to align files (Phred score > 25) 
$ bowtie2 -t -x reference genome file -U filename.fastq -S filename.sam 
 
# Will produce a .sam file in your working directory  
 
 
7.2.3.c Samtools Code for .bam conversion, sorting and indexing - Python 
 
#To install samtools without conda due to ncurses issue/incompatibility 
 
xcode-select --install 
 
ruby -e "$(curl -fsSL https://raw.githubusercontent.com/Homebrew/install/master/install)" 
 
Press RETURN to continue or any other key to abort 
 
brew install caskroom/cask/brew-cask 
 
brew update 
 
brew install openssl 
 
brew install samtools 
 
#create a conda environment for Samtools  
 
#Find where samtools is installed and drag contents of the /bin folder into your conda env 
bin folder (specifically for SAM) 
 
#check samtools version  
  
samtools --version 
 
#Generate SAM to BAM file  
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samtools view -Sb filename.sam > filename.bam 
 
#Sort BAM file  
# Can also be done in IGV by igvtools option —> Tools —> igvtools —> Command:Sort —> 
Input BAM file —> filename.sorted.bam 
 
samtools sort filename.bam -o filenamesorted.bam  
 
# Generate index file (.bai) for visualising in IGV  
# Can be done using samtools however did not work for me  
 
samtools index filenamesorted.bam 
 
# Index file generation using IGV  
Tools —> igvtools —> Command:Index —> Input IGV sorted bam file —> output sorted.bai 
file  
 
#Can visualise in IGV by inputting IGV sorted bam file with .bai file in the same location/file 
path 
 
7.2.3.d DiffBind code – R programming language 
 
##All Columns should start in row A. 
##Column headings are case sensitive. 
##(no spaces eg. Treatment = "100 nM Dex 6hrs", should be written as "100nMDex6hrs") 
##file names must match sampleSheet.csv sampleSheet. 
##move files (sampleSheet.csv, reads(.bam) and peaks(.bed)) to Diffbind/extra folder. 
 
#1) load libraries 
library(DiffBind) 
library(rgl) 
 
#2) Read file path to sample sheet 
samples <- read.csv(file.path(system.file("extra", package = "DiffBind"), "bed.csv")) 
names(samples) 
samples 
 
#3) Create DBA from files and sample sheet  
basedir <- system.file("extra", package="DiffBind") 
l <- dba(sampleSheet = "bed.csv", dir=basedir) 
op <- par(oma=c(5,7,1,1)) 
dev.off() 
l 
 
#4)Correlation heatmap, using occupancy (peak caller score) data 
##Heatmap indicates correlation between the location of peaks between samples 
##For large plots change the width and height when exporting 
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par(mar = rep(2, 4)) 
plot(l) 
 
#5) Establishing a contrast between samples by tissue type 
##comparison between the tissues as per sampleSheet.csv. 
##minMembers refers to the number of replicates in each condition, 3 is assumed. 
##We use this line to establish contrasts between replicates of the same tissue for QC of 
consensus peaks 
##input is step 3) DBA data 
DGF_peakset_Tissue <- dba.peakset(l, consensus=DBA_TISSUE) 
 
#6) Visualise consensus peaks between replicates and calculate the % of peaks shared by at 
least 2 replicates 
##Repeat for each sample 
##QC cut-off is 75%  
##If samples fail the replicate consensus QC check remove them from your sample sheet 
and begin at step 2) to 4) and skip to 7)  
par(mfrow=c(1,1)) 
dba.plotVenn(DGF_peakset_Tissue, DGF_peakset_Tissue$masks$”Tissue”,main="Consensus 
Overlaps") 
 
#7) Create correlation heatmap, using affinity (read count) data 
## trimmed mean of M (TMM) normalized (using edgeR), using ChIP read counts minus 
Control read counts and Full Library size 
##For an in depth explanation of this normalisation method see: 
https://genomebiology.biomedcentral.com/articles/10.1186/gb-2010-11-3-r25 
##For a discussion on NGS normalisation methods see: 
https://www.biorxiv.org/content/biorxiv/early/2014/06/19/006403.full.pdf  
##Helpful blog: http://crazyhottommy.blogspot.com/2016/04/library-size-and-
normalization-for-chip.html  
##Heatmap indicates correlation between the location and signal strength of peaks (number 
of reads/read depth) between samples 
l_count_TMM_MINUS_FULL <- dba.count(l, minOverlap=2, 
score=DBA_SCORE_TMM_MINUS_FULL, summits=1000) 
op <- par(oma=c(5,7,1,1)) 
dev.off() 
l_count_TMM_MINUS_FULL 
par(mar = rep(2, 4)) 
plot(l_count_TMM_MINUS_FULL) 
 
 
#8) Differential Binding Analysis between tissues in samplesheet, using normalised read 
count data 
l.DBAContrast_TMM_MINUS_FULL <- dba.contrast(l_count_TMM_MINUS_FULL, 
categories=DBA_TISSUE, minMembers = 2) 
l.DBA.analyse_TMM_MINUS_FULL <- dba.analyze(l.DBAContrast_TMM_MINUS_FULL) 
op <- par(oma=c(5,7,1,1)) 
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dev.off() 
l.DBA.analyse_TMM_MINUS_FULL 
par(mar = rep(2, 4)) 
plot(l.DBA.analyse_TMM_MINUS_FULL, contrast='X') 
 
#9) Retrieving the differentially bound sites 
##repeat for all contrasts of interest (contrast is selected for by the number in "contrast=x") 
l.DB_TMM_MINUS_FULL <- dba.report(l.DBA.analyse_TMM_MINUS_FULL, contrast=1) 
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7.3 – Chapter 4: Supplementary Figures, Tables and Code 
 
7.3.1 Supplementary Figures 
 
 
  
| Figure 7.6. An example of GC content distribution of the sequence amplified by Seq_1 
primer set within 30bp windows.  
y-axis displays the percentage of GC within each 30bp window and x-axis displays bp from the 
start and end of the amplified sequence. Metrics of the length of the amplicon and base pair 
quantities and percentages overall are displayed (bottom). 
| Figure 7.7. Display of predicted transcription factor binding sites (TFBS) using the JASPAR 2020 Database 
and mapped at Jurkat SNV10 – chr1:47,705,674 
 (Table 4.9) across the TAL1 locus with regulatory markers (DHS, H3K27ac and H3K4me3 – as seen in chapter 
3) (Top Panel), respectively. JASPAR 2020 predicted sites display scoring of TF binding probability within a 
minimum p-value of < 10-4 (light grey) (as stated by JASPAR 2020 in the UCSC genome browser). The higher 
the predicted probability of TF binding is displayed the darker the shade of the TF boxes are shown.  
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| Figure 7.8. Display of predicted transcription factor binding sites (TFBS) using the JASPAR 2020 
Database and mapped at Jurkat SNV8 – chr1:47,704,240  
(Table 4.9) across the TAL1 locus with regulatory markers (DHS, H3K27ac and H3K4me3 – as seen in 
chapter 3) (Top Panel), respectively. JASPAR 2020 predicted sites display scoring of TF binding 
probability within a minimum p-value of < 10-4 (light grey) (as stated by JASPAR 2020 in the UCSC 
genome browser). The higher the predicted probability of TF binding is displayed the darker the shade 
of the TF boxes are shown. 
| Figure 7.9. Display of predicted transcription factor binding sites (TFBS) using the JASPAR 
2020 Database and mapped at Jurkat SNV9 – chr1:47,704,674  
(Table 4.9) across the TAL1 locus with regulatory markers (DHS, H3K27ac and H3K4me3 – as 
seen in chapter 3) (Top Panel), respectively. JASPAR 2020 predicted sites display scoring of TF 
binding probability within a minimum p-value of < 10-4 (light grey) (as stated by JASPAR 2020 
in the UCSC genome browser). The higher the predicted probability of TF binding is displayed 
the darker the shade of the TF boxes are shown. 
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| Figure 7.11. Display of predicted transcription factor binding sites (TFBS) using the JASPAR 2020 
Database and mapped at Jurkat SNV6 – chr1: 47,697,125 
(Table 4.9) across the TAL1 locus with regulatory markers (DHS, H3K27ac and H3K4me3 – as seen in 
chapter 3) (Top Panel), respectively. JASPAR 2020 predicted sites display scoring of TF binding 
probability within a minimum p-value of < 10-4 (light grey) (as stated by JASPAR 2020 in the UCSC 
genome browser). The higher the predicted probability of TF binding is displayed the darker the shade 
of the TF boxes are shown. 
| Figure 7.10. Display of predicted transcription factor binding sites (TFBS) using the JASPAR 2020 
Database and mapped at Jurkat SNV7 – chr1: 47,703,613 
(Table 4.9) across the TAL1 locus with regulatory markers (DHS, H3K27ac and H3K4me3 – as seen in chapter 
3) (Top Panel), respectively. JASPAR 2020 predicted sites display scoring of TF binding probability within a 
minimum p-value of < 10-4 (light grey) (as stated by JASPAR 2020 in the UCSC genome browser). The higher 
the predicted probability of TF binding is displayed the darker the shade of the TF boxes are shown. 
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|Figure 7.12. Display of predicted transcription factor binding sites (TFBS) using the JASPAR 2020 
Database and mapped at Jurkat SNV5 – chr1:47,695,997 
(Table 4.9) across the TAL1 locus with regulatory markers (DHS, H3K27ac and H3K4me3 – as seen in 
chapter 3) (Top Panel), respectively. JASPAR 2020 predicted sites display scoring of TF binding 
probability within a minimum p-value of < 10-4 (light grey) (as stated by JASPAR 2020 in the UCSC 
genome browser). The higher the predicted probability of TF binding is displayed the darker the 
shade of the TF boxes are shown. 
| Figure 7.13. Display of predicted transcription factor binding sites (TFBS) using the JASPAR 
2020 Database and mapped at Jurkat SNV4 – chr1: 47,693,220 
 (Table 4.9) across the TAL1 locus with regulatory markers (DHS, H3K27ac and H3K4me3 – as 
seen in chapter 3) (Top Panel), respectively. JASPAR 2020 predicted sites display scoring of TF 
binding probability within a minimum p-value of < 10-4 (light grey) (as stated by JASPAR 2020 
in the UCSC genome browser). The higher the predicted probability of TF binding is displayed 
the darker the shade of the TF boxes are shown. 
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| Figure 7.14. Display of predicted transcription factor binding sites (TFBS) using the JASPAR 
2020 Database and mapped at Jurkat SNV3 - chr1: 47,693,116 
(Table 4.9) across the TAL1 locus with regulatory markers (DHS, H3K27ac and H3K4me3 – as 
seen in chapter 3) (Top Panel), respectively. JASPAR 2020 predicted sites display scoring of TF 
binding probability within a minimum p-value of < 10-4 (light grey) (as stated by JASPAR 2020 
in the UCSC genome browser). The higher the predicted probability of TF binding is displayed 
the darker the shade of the TF boxes are shown. 
| Figure 7.15. Display of predicted transcription factor binding sites (TFBS) using the JASPAR 2020 
Database and mapped at Jurkat SNV2 – chr1: 47,692,786 
 (Table 4.9) across the TAL1 locus with regulatory markers (DHS, H3K27ac and H3K4me3 – as seen in 
chapter 3) (Top Panel), respectively. JASPAR 2020 predicted sites display scoring of TF binding 
probability within a minimum p-value of < 10-4 (light grey) (as stated by JASPAR 2020 in the UCSC 
genome browser). The higher the predicted probability of TF binding is displayed the darker the shade 
of the TF boxes are shown. 
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7.3.2 Supplementary Tables 
 
| Table 7.26. List of MSRE Primers, Primer3 outputs and sequences of MSRE primer amplicons 
from Chapter 4 (Methods: 4.2.1) 
Primer Name  Forward Primer (5’-3’) Reverse Primer (5’-3’) 
MSRE_1 AGGCGGAGGATCTCATTCTT CTAATCTCCAGGTCCCCACA 
MSRE_2 CTGTCCTGAGCCTTCCTCAC AAAAAGGGGGAAAGCAAAGA 
MSRE_3 GAACATTTTCGAACCCTCCA CTATTCGCCTTTCCCAACAC 
MSRE_4 GGTTCTCCCTAAACCCCAAA ATAAACTCGGCTGCTCATCA 
MSRE_5 CGCATGTGCATTCTCTCTGT TGCCTTGCTTCTATGGGGTA 
Total Sets = 5 
 
7.3.2.a MSRE primer set and amplicon sequences (Methods: 4.2.1) 
 
MSRE_1 
Using 1-based sequence positions 
OLIGO            start  len      tm     gc%   any    3' seq  
LEFT PRIMER         13   20   60.18   50.00  4.00  1.00 AGGCGGAGGATCTCATTCTT 
RIGHT PRIMER       174   20   59.92   55.00  3.00  0.00 CTAATCTCCAGGTCCCCACA 
| Figure 7.16. Display of predicted transcription factor binding sites (TFBS) using the JASPAR 
2020 Database and mapped at Jurkat SNV1 – chr1:47,692,281 
 (Table 4.9) across the TAL1 locus with regulatory markers (DHS, H3K27ac and H3K4me3 – as 
seen in chapter 3) (Top Panel), respectively. JASPAR 2020 predicted sites display scoring of TF 
binding probability within a minimum p-value of < 10-4 (light grey) (as stated by JASPAR 2020 
in the UCSC genome browser). The higher the predicted probability of TF binding is displayed 
the darker the shade of the TF boxes are shown. 
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SEQUENCE SIZE: 200 
INCLUDED REGION SIZE: 200 
 
PRODUCT SIZE: 162, PAIR ANY COMPL: 4.00, PAIR 3' COMPL: 1.00 
 
    1 TACTTCATGGCCAGGCGGAGGATCTCATTCTTGCTGAGCTTCTTGTCCGGGGGATGTGTG 
                  >>>>>>>>>>>>>>>>>>>>                             
 
   61 GGGATCAGCTTGCGGAGCTCGGCAAAGGCCCCGTTCACATTCTGCTGCCGCCATCGCTCC 
                                                                   
 
  121 CGGCTGTTGGTGAAGATACGCCGCACAACTTTGGTGTGGGGACCTGGAGATTAGGAGGAC 
                                        <<<<<<<<<<<<<<<<<<<<       
 
  181 AAGAGTTAGGAGAATGGGCT 
                           
>chr1:47685696+47685857 162bp AGGCGGAGGATCTCATTCTT CTAATCTCCAGGTCCCCACA 
AGGCGGAGGATCTCATTCTTgctgagcttcttgtccgggggatgtgtggg 
gatcagcttgcggagctcggcaaaggccccgttcacattctgctgccgcc 
atcgctcccggctgttggtgaagatacgccgcacaactttggTGTGGGGA 
CCTGGAGATTAG 
 
MSRE_2 
OLIGO            start  len      tm     gc%   any    3' seq  
LEFT PRIMER         40   20   59.99   60.00  4.00  1.00 CTGTCCTGAGCCTTCCTCAC 
RIGHT PRIMER       237   20   60.05   40.00  2.00  0.00 AAAAAGGGGGAAAGCAAAGA 
SEQUENCE SIZE: 250 
INCLUDED REGION SIZE: 250 
 
PRODUCT SIZE: 198, PAIR ANY COMPL: 5.00, PAIR 3' COMPL: 3.00 
 
    1 TCCCCTCCCCCCACCCCCAATCTGAGAATGGGCTCTCCTCTGTCCTGAGCCTTCCTCACC 
                                             >>>>>>>>>>>>>>>>>>>>  
 
   61 CCAGGCCGGAACACAAGGCCTTCCTAGACACCGTTTCCACCGGCACCATTCCCCTGAAAA 
                                                                   
 
  121 CTCACCTGGGGCATATTTAGAGAGACCGGCCCCTCTGAATAGGATCTCCACTCCGCCGGA 
                                                                   
 
  181 AAGGGGCGGAAGCCGAGGAAGAGGATGCACACCCGGGTCTTTGCTTTCCCCCTTTTTCGC 
                                           <<<<<<<<<<<<<<<<<<<<    
 
  241 TGAGAGGCCT 
 
>chr1:47694782+47694979 198bp CTGTCCTGAGCCTTCCTCAC AAAAAGGGGGAAAGCAAAGA 
CTGTCCTGAGCCTTCCTCACcccaggccggaacacaaggccttcctagac 
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accgtttccaccggcaccattcccctgaaaactcacctggggcatattta 
gagagaccggcccctctgaataggatctccactccgccggaaaggggcgg 
aagccgaggaagaggatgcacacccgggTCTTTGCTTTCCCCCTTTTT 
 
MSRE_3 
OLIGO            start  len      tm     gc%   any    3' seq  
LEFT PRIMER         20   20   59.91   45.00  6.00  0.00 GAACATTTTCGAACCCTCCA 
RIGHT PRIMER       189   20   59.57   50.00  2.00  0.00 CTATTCGCCTTTCCCAACAC 
SEQUENCE SIZE: 200 
INCLUDED REGION SIZE: 200 
 
PRODUCT SIZE: 170, PAIR ANY COMPL: 4.00, PAIR 3' COMPL: 0.00 
 
    1 CCTCCCGACAGGCTGTCTGGAACATTTTCGAACCCTCCAACTGGGATCGGTCTGGTTCAG 
                         >>>>>>>>>>>>>>>>>>>>                      
 
   61 TGTTTGTTTTCTAAGCAGGGAGGTGTCTACGCGGTTGCCTCCTCAGCCAGGTCTCCGGCT 
                                                                   
 
  121 GCCGCTACACCGCGAAGGGATAGTCCCGGGCCTGGATGGGCGGAGGTCCGTGTTGGGAAA 
                                                       <<<<<<<<<<< 
 
  181 GGCGAATAGTCTTCAGACTC 
      <<<<<<<<<   
 
>chr1:47695312+47695481 170bp GAACATTTTCGAACCCTCCA CTATTCGCCTTTCCCAACAC 
GAACATTTTCGAACCCTCCAactgggatcggtctggttcagtgtttgttt 
tctaagcagggaggtgtctacgcggttgcctcctcagccaggtctccggc 
tgccgctacaccgcgaagggatagtcccgggcctggatgggcggaggtcc 
GTGTTGGGAAAGGCGAATAG 
 
MSRE_4 
Using 1-based sequence positions 
OLIGO            start  len      tm     gc%   any    3' seq  
LEFT PRIMER         19   20   60.16   50.00  4.00  0.00 GGTTCTCCCTAAACCCCAAA 
RIGHT PRIMER       170   20   58.48   45.00  3.00  3.00 ATAAACTCGGCTGCTCATCA 
SEQUENCE SIZE: 200 
INCLUDED REGION SIZE: 200 
 
PRODUCT SIZE: 152, PAIR ANY COMPL: 3.00, PAIR 3' COMPL: 0.00 
 
    1 CCCCACCACCAAAGGTTGGGTTCTCCCTAAACCCCAAAGCCAAGCCTCTTACCATTTTTC 
                        >>>>>>>>>>>>>>>>>>>>                       
 
   61 AAGTGTTTCTGCCTGCCCTCTCTGAGTACTGGACTATCTCTGAGCTTCTCCCCCGAGCTT 
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  121 CTTCTCCGGAAAGATGCCATGCATGCACTCTGATGAGCAGCCGAGTTTATTTTTAACAAA 
                                    <<<<<<<<<<<<<<<<<<<<           
 
  181 TCTACACTGCAGTTACTGTG 
 
>chr1:47701431+47701582 152bp GGTTCTCCCTAAACCCCAAA ATAAACTCGGCTGCTCATCA 
GGTTCTCCCTAAACCCCAAAgccaagcctcttaccatttttcaagtgttt 
ctgcctgccctctctgagtactggactatctctgagcttctcccccgagc 
ttcttctccggaaagatgccatgcatgcactcTGATGAGCAGCCGAGTTT 
AT 
 
 
MSRE_5  
Using 1-based sequence positions 
OLIGO            start  len      tm     gc%   any    3' seq  
LEFT PRIMER          1   20   60.02   50.00  4.00  0.00 CGCATGTGCATTCTCTCTGT 
RIGHT PRIMER       174   20   60.60   50.00  2.00  2.00 TGCCTTGCTTCTATGGGGTA 
SEQUENCE SIZE: 174 
INCLUDED REGION SIZE: 174 
 
PRODUCT SIZE: 174, PAIR ANY COMPL: 4.00, PAIR 3' COMPL: 1.00 
 
    1 CGCATGTGCATTCTCTCTGTCTCTAAGTCTGCTCCTCTTTCCTACCCCGGCCCTGTCTCT 
      >>>>>>>>>>>>>>>>>>>>                                         
 
   61 CCATCTCTGTCTTTAATCTGCCTCTCATCATTGCCTCCTTCCTCTTTTTTGGTCTCTGTT 
                                                                   
 
  121 CAGGCTGTCAATAAGAGCTCCAGCTGTGCACAGGTACCCCATAGAAGCAAGGCA 
                                        <<<<<<<<<<<<<<<<<<<< 
 
 
>hg19_dna range=chr1:47705095-47705268 5'pad=0 3'pad=0 strand=+ 
repeatMasking=none 
CGCATGTGCATTCTCTCTGTCTCTAAGTCTGCTCCTCTTTCCTACCCCGG 
CCCTGTCTCTCCATCTCTGTCTTTAATCTGCCTCTCATCATTGCCTCCTT 
CCTCTTTTTTGGTCTCTGTTCAGGCTGTCAATAAGAGCTCCAGCTGTGCA 
CAGGTACCCCATAGAAGCAAGGCA 
 
7.3.2.b Sequencing amplicon sequences (Methods: 4.2.5) 
 
SEQ_1 
 
>HG19_DNA RANGE=CHR1:47691795-47694488 5'PAD=0 3'PAD=0 STRAND=+ REPEATMASKING=NONE 
CAGAGACTGAGGGCCAAAAGGACAGAGATGGAGGAAGACGACAGAGACAC 
CGGAAGAAAAGGAATACAGCCAGCGACAGAAACACAGAAGGGGAAATCAG 
GAGGAAGGAAATGTACAAGGAGGCAAGAAAGAGATTACTCTGTCCCCTTT 
CTCAGGCCTAAAGGGAAGAGGAGGGAACAAATTCCGGATCGTGCTCTTTG 
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GTTTTAGCGGGGAATCTGTCAGGCAGGGGTTCGTTGCTTTAGGAACCTCC 
CTTGGCCTCTCAGCAATATTCCCAGCCCACCTACAGGCACACACCCAGAA 
ACCCGGTGCGGATGGAAGTAGGGAATTAGAAAGTGGAGGCTACGGGGACT 
GGGATCCACTCCGCCAGAGCTGGCAGAGAATAATCCCGAGGAACCAGCTC 
CCTCCACACACACACACACACACATTCGCCCCCGCTGGGGAGTGAGGGAG 
TGTCTGTCTACACTGAGCAAATCCACTGTGAGTCCTCTGCCCGCCCAGCG 
GATCTTTACTCCCACTCAGACAGAGATGAGAGGTCGCCAAGGGAAGAAGA 
TGGTGCTGGCCCAACCTCCCTGCACAGTCCACCTCGTTCTGCTCAGCTGG 
ACTCTGAAGTGAGGTCGAGTCTCAAAGAGAGGCCTGGCTGAGGTAGAATG 
GAGCTGGGCATTTGAAGGGTTCCCTGAGGCCAGTGGGGTCTGGACTCCCA 
TCCAAGAGCAGGACAGGATGTCATGAGGCCCTTGAACTCTTCCAGCCCCC 
CTCACCGCCATCTCCTGCCTTGGTGTTCTTTGGGAAATGGGAGGAATACC 
TCCTTTATGCATTTGAAAGTGCTGTGCAAACGTTCAAGTAAACATTATTA 
ACAAGGAGAATGGGCCAGTGAGAAAACTGCCTGGCCGAATGTCAAGTCAC 
TCACAGCCTATCTGTGAGAGAGCCAGACCAGAGCAATAATCTCACTTTGC 
TCAACCCTCCTGTATTCCCAGAGCAGTGAAACCACCTTGTGACCCCACAA 
GCATACTCCGAGATGACCACAGCCACTCTACTTCCCACAGGTGTGCTGGG 
GCTCTTCCATCACCTGGCTTCATCCAGATAGAGCTGGGCACCAGCAAGAA 
CCAAAACAGAAAAATCAGGAGACTCAAGGGCCAGAGTTTGTGAGTTGTGA 
GTTGTACATATATGATCAACACCACATAAGTTGTTTAAAATAAGCTTTCT 
GCTCTCTGAATTATATAATTGGGTATTTAAAAGAAGAAAACAAATACAAA 
AAAACAATTTACCCCCATGCAGAGTCCATCTAAATCATACATAGCAGCCA 
TTGAGCTCCCATACTGCCACTGCAATGCTCTGGACAGGAGTCATCCTAGG 
AACCATCCCTCCCACCCCAGAAGGGAGAATGGATCATCTGCAGCCTCCTC 
TGGAGCTTGGCTCAATTGCCACTAGACACCCAGGATGACAGAGAGTCAAG 
ATTCAGACTGCTGTACACCTTCTTTGGGAATGCCAGCCCCCCAGGTCTGG 
CACAGAAACCACAAAATTCCCTAAGTCCTGGTGTATACAAGCTGTAAAGG 
CAGTAGGTCCCTGACACTTCATTGGAAGTGAGTTTATGATTTTGGTGGAG 
ACAATAGGTCTCTATCCATAGAATGCAACCACCAAGACACCAAGGCCACT 
GGAAATGCACCAGAAGTATATCAGCCAGGTCCTCTTGCTCCCAGCAGCAG 
CGAAATGTGCCAGAAATATACCAACCCCTGGGAAACATACAAGCTTCAAG 
GTATTGGTTCCCTACCTCACTGCTCTCCGTCCTGACACACCGGTGTGAGC 
CCAGTGATCCATGCTTAAGCCCCAGCTTCTAACCGAGTGACAGTGTGCAC 
TGCAGTTGCAGACTGAGCTCAAGCTCTGTTATGACACATTTTTACCCTCC 
AATTAATTCTTAGGCTCCTGCTCTAGCGGTGGATTCCTGAGAGGCAATGG 
GAGTACATATTCCAGATGAATTGACCCTGGCCACAAATGTCCTCTCCAGA 
CACCTATAAATATCCCATCGCCAAGGTTCCTTGTAAGAAATATATGATTG 
GATCCCAGGATCTGTGGAGGACCTCTCCCGGCTCCTCCCCACATTTTAGG 
AAAATCCTGCCGGTTTAGGATTACCAGCCAGAGGTCCATGCCCCAAAGAA 
GCCACTCACAAACACTGATGGTTGTTGGCGACTAAGCTGCATCACTTGAT 
TTGGATTACAGAAAGGAACGCCCGAGAGATTTTGTTTGTTTTTATTTGGG 
GAGAATGAAGGAGGAGGGAGATTTTAGACTGAATCGTTCTAGAGTATTTG 
ACGACTACAGCTCCTCTCTCTTTGTACTACGGAGACCCTGCTTATAGCCC 
CCAACAGGAAATCCTCATCTGCAGTTGCCAGACAGCCAGAATATTTCCAC 
CTGTGCCAGAACAAGACAGAAGACCCCAGGAGATTCTTCCTGGGGACAGG 
TCTCAAGCAGACCCAATCCCCCATACAGAGAATTTCTTAGATGAAAACAG 
CCTCAGGCCCTTAGACCCAGCCTCTGGTCTCTCTTCTGGGCCCACACCAG 
CACAACACCCTGGAGAAGCCCCAAGCCTGCACAAGTACCAAACCCACCAG 
GGAACAGCACCACCATCCTCGCCTCTACCGGAGAAGAGGGGTGTTCCTGC 
CTCCCCACCCTAGGCCTCAGGCCTGGGATCAGGGCCCACTCGAG 
 
 
SEQ_2 
 
>HG19_DNA RANGE=CHR1:47694309-47697743 5'PAD=0 3'PAD=0 STRAND=+ REPEATMASKING=NONE 
ACCCAGCCTCTGGTCTCTCTTCTGGGCCCACACCAGCACAACACCCTGGA 
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GAAGCCCCAAGCCTGCACAAGTACCAAACCCACCAGGGAACAGCACCACC 
ATCCTCGCCTCTACCGGAGAAGAGGGGTGTTCCTGCCTCCCCACCCTAGG 
CCTCAGGCCTGGGATCAGGGCCCACTCGAGCTGGGACTGCACTAGCCAGG 
AAGGCTGCCGCCTTCCTCCTGCGGGAGCTCCAGGCACAGTCTGTACCACC 
CGGATACAGCCGCCCCAAAGTTACCGGCCTTGGGAAACGTCCACAGAACC 
GGGACCAATGGGAAAGGCCTGGACGACTAAGTCCAACTAGCTGGTTTTAC 
CCTGGGTGGAAAAGGGAAAAAGCCGCTGAATGCCACAGAGGCAGCTACAG 
CAGTCAGATCCCGATTCCAAGCTCTGGCTGGTCCTCCCCTCCCCCCACCC 
CCAATCTGAGAATGGGCTCTCCTCTGTCCTGAGCCTTCCTCACCCCAGGC 
CGGAACACAAGGCCTTCCTAGACACCGTTTCCACCGGCACCATTCCCCTG 
AAAACTCACCTGGGGCATATTTAGAGAGACCGGCCCCTCTGAATAGGATC 
TCCACTCCGCCGGAAAGGGGCGGAAGCCGAGGAAGAGGATGCACACCCGG 
GTCTTTGCTTTCCCCCTTTTTCGCTGAGAGGCCTGCAGTTACGCTGCGGT 
GTGGTCCTGGGCGATCTGCCGCGCCCAAAGCGAGTTTCCAGGAAAGATAG 
GGGTGGAGAGAAAGAGGCAGGGCAAGAGGGAGGGAGAGAGAGAAATGGGG 
GTCAATGGCTGGGAATTACCTCCTGTCCCCGACCAACCAGTCCAGGGAAT 
CGCAAACAGCTTTCCGCCCCCAACCTGCAGGTGTTTGGAGCCTTTCCTCT 
ACCCCCTCCTCCCCCCACCCGCCTTAAAAAACCCTATACATGACCAATCA 
GGAATAGCTATTTAGTCCAACAGCAACAACAACCCCTCCCGACAGGCTGT 
CTGGAACATTTTCGAACCCTCCAACTGGGATCGGTCTGGTTCAGTGTTTG 
TTTTCTAAGCAGGGAGGTGTCTACGCGGTTGCCTCCTCAGCCAGGTCTCC 
GGCTGCCGCTACACCGCGAAGGGATAGTCCCGGGCCTGGATGGGCGGAGG 
TCCGTGTTGGGAAAGGCGAATAGTCTTCAGACTCTGGTCGGTGGGACAGA 
ACCTTGAAGTCCCCCCCACCTCATTCTCTCTCTGACCCCCATCCACCCAC 
CTCCAGCCCAAAGCGAAACCAGAACCCAATTCCAGGGGCTGTACTTTCCT 
ACAGAAATGGAGTTGGGAAGGGGGCTTGGAGAGAGATATCTGATCTGTTC 
AGGTCCTTTCTCGTCTCCCTACTGATTAAGAGAAAGAAGAAAGAGAGAGG 
AAGAGAGAGACAGAAAAAGAAAAGGAAATAAAGACCAACAAAGGGGGAAA 
GAAAGAAACAAAGGGGAAAAGTCCCCCACCTTCCCCTCCACCACCCCTAC 
GAAATGATTTTCGATTTTTCGGGGTTTAGACAGAGTAAGGGAGAATTCTA 
ATGATTTGTTACAGCAATAAACAAGGTAAAAGGAAAGGAGGTAAAAACAA 
ACCCGACACTACTTTCAAGGATGTAGCAGGATTGAGCTTGCTTTTATTTT 
TTCCTAGTGGATTTTGTTTAATTTGTTTTGCCTAAATCGTCAGGCTTATG 
ATCACACATCGAAGTCTTGGATTAACTGCGAAGGCCTCCTTCTATTTGCC 
GCGGCTTTGGTGGACATATAGGAATAATTCTTCCCTGGATTGCAATACAA 
TGCGGAAGATTTTCTTTCTCCTCTTCTAATCCAAAAGAGGGGAGGGGAGG 
AAAGAAGAGGGGAATCCATCCATTCCCGGCGTGTTCGCGGGGGGTTAATG 
TTGCGTGTTCGCTGGGGGTTAATGTTTGCCTTATGACCAAGTCTCTGTGT 
CCGTGCCTCTCTCCATTTTCTCTTCCTACCTCAAACCCAGCAACTTAGAA 
AACGGCTGTAGCGGAAAAAAACCCGCTGCTTTGTTCTCCCGCCAAAGGAG 
CCAAAAGGGACAAACTGCTGCGCTCTGGGATGATTATTTTAATTAAAATA 
GATGTTAATGATGACGATTGTGATGGTGATGGCATTAGCAATTACAATAA 
TTGACAAAACAAAATTCTTTCAACCCGAGCTAGGGCCCCACTAACCCGGT 
CCCTCCCAGAGCCCGGATTCGGCCTCGGTCTCGGATGCGACGGGTATCAG 
ACCCAAGCGGCAACGTCGCTCACCCGAAGAGGGGGCGGGAAAATCTTCCC 
AGGAGGTGATCCCGAATGTCCCCACCCGAGGCTCGAGGCCTGGTGAATGT 
GCCCATTGTCCTTTCGGGGCCTCTCCCTTGGAGCCCGGCGGCCGCACCCA 
CGAAACTGACCAGAAATGGATGAAGCCGGAGTGCAGCGGGAACCGAAGCC 
CGCAGCTACCGGCTCGAAGGCGCCGGCCTCGGCGAGCGCTGCTCAGCTTC 
AAGCCTGGAGGAGCCTCCCACTCACCAACGAACCCCTCAAACACCTAGGC 
ACAGGCGGGCCTCCGGGCAGAGCAGCCGCCGACCGGGCGCTGTCCGCCCA 
CCCAAGCCAACAACTGGCTCCCGAATACATCATAATTTGGAATAAAATGT 
GAAATCCCGCTCCCCGCCCCCATGCCGCCGCCCCCACCAGCGCCTCGATC 
TCTCGCTCGCCCTCCCCCCACTCCCGCCCCCAGCGATTTGCAAACGCACC 
TCTAAAGGACACAGGCACACAGGCATACAACTCAGTGCGGACAGGACCAC 
ACAGGGTCCAGCCCCACAGAAGGGCAGCAAACAAACACCACCTAGCACTG 
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CCCCAGAAGCCGACTTGGTCAGCCCCGCACACTGCCCAACAGGACACAAC 
GAAATCAGTCAAACGCAGCGGCTCACGGACACACAATCCAGCACAGTCGG 
GATCACACACGCCCGACATAACGACGACACCACCCAAACACAGTCGCAGG 
GGCCACACACCCCCACACACAGAATCAGATCCCTGCTGAGAACACCAACG 
GAGCACAATCGTACGCAACGAAGAAAACGCAGAAGGGCCTCGAAGGGTCC 
ACATCTACACACCCCAACCGCGCAGGCACACCACACTCGGACACAGAGCC 
TGTCGCCAAGAAGACCACACTTAGAAGCAGCCAACGCCGCCCACAGTTCT 
CATGAACGCACTCTCACAATCCCACCGCATGCACACAACCACGAAGAAGA 
AATGAAAACCAACCACAGCCTCGCGCATTTCTGTATATTGCGTAAGGAAA 
AGGGGGAAGGAAGGAAGAGAGTCTCCGAGGCGGGAGGGGCGGCGGCAGCC 
GGGGCGGGGGCGTCCGTGGAAAATGCCCCCCCACCGCCCCCCCCGGCCAT 
CGAAAGGAACCGAGGGAAAGGGAGCGAAGACCTCT 
 
SEQ_3 
 
>HG19_DNA RANGE=CHR1:47697580-47701354 5'PAD=0 3'PAD=0 STRAND=+ REPEATMASKING=NONE 
CGCGCATTTCTGTATATTGCGTAAGGAAAAGGGGGAAGGAAGGAAGAGAG 
TCTCCGAGGCGGGAGGGGCGGCGGCAGCCGGGGCGGGGGCGTCCGTGGAA 
AATGCCCCCCCACCGCCCCCCCCGGCCATCGAAAGGAACCGAGGGAAAGG 
GAGCGAAGACCTCTTTTGCGGACGTGGGGAAAAAGAGGAGGAAATTGATG 
AAGAATTCGGTGGGAGGCCGCGGGTTGCTTTTCCCCTAGAAAAAGGCCAG 
AATGCTCACGTTTTTCCGCTACGGGGGTACGCGTGTGGCCATTTTGAGGC 
CCGGTCCTGAGCGGCGGCGGCCCGGCCCCTCCCGCGGCCCCCGCTCCCCC 
GCCCGCCCCGCGCCCGCCCGGCCCCTCCACCGACGCGCTGTAATCCCACT 
CACGTTCCAGGCCTCGTTAGCATGGGCCGAGGCGCGCCGGGGCCGTGTGC 
GCCGCAGAGATAAGGCACTGCCGCGGGTCCGCCCGCCCCCGATAAGCGCC 
TCGGCCATTATGGGCCAAATGATTCATTTTAATTTGGCAATTTCACCGGA 
GGGAGTGGGGACTGGTTGAGCGGCGCTAGGACCGGCTCCGGAACGCGCTG 
CGGGGAGCGTTGGACGCGCTGTCTAGGACCCAGCAGATCCAGCCCCCATC 
TCTAATCCCAAGGCCTCTCAGGAACCCCAGCTTCCCACAACCTCAGTCCC 
TTAACCTTTCAGACACCTTTCTTCAGCGACTCTCACCCCAGCACTCTGTC 
CCTACCTCTGAAGACCACCATGATACCAAAATCGTCACCTCCCAGGGCTT 
CTTTCTTATTCTTCCTCCAGTGTCCCAGACACCCAGATTTCAATGGGCAG 
TCTCCCTATCCCAGAAAGCTCCCCAGCCCTTCCCTACCTCTTCACCCCCT 
TCTAAAATAGAGCCGGTAACTCAAATCCATGGGCTCTACGGCGGCCTGGC 
AGAACCCCTGTCAATAGGGACATAAAATGCCTATTCTGCTAGGTTTCAGG 
CTGAGCCCAGAGCCCAGGAACACTGCTCCCCACATGGTATTTAAAAAAAA 
AAAAAAAGTTTAATCTAGCGACTGTAACACTATTCTAGGCATTCTGCAAA 
TACTAATCTACTCTTCACAAACAGTCCTGAGAAGCTGGATCCTTAATTTA 
CAGAAGAGAAAACTGAGGCACAGAAAGTCAAAGTAACTTTTCGAATGATA 
CATAGCTAGTGCTTGGTGGAGTCTGCCTTGGAAGGAAATTTGACACGGAG 
TCTTCTCTGCGGCTCAGCTGATGAAGAGGGGCAGCCAAAACCTAGCCAGG 
GAAAGGGACCTGGGCTCAACTCATTGCAGAGACCAGGGTCTTTACTGTGG 
GGTAGAAATCTGAGTTCAGTGCCAGCTGGATGATGCGCTCAGCCCACGGA 
GGGTCTCTGGGTTCATTCTTTCATGGTGGAGTGGAAAGAACACATGTTCG 
AATTTTAGTCACTGATCTCTGAACCTCAGTTTTCTCATTTGTAAAATGGG 
GAGATAATGTCGACGTCACAAAGTTATGAGAACTAACTTATATGACCTTT 
AAAAGGTGGTGGTGAGGATAATAATGTATGGAACGTCACTCAGTCCACAG 
CCCAGGAAAACATCATATGCACTTGCATGGGAGTTCTGGTTATCATCATA 
GAGAAAGAAATTAAGACACAGAGAGATGTGACTTAGCCAAAACTTACAGT 
AACCCAAAGGAAAAGCCAGGACCCAAACTTTGGTGTCCAATTCCCAGTCC 
ACAACTCTACTTTCCATGCCAGGCTGATTTGTCCTTCTAGTGTCTCTGCT 
TTTGAGCTTTTTTTGGAGCCTGAGAACTGGGGGAAAACCCCTACTCTGGT 
AACAAACTGAGTCCCAGTCAAAGACTGAGCAGAGAGCATGGCCCCAGTCT 
GGGATCTGGCTTCTCCTTGGTCATCAGGTTGACCCTCTGAGAAGATACAG 
TTAATTCAGTGCCGCCTGTCCCCTCTGTTCCTCCTGTGCTCTCTGAAGGA 
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AGTCAGGCTGTCATGGGGATACAGATAACTCTCACAGAATCCCACATCCT 
AAGAAAAAGTCTAGTTCCCCCCTACCATAAGGCCTTTGCTTGGCTCCATC 
ACTTATTAGAAAATGAGAGTCATATAATTCTGAGTCTGAAACACAACTCT 
GCCATTCCTGGGCTGTGGGACCCTTAGAGAAGTGATTTCATGTCTCTGAG 
CCACTGTAAAAACAGGCTAGCCATTCCCATATGGGAGAGCCCAGGTGGGG 
ACTGCTTCTCTGAGAAAATGAGGCCTGGACTGAGATCTAAGAGTGAAATT 
TGGGGGTGCGAAGAAGGGGGGTGGGGAGAAGCATCAGTATCCAGAACCTT 
CCAGGTGGGCTGAGGAAACAGCTGGACCAAGGGCTAGAACAGAAGGGTGG 
TAGGTTCGTGAAAAGAATAGAAAAGTGTCCAGTATGGCTGGAGCATGCTT 
GTGGACAAGTTAAAAGATTTTTTGACATTTTTTTGTTTGTTTGGTTTGAA 
GGTGGGGGTGGTACCTTGTATAGAATAAGATTTGCATTTCTAGAAAGTTC 
TTTGGATGAAGTGTGGAGGGGGAAGGACTCTGGGAGGCCAGTTGTGGAGC 
CAATGCAGTGGTTAGGGGAAGCGGATTAGAGCTTGGACCACTGTGCTGGC 
AGAAGAGATGACAAGAGGCAAGTGAAGATGACATGTATTTGGGGTATAAA 
ACTGGGTTTATAATAATTGGATTTGGGCCAGGCATGGTGGCTCATGCCTC 
TAATCCCAGCACTTTGGGAGGCCCAGGCAGGCGGGTCACGAGGTCAAGAG 
ATCGAGACCATCCTGGCCAACATGATGAAACCCTGTCTCCACTAAAAATA 
CAAAAATTAGCTGGGTGTGGCAGCGCACGCCTGTAGTCTCAGCTACTCAG 
GAGGCTGAGGCAGGAGAATCACCTGAACCCAGGAGGCAGAGGTTGCAGTG 
AGCCGAGATCGCGACACTGCACTCCAGCCTGGCGACAGAGCGAGACTCTG 
TCTCAAACAAACAAACAAAAAAAGAATTGGGTTTGGGGGGATGAGGGAGA 
GGAAGGAATCCAGGAAAACCCCTGGGTTTCTGGCTGTCCTGCAGAGCTAG 
TGGTGGTTATTCCTGGAGATGGGGAACCTGGAGGCTGAGGGGACATGGGG 
AGGGCTTATATATTTGGTTTTGAACTCCTTAAGTTTAGATGCCTTTGAGA 
CACCTGCAGACTGTTGGATTATTTTACAGGGCATTAAATGTCCCCAGCCA 
GCACCTCCAAGGAAAGTGTCCTTTCCTGTGGTGAAGGAATATGGACAGGT 
GGAAAGGCGTTTCTCAGCCCTGTGGCAGAGGGTGTGCCCAGGCCTCTGTC 
TGTGGAGCGAGGAGGTGACGTTCACCAACCCTCCAATTCCACACATTTGT 
TCTCTGCCAAGCTCCAGATTCTGACAGTCAGGCAGCCACTCCCGACCTCA 
TCCACCAAAGCCCTGCCAGGGGCTGGGGTCTCATGACGTCTACATCTGCC 
CCCTCCCCTGTTTCCGATGGTCAGTGGAAAAACGGAAGCTGTGCGCTAAG 
CGGGGCGCTGCCTGAAATAGCATCTGGTGCCTGTCGGTCAGCGAGTTGTC 
CGAGCGTCCACGAGAGAGTGACAGGCCGGGGCCAGCCAGGAAATGCCACC 
CCTCCTCCACCCGCCCCAAACGGAGGCCCCAGTCGGGCAGGAAACCCGGA 
GCGCCTGGGGTGGGGGTGGCGAGGAGGGAGGGGAGGTTGAGACCCAGACT 
GGTAAGTCTGGAGTCTGGAACTGGG 
 
 
SEQ_4 
 
>CHR1_47699942_47702280  
AGGAAACAGCTGGACCAAGGGCTAGAACAGAAGGGTGGTAGGTTCGTGAA 
AAGAATAGAAAAGTGTCCAGTATGGCTGGAGCATGCTTGTGGACAAGTTA 
AAAGATTTTTTGACATTTTTTTGTTTGTTTGGTTTGAAGGTGGGGGTGGT 
ACCTTGTATAGAATAAGATTTGCATTTCTAGAAAGTTCTTTGGATGAAGT 
GTGGAGGGGGAAGGACTCTGGGAGGCCAGTTGTGGAGCCAATGCAGTGGT 
TAGGGGAAGCGGATTAGAGCTTGGACCACTGTGCTGGCAGAAGAGATGAC 
AAGAGGCAAGTGAAGATGACATGTATTTGGGGTATAAAACTGGGTTTATA 
ATAATTGGATTTGGGCCAGGCATGGTGGCTCATGCCTCTAATCCCAGCAC 
TTTGGGAGGCCCAGGCAGGCGGGTCACGAGGTCAAGAGATCGAGACCATC 
CTGGCCAACATGATGAAACCCTGTCTCCACTAAAAATACAAAAATTAGCT 
GGGTGTGGCAGCGCACGCCTGTAGTCTCAGCTACTCAGGAGGCTGAGGCA 
GGAGAATCACCTGAACCCAGGAGGCAGAGGTTGCAGTGAGCCGAGATCGC 
GACACTGCACTCCAGCCTGGCGACAGAGCGAGACTCTGTCTCAAACAAAC 
AAACAAAAAAAGAATTGGGTTTGGGGGGATGAGGGAGAGGAAGGAATCCA 
GGAAAACCCCTGGGTTTCTGGCTGTCCTGCAGAGCTAGTGGTGGTTATTC 
  
197 
CTGGAGATGGGGAACCTGGAGGCTGAGGGGACATGGGGAGGGCTTATATA 
TTTGGTTTTGAACTCCTTAAGTTTAGATGCCTTTGAGACACCTGCAGACT 
GTTGGATTATTTTACAGGGCATTAAATGTCCCCAGCCAGCACCTCCAAGG 
AAAGTGTCCTTTCCTGTGGTGAAGGAATATGGACAGGTGGAAAGGCGTTT 
CTCAGCCCTGTGGCAGAGGGTGTGCCCAGGCCTCTGTCTGTGGAGCGAGG 
AGGTGACGTTCACCAACCCTCCAATTCCACACATTTGTTCTCTGCCAAGC 
TCCAGATTCTGACAGTCAGGCAGCCACTCCCGACCTCATCCACCAAAGCC 
CTGCCAGGGGCTGGGGTCTCATGACGTCTACATCTGCCCCCTCCCCTGTT 
TCCGATGGTCAGTGGAAAAACGGAAGCTGTGCGCTAAGCGGGGCGCTGCC 
TGAAATAGCATCTGGTGCCTGTCGGTCAGCGAGTTGTCCGAGCGTCCACG 
AGAGAGTGACAGGCCGGGGCCAGCCAGGAAATGCCACCCCTCCTCCACCC 
GCCCCAAACGGAGGCCCCAGTCGGGCAGGAAACCCGGAGCGCCTGGGGTG 
GGGGTGGCGAGGAGGGAGGGGAGGTTGAGACCCAGACTGGTAAGTCTGGA 
GTCTGGAACTGGGGCAGCAAGAGCAGGGGACAAGAACAGGCTAGCTAGGC 
TCTGGCCCTGAGGCCGTTGTTCCCCACCACCAAAGGTTGGGTTCTCCCTA 
AACCCCAAAGCCAAGCCTCTTACCATTTTTCAAGTGTTTCTGCCTGCCCT 
CTCTGAGTACTGGACTATCTCTGAGCTTCTCCCCCGAGCTTCTTCTCCGG 
AAAGATGCCATGCATGCACTCTGATGAGCAGCCGAGTTTATTTTTAACAA 
ATCTACACTGCAGTTACTGTGTGACAAGTACTGTCCTAGGCACTTTGTAA 
GTATTAATTCAGTTAATCCTTGCAAGAACCTAATGAAGTAGGGACTACTC 
CATTTTGTAGGTAGCACAGAGAGGTTGAGCAACTTGCAGAGAACACCCAG 
CAGGTAAGTGGTGGAGGCAAAATTCACACCTAGGGCAGTCTGGCTTCAGG 
CCACAGTGCTTCGAAAGCAGCAAAGCAAGCACAATGGTCAGGCAGACCTG 
AGCTCCTATCCCTGCTCCCCTAGTTGCCAGCTGTATGATACCAGGCAAAT 
TACTTAATCTCTGAGGTTCACTTTCCTTATTTGCAGAAGAGAGGTGCTCA 
TTTTCCATACATAATACTGTTTATATAAGGATTATTTTTAATGAGGAAAA 
TTTCAATTTGAGGAAATGTCATTATTTCCCTCTTCCACTTTCAAAGGACT 
ATTCTCTCCATTTTTGCCTCTGTCTCTTGCCCTGGAAGAACCCCTACCCC 
ATCAGTAAGCAGGCCTCAAGAATTCCGAGCTTGGGAGTCACGTCTGTGCT 
TCCAAACCCCAACGCTGCTGTCAGAATTCTCAGGGATGGAAGGAACTTCA 
CTCTCAGTGGCTCTCAAAGTGGATGGTCAGCATCACCGAGGAACCTGTTA 
GAAAAGCAAATTCTCAGGCCTCACCCCAGGCCTACTACT 
 
SEQ_5 
 
>CHR1_47701548_47704837  
GCCATGCATGCACTCTGATGAGCAGCCGAGTTTATTTTTAACAAATCTAC 
ACTGCAGTTACTGTGTGACAAGTACTGTCCTAGGCACTTTGTAAGTATTA 
ATTCAGTTAATCCTTGCAAGAACCTAATGAAGTAGGGACTACTCCATTTT 
GTAGGTAGCACAGAGAGGTTGAGCAACTTGCAGAGAACACCCAGCAGGTA 
AGTGGTGGAGGCAAAATTCACACCTAGGGCAGTCTGGCTTCAGGCCACAG 
TGCTTCGAAAGCAGCAAAGCAAGCACAATGGTCAGGCAGACCTGAGCTCC 
TATCCCTGCTCCCCTAGTTGCCAGCTGTATGATACCAGGCAAATTACTTA 
ATCTCTGAGGTTCACTTTCCTTATTTGCAGAAGAGAGGTGCTCATTTTCC 
ATACATAATACTGTTTATATAAGGATTATTTTTAATGAGGAAAATTTCAA 
TTTGAGGAAATGTCATTATTTCCCTCTTCCACTTTCAAAGGACTATTCTC 
TCCATTTTTGCCTCTGTCTCTTGCCCTGGAAGAACCCCTACCCCATCAGT 
AAGCAGGCCTCAAGAATTCCGAGCTTGGGAGTCACGTCTGTGCTTCCAAA 
CCCCAACGCTGCTGTCAGAATTCTCAGGGATGGAAGGAACTTCACTCTCA 
GTGGCTCTCAAAGTGGATGGTCAGCATCACCGAGGAACCTGTTAGAAAAG 
CAAATTCTCAGGCCTCACCCCAGGCCTACTACTACTACTCTGAGGGTGAG 
GCCCAGCAATTTGTTTTCACAAGCCTTCCTGATGATTTCTGACACACACA 
CAAAATTTGAGAACCACTTCTCTAGTTTACAACCCCCATCTGTAGCAAAG 
GCCAAAGTAAAATTGTGTTAAGAAAACACCGTGCTTTTTTTTTTTTTTGA 
GACAGAGTTTCACTCTGTCTCCCAGGCTGGAATACAATGGTGTGATCTCG 
GCTCACTGCAACCTCTGCCTCCTGGGTTCAAGCAATTCTCCTGCCTCAGC 
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CTCCTGAGTAGCTGGGACTACAGGTGCATGCCGCCACACCCAGCTAATTT 
TTTTTTTTTTTTTTTTTTGAGACAGAGTCTCCCTCTGTCACCCAGGCTGG 
AGTGCAATGGCACAATTTTGGCTCACCACAACCTCTGCCTCATGAGTTCA 
AGCAATTCTTGTGCCTCAGCCTCCCAAGAAGCTGGGACTACAGGCATGCA 
TCACCACGCCCAGCTAATTACTTATATTTTTAGTAGAGACAGGGTTTTAC 
CATGTTGGCCAGGCTGGTCTCGAACTCCTGACTTCAGGTGATCCGCCCGC 
CTTGGCCTTCCAAAGTGCTGGGATTACAGGCATGAGCCACCACACCCGGC 
CTTTTTTGTATTTTTAATAGAGATGAAGTTTCACCATGTTAGCCAGGCTG 
GTCTCAAACTCCTGACCTCAGGTGATCTGCCGATCTCAGCCTCCCAAAGT 
GCTGGGATTACAGGCATGAGCCACCGCCCCCGGCCTGTGCTTTTTAATGT 
TTCAAAGCCATTTCCCTTTCCCTAACCCATGCGGAAGACCAAAGCATACA 
GAAGACCGAAGTTGCTTTCCAGACTTACAGAAGAGATAGTGTCTAAACTT 
AACTGTCCTCATGAGCAGAGAACCCCAATAGCTCTGCCATCAATGATTTT 
ATTCCCAGAGCTGTTAGAAAAGGACAGAACATGTGCATAGCCACCAGTTC 
TCTGGCTAGCAAATAGTCGTTGATGCTCACTGAGACAGAGTCCTGGCCCA 
GGAGTACACATTAATACATGTGGACAAGACTCCTGGGCCCCTGAAGGGGA 
CTCTATGTCCTGGGCACTGCCATGTGTGCCTGCACTGCTTCCTGCTTCTG 
CCGCTGTTCTGTCTCTTGATCCTCCACTATAACCTGCCGGGCTGCTTGTG 
TGATCCCCACTTTAAAAATGAGGAAACAGGCTCATCTCACCCAGTCACTC 
ACTTGGTATACATCCAAGTCAGCTTAGCCCCGGTGTCTTCTCCATTCCTG 
CTGGCTAGAATGAACTATGTGTTACTTTGGGAGAACTGTTTCAAAATCTT 
GAACACTTTGGATAGCATTGTGATATCCCCCGGTTTAAATCCTTTGACCT 
TAAAGAAGATAAATAGCCAAACTTATCATGAAAAGATTCTTCAACTTGTA 
TTAAGGAAACAGAAATTAAAACCACAATGAGATGCCATGACACATCCACT 
AAAATGATTAAAATTTAAAAGACTGACAATACCAAGTATTGCTGAGGATG 
TGAAGGAGCAACTGGAGTTCTCCAGCAACATTGTTGAAGGAAATGCAAAA 
ATTACTCAGCCACTTTGGAGAACTCTTTCGCAGTTCCTATGAATGTGCAG 
TTTATAAACACCCATTTACTGAGACAGCTGAAAAATATATATCCACAAGA 
ACACCTGTACATTAACAGTGATAGAACCCTTATTTGTAAAGCAAAAAACA 
ACAATTCAACTATCCATCAACAGGTGAATGGTAAACAAATTGTGGTACAT 
TCATGTAATAGAACATTACTCAGCAATAAAAAAGAAACAAATTACTGACA 
AATGCCAGAATATAGACCTCTCAACAACAGGCTCAGTGAAAGAGGCCAGA 
CACAAAAGACTATTTAGCATATGATTCCATTTATATGAAACTCTAGAAAA 
AGCAAAAATTTTTTTTTTTTTTTTTTTTTGAGACAGAGTTTCACTCTTAT 
CACCCAGGCTGGAGTGCAATGGCGCCATCTGGGCTCACGGCAACCTCCGC 
CTCCTGGGTTCAAGCGATTCTCCTGCCTCAGCCTCCCAAGTAGCTGGGAT 
TATAGGTGCCTGTCACCACTCCCAGCTAATTTTTGTATTTTTAGTAGACA 
CGGAGTTTCACCATGTTGACCTCAGATGATCCGCCCGCGTCAGCCTCCCA 
AAGTGCTGGGATTACAGGCATGAACCACTGTGCCCGGCCGGCAAAGCTAA 
TTTCTAATGGCAAAGCTCAGATCAGGGGTGATGGAAGAGGACATATGACT 
GCAAAGAGGCACAGGGAACTTTCTGCATAAAGGAAATATTCTATATCTTG 
ATTGTGGTGGTGGTTATATGAGTGTATGCATTTGTCAAAACTCAACAAAC 
TGTACACTAAAATGAGTACATCTTATAGTATGTAAATTATGCCTCAAAAA 
ATTGACTATAAACGTTCTTTGTGGCCCCACATCAATCTTATGTTGTCCAG 
GAAACCTTTTCTGATCAATACTGTCCTCAGCTGCATTTATATCTCCTCCT 
CTCACCACTTGCTCTCCTGATTAGCATACCCTGGAGCCCT 
 
SEQ_6 
 
>CHR1_47703476_47705959  
GGCTCATCTCACCCAGTCACTCACTTGGTATACATCCAAGTCAGCTTAGC 
CCCGGTGTCTTCTCCATTCCTGCTGGCTAGAATGAACTATGTGTTACTTT 
GGGAGAACTGTTTCAAAATCTTGAACACTTTGGATAGCATTGTGATATCC 
CCCGGTTTAAATCCTTTGACCTTAAAGAAGATAAATAGCCAAACTTATCA 
TGAAAAGATTCTTCAACTTGTATTAAGGAAACAGAAATTAAAACCACAAT 
GAGATGCCATGACACATCCACTAAAATGATTAAAATTTAAAAGACTGACA 
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ATACCAAGTATTGCTGAGGATGTGAAGGAGCAACTGGAGTTCTCCAGCAA 
CATTGTTGAAGGAAATGCAAAAATTACTCAGCCACTTTGGAGAACTCTTT 
CGCAGTTCCTATGAATGTGCAGTTTATAAACACCCATTTACTGAGACAGC 
TGAAAAATATATATCCACAAGAACACCTGTACATTAACAGTGATAGAACC 
CTTATTTGTAAAGCAAAAAACAACAATTCAACTATCCATCAACAGGTGAA 
TGGTAAACAAATTGTGGTACATTCATGTAATAGAACATTACTCAGCAATA 
AAAAAGAAACAAATTACTGACAAATGCCAGAATATAGACCTCTCAACAAC 
AGGCTCAGTGAAAGAGGCCAGACACAAAAGACTATTTAGCATATGATTCC 
ATTTATATGAAACTCTAGAAAAAGCAAAAATTTTTTTTTTTTTTTTTTTT 
TGAGACAGAGTTTCACTCTTATCACCCAGGCTGGAGTGCAATGGCGCCAT 
CTGGGCTCACGGCAACCTCCGCCTCCTGGGTTCAAGCGATTCTCCTGCCT 
CAGCCTCCCAAGTAGCTGGGATTATAGGTGCCTGTCACCACTCCCAGCTA 
ATTTTTGTATTTTTAGTAGACACGGAGTTTCACCATGTTGACCTCAGATG 
ATCCGCCCGCGTCAGCCTCCCAAAGTGCTGGGATTACAGGCATGAACCAC 
TGTGCCCGGCCGGCAAAGCTAATTTCTAATGGCAAAGCTCAGATCAGGGG 
TGATGGAAGAGGACATATGACTGCAAAGAGGCACAGGGAACTTTCTGCAT 
AAAGGAAATATTCTATATCTTGATTGTGGTGGTGGTTATATGAGTGTATG 
CATTTGTCAAAACTCAACAAACTGTACACTAAAATGAGTACATCTTATAG 
TATGTAAATTATGCCTCAAAAAATTGACTATAAACGTTCTTTGTGGCCCC 
ACATCAATCTTATGTTGTCCAGGAAACCTTTTCTGATCAATACTGTCCTC 
AGCTGCATTTATATCTCCTCCTCTCACCACTTGCTCTCCTGATTAGCATA 
CCCTGGAGCCCTCCGTTACAGTCTAACTCATGCTGCTCAGGGCCAGGCAC 
ACAGGGCACAAAAAAGGATCTGTAGACAAGGGAGGAACTGAATTAATGGT 
ATTTGAAAAAGTGACAGAGACATCTGCCAGGAAGTAGGGTTACGTCTTTC 
TGTGACCCTCAGTTTATCTGTAATAGGAATGGGGTGGGGCAACCACAGGA 
TCTCTCTCTCCCTTTTATCTCTTATCATCTCTTTCACTCTGCTTCTCATC 
ATGCCATCTCTATTTTAAGCGCATGTGCATTCTCTCTGTCTCTAAGTCTG 
CTCCTCTTTCCTACCCCGGCCCTGTCTCTCCATCTCTGTCTTTAATCTGC 
CTCTCATCATTGCCTCCTTCCTCTTTTTTGGTCTCTGTTCAGGCTGTCAA 
TAAGAGCTCCAGCTGTGCACAGGTACCCCATAGAAGCAAGGCATGCCGAT 
TCTCTTGCCACATTCCCGACAGGCTGGACCTGTTAGAAAGGCATAAGCTG 
GTCTATCAGCTATATGGGACTGGGGAGAAGGGGAAATGAAAAGAAGGGTA 
GAAAGGGAAGGGGAGAGATTTGGAAAGTCACCGTTCAGGAGACACACACG 
CCTGGTACACTGGATGCAGGGGATTCGGCCTGCTGGACTCTGGCAGAAGC 
TCTGAGTTCCCAAGAAAAGCTGTGGCCCTCTCCTCCACACGGCCCAGCCC 
GTGTGCCCAGTCCAGAACCCATGCCACAGGACACAGCCTATAGCTGATTA 
AGAGCACATGGTTGACTTTCACGCCACCCTGGACTAGAATGCCTCTTCAA 
CAACTTAGCAGCTGATAACCCTAAGCAAGTTACATCACTTCTGTGTGCCT 
CAGTTTCCTCATCTCTAAAATAGAGGTAAAAATAACACATGAGGCCAGGC 
ACGGTGACTCACGCCTGTAATCCCAACACTTTGGGAGGCCGAGGCAGGTG 
GATTACCTGAGGTCAGGTGTTTGAGACCAGCCTGACCAACATGGTGTAAC 
CCCGTCTCTACTAAAAATAAAAAAAATTAGCCGGGCATGATGGCGTGCTC 
CTGTAATCCCAGCTACTCAGGAGGCTGAGGCAGGAGAATCCCTTGAACCC 
TGGAGGTGGAGGTTGCAGTGAGAAGGAGAGGCAG 
 
 
| Table 7.27. Kruskal-Wallis results for DNA methylation of T-ALL, B-ALL and myeloid 
leukaemia cell lines for CpG Islands 1 and 2 within the TAL1 locus.  
CpG Island1 p-value (p<0.05) Significant? 
1 0.29 No 
2 0.4 No 
1CpG Islands tested correlate to those tested from Chapter 4 (Methods: 4.2.1) using CCLE data within the 
‘Methylation Plotter’ program 
  
200 
| Table 7.28. PCR cycling conditions as conducted for Q5 high-fidelity polymerase (per 
manufacturer’s instructions). 
Cycles Step Temperature (°C) Time 
1 Initial Denaturation 98 30 seconds 
25-35 
Denaturation 98 15 seconds 
Annealing 50-72* 20 seconds 
Elongation 72 30 seconds/kb 
Extension 72 2 minutes 
¥ Final Hold 10 -  
* Annealing temperature is dependent on predicted annealing temperature of primer pairs (*). 
 
 
| Table 7.29. Table of Proxy SNPs of tag SNPs that were found to co-localise Jurkat SNVs with 
linkage disequilibrium coefficient (r2>0.8), coordinates, alleles, distance from tag SNP, r2 
coefficient, correlated alleles and RegulomeDB values. 
Tag SNP RS_Number Coord Alleles Distance R2 Correlated_Alleles RegulomeDB 
rs741958 
rs741958 chr1:47692281 (C/T) 0 1 C=C,T=T 4 
rs2273834 chr1:47691090 (T/C) -1191 0.9944 C=C,T=T 2b 
rs2250380 chr1:47692786 (A/C) 505 0.9537 C=A,T=C 5 
rs2798349 chr1:47698703 (G/A) 6422 0.9006 C=G,T=A 1b 
rs2758742 chr1:47681779 (G/T) -10502 0.8908 C=G,T=T 4 
rs2821086 chr1:47679079 (C/G) -13202 0.8278 C=C,T=G 4 
rs2250380 
rs2250380 chr1:47692786 (A/C) 0 1 A=A,C=C 5 
rs741958 chr1:47692281 (C/T) -505 0.9537 A=C,C=T 4 
rs2273834 chr1:47691090 (T/C) -1696 0.9483 A=C,C=T 2b 
rs2798349 chr1:47698703 (G/A) 5917 0.9444 A=G,C=A 1b 
rs2758742 chr1:47681779 (G/T) -11007 0.9308 A=G,C=T 4 
rs2821086 chr1:47679079 (C/G) -13707 0.865 A=C,C=G 4 
rs2249665 chr1:47687084 (A/G) -5702 0.8383 A=A,C=G 1f 
rs6701381 
rs6701381 chr1:47704240 (A/G) 0 1 A=A,G=G 4 
rs35251419 chr1:47704128 (CT/-) -112 1 A=CT,G=- . 
rs1015890 chr1:47702229 (G/A) -2011 1 A=G,G=A 5 
rs6700838 chr1:47700027 (C/T) -4213 0.9982 A=C,G=T 5 
rs12057184 chr1:47706240 (C/T) 2000 0.9955 A=C,G=T 7 
rs12141363 chr1:47696581 (C/A) -7659 0.9937 A=C,G=A 4 
rs7534271 chr1:47693981 (C/G) -10259 0.9858 A=C,G=G 1f 
rs7525145 chr1:47693814 (G/T) -10426 0.984 A=G,G=T 4 
rs61782665 chr1:47692035 (A/G) -12205 0.9823 A=A,G=G 3a 
rs12407157 chr1:47707027 (G/T) 2787 0.9654 A=G,G=T 5 
rs911910 chr1:47706970 (G/A) 2730 0.9645 A=G,G=A 5 
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rs2984618 chr1:47690438 (G/T) -13802 0.9339 A=T,G=G 2b 
rs34087210 chr1:47689842 (C/G) -14398 0.9235 A=C,G=G 4 
rs11211481 chr1:47694167 (A/G) -10073 0.8818 A=A,G=G 1f 
rs1810658 chr1:47706733 (C/T) 2493 0.8179 A=C,G=T 7 
rs12083555 chr1:47703400 (G/T) -840 0.8174 A=G,G=T 4 
rs11211482 chr1:47704674 (A/T) 434 0.8167 A=A,G=T 5 
rs1810659 chr1:47706731 (G/A) 2491 0.813 A=G,G=A 7 
rs977747 chr1:47684677 (T/G) -19563 0.8093 A=T,G=G 7 
rs10789504 chr1:47676531 (T/A) -27709 0.8026 A=T,G=A 3a 
rs741959 chr1:47676233 (A/G) -28007 0.8026 A=A,G=G 1b 
rs11211480 
rs11211480 chr1:47693220 (A/G) 0 1 A=A,G=G 1f 
rs145295250 chr1:47691568 (CAGA/-) -1652 0.958 A=CAGA,G=- . 
rs743270 chr1:47675536 (G/C) -17684 0.9371 A=G,G=C 4 
rs4926521 chr1:47674769 (G/A) -18451 0.9371 A=G,G=A 5 
rs4134058 chr1:47670911 (T/C) -22309 0.9333 A=T,G=C 7 
rs6695898 chr1:47681761 (G/A) -11459 0.9109 A=G,G=A 4 
rs10890471 chr1:47676525 (C/A) -16695 0.9107 A=C,G=A 4 
rs6658125 chr1:47677015 (C/T) -16205 0.9098 A=C,G=T 6 
rs6692253 chr1:47680527 (G/A) -12693 0.9043 A=G,G=A 5 
rs12145836 chr1:47672289 (A/T) -20931 0.9024 A=A,G=T 6 
rs4926726 chr1:47679486 (G/A) -13734 0.8826 A=G,G=A 5 
rs11211481 chr1:47694167 (A/G) 947 0.8684 A=A,G=G 1f 
rs11211479 chr1:47680978 (T/C) -12242 0.8396 A=T,G=C 7 
rs4926725 chr1:47679366 (A/T) -13854 0.8277 A=A,G=T 3a 
rs4926524 chr1:47679258 (C/T) -13962 0.8246 A=C,G=T 4 
rs11211482 
rs11211482 chr1:47704674 (A/T) 0 1 A=A,T=T 5 
rs1810658 chr1:47706733 (C/T) 2059 0.9949 A=C,T=T 7 
rs12083555 chr1:47703400 (G/T) -1274 0.9941 A=G,T=T 4 
rs1810659 chr1:47706731 (G/A) 2057 0.9932 A=G,T=A 7 
rs10890472 chr1:47708112 (G/T) 3438 0.8827 A=G,T=T 6 
rs6701381 chr1:47704240 (A/G) -434 0.8167 A=A,T=G 4 
rs35251419 chr1:47704128 (CT/-) -546 0.8167 A=CT,T=- . 
rs1015890 chr1:47702229 (G/A) -2445 0.8167 A=G,T=A 5 
rs12057184 chr1:47706240 (C/T) 1566 0.816 A=C,T=T 7 
rs6700838 chr1:47700027 (C/T) -4647 0.8151 A=C,T=T 5 
rs12141363 chr1:47696581 (C/A) -8093 0.813 A=C,T=A 4 
rs61782665 chr1:47692035 (A/G) -12639 0.8064 A=A,T=G 3a 
rs7534271 chr1:47693981 (C/G) -10693 0.805 A=C,T=G 1f 
rs7525145 chr1:47693814 (G/T) -10860 0.8034 A=G,T=T 4 
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| Table 7.30. SNV3 Predicted JASPAR 2020 Transcription Factor Binding, Score and bp from 
start of the tested sequence for both the Jurkat alternate allele and the reference allele.  
 
SNV3 - Alternate Allele Binding Motifs SNV3 - Reference Allele Binding Motifs 
Name Score Start End Name Score Start End 
SOX10 8.62523 13 18 FOXC1 5.81625 3 10 
SOX18 8.57683 12 19 SOX18 6.55667 12 19 
FOXC1 5.81625 3 10 NFIX 5.47642 4 12 
THAP1 7.40652 5 13 MEIS1 4.2416 5 11 
SOX13 8.96537 11 21 MEIS3 5.83924 4 11 
SOX15 8.0528 10 19 NFIX 4.79315 4 12 
NFIX 5.47642 4 12 NR2C2(var.2) 2.14845 5 12 
SOX2 8.45148 11 21 TEAD3 3.82584 12 19 
MEIS1 4.2416 5 11 OSR1 6.35483 6 15 
SOX8 8.48539 10 19 NFIC 5.16094 6 11 
MEIS3 5.83924 4 11 TEAD4 5.81245 11 20 
NFIX 4.79315 4 12 MYB 5.28654 6 15 
NR2C2(var.2) 2.14845 5 12 SOX18 3.82088 7 14 
NFIC 5.16094 6 11 NKX2-8 3.33462 8 16 
NKX2-8 4.28514 8 16 MEIS1 2.30244 5 11 
HOXD8 4.11769 7 14 HOXA5 4.92049 11 18 
HOXB8 3.54515 7 14 HIC2 4.07776 5 13 
FOXC1 4.50074 12 19 THAP1 4.86476 5 13 
GSX2 2.94567 7 14 TEAD4 6.63411 10 21 
SOX4 4.97058 11 20 SOX18 3.16452 13 20 
MEIS1 2.30244 5 11 NKX2-3 3.10715 7 16 
HOXA5 2.71529 7 14 SOX18 2.96758 8 15 
HOXA7 3.24453 7 14 SP1 6.29953 2 11 
GSX2 1.91688 13 20 NR2C2(var.2) -0.513273 11 18 
SOX9 6.45561 11 19 MAFA 8.37293 2 16 
TEAD4 4.29671 11 20 GSX2 1.45032 13 20 
HIC2 3.68843 5 13 NKX2-2 6.67631 5 18 
HOXA4 1.83878 7 14 
MZF1(var.2) 5.96082 5 14 
NKX2-3 3.10715 7 16 
NFIA 0.958111 4 13 
SP1 6.29953 2 11 
SOX18 2.84569 9 16 
HOXB2 1.37048 7 14 
HOXB6 1.88026 7 14 
SOX10 4.9826 10 20 
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| Table 7.31. SNV5 Predicted JASPAR 2020 Transcription Factor Binding, Score and bp from 
start of the tested sequence for both the Jurkat alternate allele and the reference allele. 
 
SNV5 - Alternate Allele Binding Motifs SNV5 - Reference Allele Binding Motifs 
Name Score Start End Name Score Start End 
RHOXF1 8.40591 16 23 RHOXF1 8.40591 16 23 
HOXA4 7.1463 10 17 MEIS1 6.10309 11 17 
BARX2 9.94126 6 17 OTX1 7.57923 16 23 
GATA2 5.10505 12 16 OTX2 7.75458 16 23 
OTX1 7.57923 16 23 PITX1 7.59749 16 23 
OTX2 7.75458 16 23 BARX2 8.44158 6 17 
PITX1 7.59749 16 23 PITX3 7.93544 16 24 
HOXA1 5.66792 10 17 HOXA4 5.32326 10 17 
HOXA1 5.59907 10 17 GATA2 4.45396 9 13 
PITX3 7.93544 16 24 NFIX 5.12512 1 9 
HOXB3 5.81558 9 18 OTX1 4.87037 7 14 
HOXB2 5.97819 9 18 ELK1 7.15419 12 21 
NFIX 5.12512 1 9 GATA3 4.70174 8 13 
HOXA2 5.96118 9 18 PITX2 4.83765 16 23 
GATA3 5.16156 8 13 RORB 7.62901 1 11 
PBX2 9.69703 3 15 BARHL2 3.89466 6 15 
LHX1 5.08218 10 17 TFAP2A 5.30024 11 19 
GATA2 4.00011 9 13 BARHL1 3.59396 7 14 
NRL 6.7159 10 20 PAX5 7.99346 10 21 
PITX2 4.83765 16 23 NFIA 2.05303 1 10 
HOXB4 3.65896 10 17 GSC2 5.38924 6 15 
EVX1 5.25604 9 18 OTX2 3.50336 7 14 
MAFK 6.38138 6 20 BARHL2 2.74347 5 14 
RORB 7.62901 1 11 HOXA9 3.95523 10 19 
EVX2 4.90056 9 18 OTX2 5.31743 14 25 
DRGX 3.69116 7 14 LHX1 3.78116 7 14 
HOXD4 3.50964 10 17 GSC2 4.90679 15 24 
HOXC4 2.60461 10 17 TFAP2C(var.2) 3.61937 10 20 
YY1 5.12323 10 15 GATA5 3.64693 6 13 
MEIS1(var.2) 7.87987 3 15 TFAP2A 3.18783 10 20 
MEIS2(var.2) 9.39649 2 16 
EN2 4.91437 9 18 
MAFF 8.63382 5 22 
JUNB 3.05497 6 16 
FOSL1::JUND 6.6337 6 15 
GATA5 4.41207 6 13 
FOSL2 3.70788 6 16 
  
204 
NFIA 2.05303 1 10 
LHX1 4.23992 10 17 
FOXH1 3.53031 6 16 
MEOX2 5.21391 9 18 
MIXL1 4.45379 6 15 
GATA3 4.11797 11 16 
HOXB2 2.14808 10 17 
ELK1 6.22605 12 21 
FOXD2 4.12113 5 17 
POU6F1(var.2) 4.1869 8 17 
FOS::JUN 5.6358 7 13 
VAX1 4.78242 10 17 
EVX2 3.75618 6 15 
NKX6-3 2.74893 10 18 
HOXA2 3.69855 6 15 
DRGX 2.32416 10 17 
POU6F1(var.2) 3.94526 10 19 
LHX1 3.8758 7 14 
EN1 3.228 10 17 
OTX2 5.31743 14 25 
HAND2 2.5479 10 19 
LHX9 3.99238 10 17 
NKX6-2 3.98439 10 17 
BARHL2 2.31102 5 14 
VAX2 4.36839 10 17 
GSC2 4.90679 15 24 
EMX1 5.18926 9 18 
HOXA7 2.88321 10 17 
OTX2 2.94642 7 14 
HOXB5 2.35223 10 17 
FOXD2 2.58195 10 16 
ZBTB18 4.32409 9 21 
HOXB2 3.67298 6 15 
EVX1 3.67899 6 15 
TFAP4(var.2) 3.56373 10 19 
JUND -0.62119 5 15 
HOXA4 1.55011 10 17 
LHX6 3.16977 9 18 
GSX2 1.38065 10 17 
FOSL1::JUNB 6.78864 4 16 
MEOX1 3.68959 9 18 
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PRRX1 3.90165 7 14 
HOXA2 0.181628 10 17 
 
7.3.3 Chapter 4 - Command Lines Used 
 
7.3.3.a qcat code - Python 
 
#Create an environment  
$ conda create --name QCAT 
 
# To activate this environment, use 
$ conda activate QCAT 
 
# To install qcat  
conda install -c bioconda qcat 
 
# Combine all fastq into a single file (using the *.fastq option does not seem to work with --
dual) 
$cat *.fastq > single_file.fastq 
 
# Detect dual barcoded samples and trim barcodes and adaptors 
$qcat -f single_file.fastq -b workdirectory --trim --detect-middle 
 
7.4.3.b Minimap2 – Python 
 
#create an environment 
$ conda create --name Minimap2 
 
# To activate this environment 
$ conda activate Minimap2 
 
# Align .fastq file to a reference genome (put into directory e.g. hg19.fa.gz)  
 
$ minimap2 -ax map-ont hg19.fa.gz filename.fastq > filename.sam  
 
7.4.3.c Bcftools – Python 
 
#create an environment 
$ conda create --name BCF 
 
# To activate this environment 
$ conda activateBCF 
 
#BAM index file needs to be in the same folder as the input.bam (the index is required to 
find the regions specified in your .bed file) 
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$ bcftools mpileup -f hg19.fa -d 8000 -R Your_Amplicons_Regions.bed 
your_alignments.sorted.bam -a 
FORMAT/AD,FORMAT/ADF,FORMAT/ADR,FORMAT/DP,FORMAT/SP,INFO/AD,INFO/ADF,INF
O/ADR -Ob -o output_file.bcf 
  
#bcftools index 
bcftools index your_bcf_from_mpileup.bcf 
  
#bcftools call --ploidy GRCh37 -Ov -R AmpliconRegions.bed -m Input.bcf -o Output.vcf 
$bcftools call --ploidy GRCh37 -Ov -R your_Locus.bed.txt -m your_bcf_from_mpileup.bcf -o 
your_filename.vcf 
 
 
 
 
 
 
 
 
